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Abstract 
The research described in this thesis covers two fields of investigation: 
1) Development of Peptidic Inhibitors of the IgE-Fc#RI Protein-Protein 
Interaction in Allergy 
When Immunoglobulin E (IgE) binds to its high affinity receptor protein Fc"RI on 
the surface of mast cells or blood basophiles, it can cause an immediate allergic 
reaction by triggering the release of toxic inflammatory agents. Inhibition of the 
protein-protein interactions (PPIs) between IgE and Fc"RI is known to prevent the 
release of inflammatory agents; thereby effectively targeting allergic disorders. In 
this thesis, the development of a retro-#Fc"RI C-region mimic peptidic inhibitor 
(named BM1149-Am; IC50 = 77±11 µM av.) from the study of literature peptidic 
inhibitors is described. Structure-activity relationship (SAR) studies of BM1149-Am 
using alanine-scan and truncation techniques identified the key structural epitope 
along the sequence to be Tyr-Tyr-Ile-Val. One of the alanine-scan analogues, [Y8A] 
BM1149-Am showed a 10-fold improved IC50 value in ELISA assay compared to 
that of BM1149-Am.  
2) Towards Aryl Germane-Based Synthetic Mutagenesis of Peptides 
Synthetic mutagenesis of aromatic amino acids (AAAs), in particular phenylalanine 
(Phe) and tyrosine (Tyr), to give biaryl derivatives are of great interest. Such biaryl 
units are important structural elements in protein-protein interactions (PPI). Biaryls 
are generally prepared by cross-coupling between aryl metals and aryl halides. In this 
thesis, fluorous-tagged silyl germanes were studied as the precursor towards a new 
generation of aryl metals. Silyl germanes were successfully synthesised from 
commercially available germanium(IV) chloride in eight steps. Literature conditions 
reported for coupling of both metal hydride and bimetallo group 14 compounds with 
aryl halides as well as modified variants were screened. Conditions where a CuI-6-
methyl-2-(hydroxymethyl)pyridine complex was used as an additive to a Pd(OAc)2-
dppf catalyst system was found to be the best, although even these conditions had 
limited substrate scope.  
 
Declaration: I declare that I have personally prepared this thesis, and the work 
described here is my own, carried out personally unless otherwise stated. All sources 
of information are acknowledged by means of reference. 
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Chapter 1. Development of Peptidic Inhibitors of the 
IgE-Fc#RI Protein-Protein Interaction in Allergy 
1.1. Introduction 
1.1.1. The Role of Protein-Protein Interactions in Allergies 
Proteins are composed of one or more polypeptides folded into highly specific 
tertiary or quaternary structures. In turn, polypeptides are composed of 20 chemically 
and structurally different amino acids, joined together via peptide bonds. This 
complexity enables proteins to interact together as stable complexes to achieve 
particular biological functions, for example, signal transduction, which plays a 
fundamental role in many biological processes and in many diseases including 
allergies.  
 
The concept of ‘allergy’ was first introduced in 1906 by Clemens von Pirquet, a 
Viennese paediatrician.1,2 Allergic diseases include eczema, allergic rhinitis (or hay 
fever), asthma, food allergies, and insect sting allergies. Severe allergies to 
environmental or dietary allergens or to medication may result in life-threatening 
anaphylaxis. To-date, allergies have become increasingly prevalent. Different types 
of allergies affect more than a hundred million of the world population.3 Allergies 
are the largest cause of time lost from work and school, and their direct and indirect 
costs to the medical systems and economy are enormous (Direct NHS costs for 
managing allergic problems were estimated in 2001 at over one billion UK pounds 
per annum).3 
 
Allergic reactions are the result of an immune response resulting from 
immunoglobulin E (IgE) antibodies binding to the allergen, then also binding to their 
Fc receptors (Fc"RI, the high-affinity receptor &/or CD23, the low-affinity receptor) 
found on the surface of mast cells and basophils. Disrupting this specific protein-
protein interaction (PPI) between IgE and its Fc receptors could therefore provide an 
attractive opportunity for the treatment of allergies (Figure 1).4-6 
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Figure 1: Overview of allergic reactions (Figure is adapted from reference 4). 
The allergic response requires the binding of IgE both to the Allergen and to Fc receptors, which then 
triggers the release of inflammatory mediators. 
 
When allergens aggregate receptor-bound IgE, this activates mast cells and basophils 
to undergo degranulation.4,6 This process causes these sensitised cells to release 
inflammatory mediators such as histamine, interleukins, leukotrienes and 
prostaglandins into the surrounding tissues. These cause certain symptoms such as 
runny nose and watery eyes in hay fever, and airway constriction in asthma. In some 
severe cases, symptoms like vasodilation can lead to sudden drop in blood pressure, 
which can cause life-threatening anaphylaxis.  
 
The amount of IgE in a non-atopic individual is typically the least of all 
immunoglobulin isotypes. However, atopic individuals can have up to 10 times the 
normal level of IgE in their blood serum from aggregation of antigen-presenting cell 
(APC) to TH2 lymphocyte (a type of immune cell), which triggers the production of 
cytokines such as interleukin-4 (IL-4) and interleukin-13 (IL-13) (Figure 2).4  
 
 
Figure 2: Overview of IgE production (Figure is adapted from reference 4). 
Aggregation of APC triggers the interaction between TH2 cells and B cells, and the production of 
cytokines, which in turn triggers the production of IgE. 
 
The interaction between a TH2 cell and another lymphocyte B cell, along with the 
signals stimulated by IL-4 and IL-13, triggers the B cell to produce large amounts of 
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IgE antibodies. Consequently, the inflammatory mediator level in the blood serum is 
increased. 
 
In summary, the allergic reactions are fundamentally mediated by the PPI between 
IgE and its Fc receptors. However, targeting PPIs with ‘drug-like’ inhibitors 
constitutes one of the most difficult challenges in contemporary drug discovery. One 
major challenge impeding the more rapid development of antagonists of PPIs is that 
these targets are generally rather flat and featureless with large surface areas (600-
2000 Å2 per protein) in contrast to the small, functionalised pockets/clefts 
characteristic of enzyme and GPCR binding sites.7,8 
 
Nevertheless, some interface residues, which are spatially adjacent to each other can 
‘co-operatively’ organise themselves into compact ‘hot regions’.9-11 These residues 
are also called ‘hotspots’, which can either contribute significantly to the binding 
free energy (>2.0 kcalmol-1) or be conserved into a multiple structure alignment. 
Keskin et al. also suggested that ‘hotspots’ are often already pre-organised in the 
unbound (free) protein state, strengthening the view that much of the surface does 
not accommodate binding and that binding sites are pre-conserved.12 
 
Some small molecules have been discovered that bind with drug-like potencies on 
the contact surfaces of PPIs; these are now even making their way through to clinical 
trials.13-15 A selection of these is described below. 
1) Navitoclax (Collaboration between Genentech and Abbott): 
The B-cell lymphoma 2 (Bcl-2) family proteins are apoptosis regulating proteins 
encoded by the Bcl-2 gene.16 When highly expressed in tumours, these proteins are 
thought to impact tumour formation, tumour growth and cause resistance to 
conventional tumour treatment. Navitoclax is a small molecule that is designed to 
restore apoptosis by blocking the binding of tumour-related Bcl-2 to Bcl-2-associated 
death (BAD) promoter proteins (Figure 3).17,18 
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Figure 3: Structure of navitoclax; PPI inhibitor for Bcl-2 binding to BAD.17,18 
 
Navitoclax is evaluated to be used in combination with other chemotherapies or with 
tumour-targeted medicines. It is currently undergoing both Phase I and Phase II 
clinical trials. 
 
2) Ro26-4450 (by Roche): 
Interleukin-2 (IL-2) are cellular messenger proteins, which are responsible for 
regulating cell growth, differentiation and motility, thus, stimulating immune 
responses to foreign molecules, for instance, infectious agents.19 Antibodies that are 
capable of blocking the binding of IL-2 to its IL-2R# receptor has proven clinically 
effective as immunosuppressive and immunotherapeutic agents. In 1997, Roche 
reported a small molecule inhibitor Ro26-4450, which acts as a competitive inhibitor 
of IL-2 and IL-2R# interaction with an IC50 of 3 µM (Figure 4).20  
 
Figure 4: Structures of Ro26-445020 and its more potent derivative;21-23 PPI inhibitors for IL-2 
binding to IL-2R&. 
 
Researchers at Sunesis later identified an aromatic carboxylic acid derivative with 
50-fold more potency (Figure 4).21-23 It was a first report of a nanomolar inhibitor of 
a PPI discovered using tethering approach along with analysis of the X-ray crystal 
structure of Ro26-4450 binding at the ‘hot spot’ of IL-2. 
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Currently, there is no commercially available small molecule drug targeting a PPI. 
Nevertheless, the above two examples provide ‘proof of concept’ that small molecule 
inhibitors are capable of reaching late stage development and may constitute a viable 
approach towards disrupting PPIs. 
 
1.1.2. Molecular Structures of IgE and Fc#RI 
Structurally, IgE shares the same basic molecular architecture as antibodies of other 
classes, with two identical heavy chains and two identical light chains.24,25 From the 
crystal structure of the complete IgE-Fc, it was found that the IgE molecule is 
acutely bent, with the C"2 domains folded back and making extensive contact with 
the C"3 domains, and even touching the C"4 domains (Figure 5). 
  
Figure 5: The domain structure of IgE and a schematic representation of its bent conformation 
(Figure is adapted from reference 24). 
 
Fc"RI is expressed as an #!$2 tetramer on mast cells and basophils. The two 
extracellular domains of the #-chain (sFc"RI#) contain the IgE binding function, 
whereas the signalling motifs are located in the intracellular sequences of the !- and 
$-chains (Figure 6).  
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Figure 6: The IgE and Fc#RI interaction (Figure is adapted from reference 24). 
 
X-ray analyses of sFc"RI# in several different crystal forms have revealed that the 
two domains are folded back on each other exposing a hydrophobic ‘ridge’ that was 
subsequently found to be the IgE binding site. Part of this ridge is formed by the CC’ 
loop of the #2 domain (see section 1.1.6 for details). 
 
Therefore, the ability to interfere with this specific PPI between IgE and Fc"RI could 
potentially provide a powerful treatment for allergies. 
 
1.1.3. Commercially Available Drugs 
There are numerous prescription and non-prescription drugs for allergic disorders 
available commercially. Below is a brief summary of these pharmaceutical 
substances divided into five categories. 
 
1) Antihistamines: 
These drugs inhibit the action of histamine by blocking its binding to histamine 
receptors, thereby, suppressing the symptoms of an allergic reaction – e.g. a runny 
nose and watery eyes (caused by fluid escaping from capillaries into the tissues).26 
There are two types of antihistamine: sedating, e.g. chlorpheniramine;27,28 and non-
sedating, e.g. cetirizine29 (Figure 7).  
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Figure 7: Structures of antihistamines -- chlorpheniramine27,28 and cetirizine29. 
 
However antihistamines only work if taken before contact with antigens and they are 
not effective for life-threatening anaphylaxis. 
 
2) Corticosteroids: 
These drugs regulate the expression of many genes, with a net anti-inflammatory 
effect. That is, the production of inflammatory mediators is reduced and the 
migration of inflammatory cell is inhibited.30 One of the most widely used 
corticosteroids is prednisolone,31 which is a synthetic analogue of cortisol (Figure 8).  
 
Figure 8: Structure of corticosteroids ' prednisolone.31 
 
Prolonged intake of corticosteroids can result in Cushing’s syndrome;32,33 and they 
are often administered in combination with cytotoxic immunosuppressive drugs. 
 
3) Bronchodilators: 
These drugs dilate the bronchi and bronchioles, decreasing resistance in the 
respiratory airway and increasing airflow to the lungs.30,34 They are most useful in 
obstructive lung diseases, e.g. asthma and chronic obstructive pulmonary disease 
(COPD). 
 
There are three types of prescription bronchodilating drugs: !2-agonists, e.g. 
salbutamol34 (short-acting) and salmeterol35,36 (long-acting); anticholinergics, e.g. 
tiotropium bromide,37 for emergency use; and xanthine derivatives which are both 
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competitive non-selective phosphodiesterase inhibitors and non-selective adenosine 
receptor antagonists, e.g. theophylline,38 for severe cases of asthma (Figure 9). 
 
Figure 9: Structures of bronchodilators ' salbutamol,34 sameterol,35,36 tiotropium bromide37 and 
theophyline.38  
 
4) Allergen Immunotherapy (or Immunologic Desensitisation): 
This involves the administration of gradually increasing quantities of specific 
allergens to patients with IgE-mediated conditions until a dose is reached that is 
effective in reducing disease severity from natural exposure. It is a treatment option 
that modifies the allergy disease process, whereas the above mentioned therapies 
merely suppress the symptoms.39,40 
 
Immunotherapeutic agents can be administered under the tongue (sublingually) or 
under the skin (subcutaneous). Grazax® is currently recommended for the treatment 
of grass pollen allergy in the UK for patients who don’t respond appropriately to 
symptomatic based treatment strategies.41,42 Potential adverse effects range from 
sensitisation to the allergen (if therapy is used inappropriately) to life-threatening 
anaphylaxis. 
 
5) Monoclonal antibodies (mAbs): 
mAbs are monospecific antibodies that are identical to each other because they are 
made by identical immune cells that are all clones of a unique parent cell.43-45 The 
most renowned example of a monoclonal antibody for allergic treatment is 
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omalizumab (Xolair®).46 This compound is a recombinant DNA-derived humanised 
IgG1k mAb that blocks the binding between IgE and its high affinity receptor Fc"RI. 
Omalizumab treatment results in a rapid reduction in free IgE levels and 
downregulation of Fc"RI on basophils, mast cells, and other inflammatory cells 
(Figure 10). 
 
Figure 10: Omalizumab's mode of action (Figure is adapted from references 4 and 33).  
The anti-IgE antibody blocks binding to the IgE receptor and so downregulates the inflammatory 
response. 
 
Omalizumab binds to the C"3-region of IgE, which prevents the IgE from binding to 
Fc"RI.46,47 When Fc"RI-bound IgE becomes unbound, omalizumab can immediately 
capture unbound IgE. Consequently, the level of circulating free IgE decreases and 
the IgE-free Fc"RI becomes unstable and eventually degrades. Omalizumab does not 
bind to the variable region of IgE, where allergens usually bind and so it is able to 
inhibit allergen-induced responses regardless of allergen specificity. Additionally, 
omalizumab does not bind to Fc"RI-bound IgE, thus potential anaphylaxis is 
avoided.47 Overall, omalizumab is effective in anti-IgE treatment. 
 
Omalizumab has been approved in the United States, the European Union, and 
several other countries for treating patients 12 years and older.48 It is required to be 
administered every 2 to 4 weeks via injection, and is only used for patients with 
moderate-to-severe allergic asthma. Omalizumab is very expensive (ca. £6k per 
person per year) due to the complexities of producing recombinant antibodies and 
cannot be safely administered to patients with elevated body mass indices (BMIs). 
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Furthermore, the long-term effectiveness and side effects of omalizumab are still 
under investigation, which prevent it being used commonly. 
 
Nevertheless, the effectiveness of omalizumab inhibiting the allergic cascade has 
provided prima facie ‘proof of concept’ for anti-allergenic agents that act by 
inhibiting the binding between IgE and its receptors. 
 
1.1.4. Current Research 
Over the past three decades, the focus of drug discovery has shifted from the 
development of high-throughput screening (HTS) using large combinatorial libraries 
to small, focused collections of ‘more natural-product-like’ structures (also known as 
‘Diversity Oriented Synthesis’ libraries). An analysis of the origin of the drugs 
developed between 1981 and 2006, by Newman and co-workers, showed that 52% of 
all new chemical entities (NCE) are either natural products, natural product-derived 
or natural product-mimic compounds.49 
 
1.1.4.1. Small Molecule Inhibitors 
1) Xantryl® (PH-10, by Provectus Pharmaceuticals Inc.): 
Rose Bengal (RB) is commonly used as a stain in eye drops form to identify damage 
to the eyes, and has also been used as an insecticide. In 2009, preliminary data for 
the Phase II clinical trial showed that the RB disodium form – PH-10, is effective in 
the treatment of eczema and psoriasis (Figure 11).50 
 
Figure 11: Structure of Xantryl (PH-10 or RB disodium) developed by Provectus 
Pharmaceutical Inc.50 
 
Around the same time, the sterile, non-pyrogenic solution of PH-10 (10% RB) – PV-
10, was reported to be effective in the treatment of melanoma and breast cancer with 
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Phase II clinical trial data.51,52 These distinctively different properties of RB suggest 
the possibility of it being a promiscuous protein binder.  
 
2) Natural Product Inhibitors: 
One natural product, which has been shown to target the interaction between IgE and 
Fc"RI, is aspercyclide A from Aspergillus sp. found in soil extracts collected in 
Tanzania (Figure 12).53  
 
Figure 12: Structures of aspercyclide A53 and its methyl ether derivative.54 
 
Recently the synthesis and ELISA studies of (±)-aspercyclide A were reported by 
Spivey et al.54 Interestingly, (±)-aspercyclide A and its methyl ether derivative were 
found to be comparably potent antagonists of the IgE-Fc"RI interaction, with IC50 
values of 95±10 %M and 110±10 %M respectively. Structure-activity relationship 
(SAR) studies of both compounds are currently ongoing in the Spivey group. 
 
1.1.4.2. Peptidic Inhibitors 
Another type of naturally occurring compound of interest in the context of drug 
discovery, particularly in the area of PPIs, is the protein itself or peptides derived 
therefrom. Forty years since Merrifield first described solid-phase based peptide 
synthesis, peptide research in drug discovery has become one of the most promising 
fields in the development of the new drugs.55 
 
Peptides are short proteins that typically have thirty or less amino acids. In many 
instances they can display molecular recognition and biological activities comparable 
to their native protein counterparts. But they can also offer novel structures, 
improved bioavailability, as well as the possibility to be modified into small 
molecule mimetics.  
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Proteins achieve their various functions by folding into compact, well-ordered 
structures. The formation of these tertiary and quaternary structures, in turn, depends 
on the formation of stable secondary structures, including #-helices, turns and !-
sheets. Molecules that fold to mimic protein secondary structures have emerged as 
useful compounds en route towards synthetic molecules with protein-like properties 
and as drugs that block PPIs55,56. 
 
Fifty years since Stanworth’s studies using peptides for mapping the binding interface 
between IgE and its high affinity receptor Fc"RI,57 a vast number of peptidic 
compounds have been reported as having good affinities towards either IgE or 
Fc"RI.58,59 Some of these peptides were developed for mapping the binding 
interface,60-64 as synthetic vaccines,65,66 as biochemical tools for antibody 
purification,67-75 as derivatives of natural peptides (e.g. bee venom peptides76-84) or as 
potential therapeutic leads.85-98 Oligonucleotide fragments have also been described 
as IgE-Fc"RI PPI inhibitors.99,100 Those peptides which were epitope mimics of either 
IgE or Fc"RI, are described below. 
 
1) ‘Proline sandwich’ mimics: 
A 15-residue disulfide-constrained cyclic peptide, IGE07 was identified by 
Genentech Inc. (San Francisco, California) using a direct binding assay of a phage-
display library. This compound forms a stable !-hairpin structure in solution and 
inhibits IgE binding to Fc"RI# with an IC50 of 1.0 %M using a Surface Plasmon 
Resonance (SPR) assay and is capable of inhibiting histamine released from cultured 
cells (Figure 13).94 
 
Figure 13: Structure of peptide inhibitor – IGE07 identified by Genentech Inc.94 
 
Alanine-walk analysis identified Gly8, Pro9, and Trp10 residues as being crucial for 
activity. Analyses of NMR studies suggested that a ‘proline sandwich’ pocket on the 
surface of the receptor where the Pro9 residue packs intimately between Trp87 and 
Trp110 was probably responsible for the activity;95 a similar arrangement is seen for 
Pro426 of IgE in the IgE-Fc"RI# complex. 
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Also identified by the same group was a 21-residue disulfide-constrained bicyclic 
peptide, e131 with an IC50 of 36 nM. Its backbone conformation resembles the Greek 
letter zeta (&), therefore, it was named a ‘zeta-dimer’ (Figure 14).96 
 
Figure 14: Structure of peptidic inhibitor -- e131 identified by Genentech Inc.96 
 
By peptide-phage alanine scan Pro4 and Pro16 residues were identified as being 
crucial for maintaining activity. An X-ray crystal structure of peptide-receptor 
complex revealed the Pro16 residue intercalating between Trp87 and Trp110 of the 
receptor.95 Given that the proline sandwich motif is found at several PPIs, it is 
conceivable that the reason of the zeta-dimer e131 and the !-hairpin IGE07 were not 
progressed to the clinic was a lack of selectivity for the target PPI. 
 
2) IgE-mimics: 
A 21-residue disulfide constrained cyclic peptide was reported by Helm et al. with an 
IC50 of 12 µM using a 5-hydroxytryptamine secretion assay.101 This compound was 
initially developed from a series of recombinant peptides85-87,102,103 and designed to 
mimic an exposed ' loop spanning the A-B !-strand of the C"3 domain of IgE, 
containing residues Leu340-Thr357 of the native protein (Figure 15).  
 
Figure 15: Structures of peptidic inhibitors – A-B loop peptide and its tolan-constrained 
analogue reported by Helm101 and Spivey104 respectively. 
 
A 19-residue peptide loop was then developed by replacing the flexible and labile 
disulfide bridge with a more rigid and robust tolan functionality (Figure 15).104 Initial 
binding studies using a histamine release assay and SPR assay on this structurally 
constrained peptide showed comparable inhibition to that of the disulfide variant. 
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The synthesis of a focused library of related tolan-constrained peptidic inhibitors 
with shorter loop sequences is currently being explored by the Spivey group. 
 
3) Fc!RI-mimics: 
A 13-residue disulfide-constrained cyclic peptide based on an epitope in the #2 C-
C’-loop region of Fc"RI as well as a retro-D peptide congener were developed by 
Sutton et al. as antagonists of the Fc"RI-IgE PPI (Figure 16).91-93 
 
Figure 16: Structures of peptidic inhibitors – C-C' cyclo-L-262 loop peptide and C-C' cyclo-
retro-D-262 loop peptide reported by Sutton et al.91-93 
 
These cyclic peptides showed IC50 values of 30 %M and 100 %M respectively using a 
!-hexosaminidase release assay. Analysis of 1H NMR and circular dichroism (CD) 
spectra indicated a well-defined !-structure similar to that of the native C-C’ loop in 
the # domain of Fc"RI. 
 
Based on the same epitope of Fc"RI, a 21-residue disulfide-constrained cyclic 
peptide, Ro25-7162 reported by Roche Inc. (Nutley, USA) showed an IC50 of 40 %M 
using a histamine release assay (Figure 17).88-90 
 
Figure 17: Structure of peptidic inhibitor -- Ro25-7162 reported by Roche Inc.90 
 
Various strategies were pursued for stabilising the !-strand conformation of 
compounds related to Ro25-7162, including the synthesis of bicyclic analogues, 
cyclic analogues with lactam link, and homo- and heterodimers.90 Of these 
compounds Ro25-9612 displayed an IC50 of 30 %M and Ro25-9960 displayed an 
IC50 of 2 %M in an undisclosed binding assay (Figure 18). 
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Figure 18: Structures of peptidic inhibitors – Ro25-9612 and Ro25-9960 reported by Roche 
Inc.90 
 
Recently, Ruvo and co-workers reported a series of polypeptidic inhibitors based on 
the epitopes in the B-C, C’-E and F-G loops of the Fc"RI D2 domain, which are 
joined by a linker.97 These polypeptidic inhibitors were designed to bind to IgE via a 
two-site mechanism (Figure 19). 
 
Figure 19: Structure of polypeptidic inhibitor – IgE-trap reported by Ruvo and co-workers.97 
 
SPR analyses showed that the best inhibitor, named as IgE-trap, has an KD value of 6 
%M. Further investigation resulted a polypeptidic inhibitor, PepE, with an increased 
affinity by 30-fold, which contains the receptor loops C’-E and B-C joined by a linker 
made of a Lys side chain and a !-Ala.98 Introduction of the !-Ala was crucial to the 
improvement of binding affinity of the inhibitor, as it was found with IgE-trap that 
the distance between the loop C’-E and loop B-C was too short to properly reach the 
two independent sites on the IgE; and !-Ala increased this distance by about 5Å. 
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1.1.5. Aim & Objectives 
The aim of this part of the project was to identify new peptidic inhibitor leads that 
would be able to inhibit the PPI between IgE and Fc"RI, and to carry out detailed 
kinetic binding and structure-activity studies on these leads. It was then planned to 
use these data to develop more potent and less peptidic inhibitors. Thus, an iterative 
process of structural modification was envisaged to be carried out involving: 
1) The synthesis of selective peptidic inhibitors reported in the literature; 
2) Testing the activities of these peptides as antagonists of the Fc"RI-IgE PPI 
using a standard binding assay to prioritise leads; 
3) Identifying ‘key’ residues via structure-activity relationship studies (e.g. 
alanine walk); 
4) Re-designing, synthesising and testing selected leads for better potency and 
reducing the peptidic contents of the structures. 
 
It was hoped that not only would the study of these processes lead to a molecular 
understanding of the manner in which the IgE-Fc"RI interaction can be disrupted, but 
that the molecules developed would provide new and exciting leads in the 
development of anti-allergic drugs. 
 
1.1.6. Choice of Starting Points from the Reported Peptidic Inhibitors 
The majority of the IgE-Fc"RI peptidic inhibitors mentioned in the section 1.1.4.2 
are either IgE-mimics or Fc"RI-mimics, which means that they can be classified as 
the protein epitope mimietics (PEMs) (Table 1).  
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Entry Category Peptide IC50/ µM Assay Type References 
1 
‘Proline 
sandwich’ 
mimic 
IGE07 1.0 Histamine release 94 
2 
‘Proline 
sandwich’ 
mimic 
e131 0.032 Histamine release 96 
3 
IgE 
mimic 
A-B Loop 12 
5-
Hydroxytryptamine 
release 
101 
4 
IgE 
mimic 
Tolan-
Constrained 
A-B Loop 
-- 
5-
Hydroxytryptamine 
release 
104 
5 Fc"RI mimic 
C-C’ Cyclo-L-
262 Loop 
30 
SPR & !-
hexosaminidase 
release 
91-93 
6 Fc"RI mimic 
C-C’ Cyclo-D-
262 Loop 
30 
SPR & !-
hexosaminidase 
release 
91-93 
7 Fc"RI mimic Ro25-7162 40 Histamine release 90 
8 Fc"RI mimic Ro25-9612 30 Histamine release 90 
9 Fc"RI mimic Ro25-9960 2 Histamine release 90 
10 Fc"RI mimic IgE-trap 6 
SPR, ELISA & 
flow cytometry 
97 
11 Fc"RI mimic PepE 0.5 
SPR & !-
hexosaminidase 
release 
98 
 
Table 1: Summary of literature reported IgE-Fc#RI peptidic inhibitors. 
 
PEMs are often used to target PPIs in drug discovery.56 PEM ‘technology’ refers to 
the design of synthetic molecules that mimic the functionally important epitopes in 
biologically relevant peptides and proteins. Hence epitopes at the binding interface 
are often re-synthesised as peptidic antagonists to inhibit the PPIs between their 
natural counterparts.  
 
In 2000, Jardetzky and co-workers solved the crystal structure of a complex between 
the Fc binding region of the human IgE and the # domain of Fc"RI.25 From the 
crystal structure two interaction sites on the receptor surface for the C"3 domains of 
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the IgE-Fc can be identified: site 1 is formed by the C-C’ loop in the receptor D2 
domain; site 2 involves the four solvent-exposed tryptophans (Figure 20). 
 
 
Figure 20: Two interaction sites on the Fc#RI surfaces for IgE (PDB code: 1f6a). 
 
C-C’ cyclo-L-262 loop peptide, as suggested in the name, mimics the CC’ loop 
region of the #-chain D2 domain;91 whereas Ro25-7162 mimics the C-F region; and 
Ro25-9612 and Ro25-9960 mimic the C region of the same domain.90 Also as 
mentioned above, 1H NMR studies of IGE07 showed that the Pro9 residue of this 
sequence packs intimately between the Trp87 and Trp110 residues on the surface of 
the receptor, similar to the arrangement seen for Pro426 of IgE in the IgE-Fc"RI# 
complex.94 The crystal structure of peptide-receptor complex of e131 also revealed a 
similar Trp-Pro-Trp sandwich structure. 
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A well-known issue with peptides is that most lack fixed three-dimensional 
structures in aqueous solutions, which has hindered their development into 
pharmaceutically acceptable drugs due to their limited conformational stability. A 
further problem with peptides as drugs is that they generally lack oral activity and are 
often rapidly cleared from the circulation by endogenous proteases.105,106 There are 
many different strategies for generating bioactive peptide mimics with improved 
biostability, including for example, the preparation of cyclic peptides.107 To 
incorporate structurally rigid templates into cyclic peptides, non-peptide linkers have 
often been introduced, including Cys-Cys disulfide linkers (7 rotatable bonds); 
dipeptide linkers (4 rotatable bonds); and biaryl linkers (1 rotatable bond), e.g. tolans 
(Figure 21).108  
     
Cys-Cys Disulfide Linker 
(7 Rotatable Bonds) 
Dipeptide Linker 
(4 Rotatable Bonds) 
 Tolan Linker 
(1 Rotatable Bonds) 
 
Figure 21: Introduction of rigid templates into cyclic peptides via non-peptide linkers. 
 
Disulfide linkers are often selected as starting points as they are relatively easy to 
form and introduce some rigidity and enough degrees of flexibility to allow !-hairpin 
formation via intramolecular H-bonding (Figure 22).107  
 
Figure 22: !-Hairpin formation via intramolecular H-bonding. 
 
Interestingly, about half of all loops and turns in natural proteins occur as !-
hairpins,55,107 which emphasises the key functional role of !-hairpins in PPIs. 
Furthermore, as protease digestion is one of the major routes by which peptides are 
degraded, cyclisation, which reduces the propensity of peptides to hydrolyse, can 
enhance biological activity.56 Therefore, cyclic peptides have often been found to 
display higher potency and longer-lasting action. 
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With all the above knowledge in mind, five known disulfide-linkered peptides were 
chosen as starting points for targeting the PPI between IgE and Fc"RI (Table 1, 
entries 1, 3, 5, 8 & 9). Among these chosen peptidic inhibitors, C-C’ cyclo-L-262 
loop, Ro25-9612 and Ro25-9960 mimic the binding region of Fc"RI (entries 5, 8 & 
9) whereas IGE07 and C-C’ cyclo-L-262 loop have been reported to adopt !-hairpin 
structures (entries 1 and 5, Figure 23).92,94 
  
  
IGE07  C-C' Cyclo-L-262 Loop 
 
Figure 23: IGE07 (PDB code: 1jbf) and C-C' cyclo-L-262 loop (PDB code: 1xbh) peptides show 
!-hairpin shape in ribbon form (disulfide linker indicated in orange colour in stick form) 
 
However, Ro25-7162 is also a disulfide-constrained peptidic inhibitor, which mimics 
the binding region of Fc"RI, but it exhibits a poorer IC50 value compared to those of 
Ro25-9612 and Ro25-9960, where the disulfide bridge merely links two identical 
linear chains. 
 
For future peptidic inhibitor modification purposes, it was also of interest to find out 
the activity of the monomeric version of Ro25-9960, which is referred to here as 
#Fc"RI C-region mimic Y116-D123 peptide. With an eye towards improving 
bioavailability, the retro-monomeric version of Ro25-9960 was also of interest. This 
is referred to here as retro-#Fc"RI C-Region Mimic Y116-D123 peptide (Figure 24). 
  
Figure 24: Monomeric versions of Ro25-9960 – &Fc#RI C-region mimic Y116-D123 and its retro-
analogue. 
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All the active peptides mentioned above were reported by different research groups, 
who employed different types of assays and conditions to evaluate their activities. 
Therefore, in order to identify a lead compound for the IgE and Fc"RI interaction, it 
was planned to re-synthesise the PEM inhibitors indicated above, then use one 
standard assay to test them under standard conditions (Table 2). 
Entry Category Peptide 
1 Phage IGE07 1 
2 IgE mimic A-B Loop 2 
3 Fc"RI mimic C-C’ Cyclo-L-262 Loop 3 
4 Fc"RI mimic Ro25-9612 4 
5 Fc"RI mimic Ro25-9960 5 
6 Fc"RI mimic Fc"RI C-Region Mimic Y116-D123 peptide 6 
7 Fc"RI mimic retro Fc"RI C-Region Mimic Y116-D123 peptide 7 
 
Table 2: Peptidic inhibitors selected for 1st phase development. 
 
These peptidic inhibitors in Table 2 could be potential starting points with IGE07 1 
targeting the 2nd interaction site of tryptophan sandwich (entry 1), A-B loop 2 
mimicking IgE (entry 2) and peptidic inhibitors 3-7 targeting the 1st interaction site 
of CC’ loop (entries 3-7). 
 
1.1.7. Choice of Assays for Peptidic Inhibitors Testing 
Many assay techniques for detecting protein-protein interactions to identify active 
peptidic inhibitors have been reported in the literature. The work in this thesis has 
used a variety of assay technologies, making use of their availability within the 
laboratories of our project collaborators (Dr. Andrew J. Beavil and Prof. Brian J. 
Sutton at King’s College London). These techniques are briefly described below: 
 
1) Enzyme-linked immunosorbent assay (ELISA): 
ELISA is a rapid immunochemical test used here to measure the IC50 values of 
peptidic inhibitors against the IgE-Fc"RI interaction. The principle of ELISA 
involves a biochemical reaction between an enzyme and its substrate to yield a 
detectable signal via a colour change (Figure 25).109 
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Figure 25: ELISA technique in the context of inhibiting IgE-Fc#RI interaction with a peptidic 
inhibitor (Figure is adapted from reference 109). 
 
In the context of inhibiting the IgE-Fc"RI interaction, a saturated amount of #Fc"RI 
is absorbed onto the surface of a 96-well plate, and then a mixture of the IgE:Fc and 
inhibitor is added to allow competitive binding. That is, the inhibitor either binds to 
#Fc"RI by competing with IgE:Fc or binds to IgE:Fc by competing with #Fc"RI. To 
evaluate the inhibition of the IgE-Fc"RI interaction by the inhibitor, a biotin-labelled 
anti-IgE antibody is applied over the surface so that it can bind to #Fc"RI-bound IgE. 
Horseradish peroxidase (HRP)-conjugated streptavidin is then added where 
streptavidin preferentially binds to biotin and then conjugated HRP provides enzyme 
activity for detection using o-phenylenediamine (OPD) as a substrate. When oxidised 
by HRP, OPD gives a yellow-orange coloured product 2,3-diaminophenazine, which 
is detectable at 492 nm (Scheme 1).110  
 
Scheme 1: Oxidation of OPD by HRP to give a yellow-orange coloured 2,3-diaminophenazine.110 
NH2
NH2
N
N
NH2
NH22 ! H2O2 + 2 !
Peroxidase
OPD 2,3-Diaminophenazine
+ 4 ! H2O
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Between each step, the plate is washed with a mild detergent solution to remove 
anything that is not specifically bound. ELISA tests are generally highly sensitive 
and easy to perform. However, although ELISA can measure IC50 values of 
inhibitors, it cannot provide definitive answers about which protein partner the 
inhibitor binds to. 
 
2) Surface plasmon resonance (SPR): 
SPR is an optical technique that measures changes in refractive index very close to a 
sensor surface. SPR measures the binding of an inhibitor to IgE or #Fc"RI directly or 
competitively against the other protein partner under continuous flow conditions 
(Figure 26).111-113 
 
Figure 26: SPR technique in the context of inhibiting IgE-Fc#RI interaction with a peptidic 
inhibitor (Figure is adapted from reference 111). 
 
In the context of the IgE-Fc"RI interaction, either IgE or Fc"RI (called the ligand) is 
immobilised onto the sensor surface. The sensor chip consists of a glass surface 
coated with a thin layer of gold, which is modified with a carboxymethylated dextran 
layer. This dextran hydrogel layer forms a hydrophilic environment for attachment of 
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the IgE or Fc"RI proteins, preserving them in a non-denatured state. The inhibitor 
(called the analyte) is then injected in aqueous solution through the flow cell under 
continuous flow. As the inhibitor binds to IgE or Fc"RI, the accumulation of protein 
on the surface results in an increase in the refractive index. The changes in refractive 
index are measured in real time, and from the data it is possible to calculate an IC50 
value. 
 
Under continuous flow conditions and using real-time measurements, SPR’s direct 
binding method can be used to determine the inhibitor’s binding partner, IgE or 
Fc"RI. However, the sensor chip is very sensitive to the solution environment and 
requires extreme care for coating proteins on the surface. Furthermore, the sensor 
surface deteriorates over time and with re-use.  
 
3) "-Hexosaminidase Release Assay: 
The !-hexosaminidase release assay is a biochemical technique often used to monitor 
the capacity of an inhibitor to block mast cell degranulation within a rat basophilic 
leukemia cell line (in the case of this project: RBL-SX38). The surfaces of these 
RBL-SX38 cells are abundant with Fc"RI. As suggested in the name, this assay 
measures the amount of !-hexosaminidase released by the cell degranulation when 
stimulated with antigen (Figure 27).114,115 
 
Figure 27: !-Hexosaminidase release assay technique in the context of inhibiting IgE-Fc#RI 
interaction with a peptidic inhibitor (Figure is a graphic representation created according to the 
word descriptions in references 114 and 115). 
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The RBL-SX38 cells are sensitised with IgE. The peptidic inhibitor is added at the 
same time to titrate the IgE-Fc"RI interaction. Then addition of antigen stimulates 
the cells by binding to Fc"RI-bound IgE and causes the cells to degranulate and 
release !-hexosaminidase. In order to determine the amount of !-hexosaminidase 
being released by the cells, the cell supernatant is mixed with !-hexosaminidase-
substrate (4-methylumbelliferyl-N-acetyl-!-D-glucosaminide) at pH 4.4. The 
substrate is hydrolysed in the enzymatic reaction to produce a fluorescent product 4-
methylumbelliferone (Scheme 2).116  
 
Scheme 2: Hydrolysis of !-hexosaminidase-substrate to give fluorescent 4-
methylumbelliferone.116 
 
This reaction is finally quenched using 0.1M glycine-carbonate buffer at pH 10.0. 
The amount of 4-methylumbelliferone, which is proportional to that of !-
hexosaminidase released by the cells, is quantified using a fluorescence microplate 
reader at 360 nm excitation and 450 nm emission. 
 
The !-hexosaminidase release assay is a homogeneous assay. It can monitor 
sensitisation and activation of cells in real time. However, its main disadvantage is in 
the use of cultured cells, which requires a long time to obtain sufficient amounts and 
involves the inherent risk of contamination. 
 
In terms of using one of the above assays for testing peptidic inhibitors in this 
project, ELISA was chosen as the frontline method to prioritise leads due to its easy 
handling procedures and already optimised conditions available. At the same time, 
the optimisations of the SPR assay and the !-hexosaminidase assay were investigated 
by Dr Balvinder Dhaliwal and Dr Fabienne Saab (King’s College London). 
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1.2. Results and Discussion 
1.2.1. 1st Phase: Development of Peptidic Inhibitors 
1.2.1.1. Synthetic Challenges 
The preparation of the seven peptides selected for initial studies (see Table 2 section 
1.1.6) presented two synthetic challenges: one being the oxidation step to form the 
disulfide linker; the other involved the use of liquid-chromatography-mass-
spectroscopy (LCMS) to identify and then purify the products (Figure 28). 
  
Figure 28: The standard procedure used for peptide synthesis. 
 
1) Disulfide Oxidation Challenges: 
Literature procedures for DMSO-mediated oxidation were initially followed,117 
where the reaction mixture was left stirring in air at rt over 48 h. However, this is a 
slow reaction and insufficient stirring to mix the reaction mixture hinders the 
disulfide linker formation. To speed up the reaction with adaption from air oxidation 
protocol, oxygen gas was bubbled into the reaction mixture for 30 min then the 
reaction was left to stir vigorously under an oxygen balloon to allow as much oxygen 
to be absorbed into the reaction mixture as possible. In this case, most reactions 
seemed to proceed to completion within 20 h, as judged by following the reaction by 
LCMS observation (despite some challenging problems associated with LCMS, see 
details later). 
 
Fmoc AA1(PG) Resin
1) Piperidine, DMF, rt, 30 min
2) HBTU, Fmoc-AA2(PG), NMM,
    NMP, rt, 3 x 35 min
Fmoc AA2(PG) AA1(PG) Resin
Repeat the above step n+1 times
1) Piperidine, DMF, rt, 30 min
2) TFA/TIS/H2O/EDT, rt, 2 h
Fmoc AAn+1(PG) AAn(PG) AA1(PG) Resin
AAn+1(PG) AAn(PG) AA1(PG)
SH SH
AAn+1(PG) AAn(PG) AA1(PG)
S S
DMSO/Acetic Acid/H2O, rt, 16 h
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The DMSO-mediated oxidation reactions are usually carried out in DMSO solutions 
(20% aqueous solution with 5% acetic acid at pH 3-8). However, none of the linear 
peptides obtained from the peptide synthesiser were soluble in aqueous solutions 
even with 20% DMSO. Precipitation was invariably observed. Therefore, all 
oxidation reactions to form the disulfide linkers were heterogeneous, which led to 
complications associated with the use of LCMS. 
 
2) Use of LCMS: 
Reaction mixtures from oxidation were purified to obtain cyclic peptides using 
LCMS, where desired fractions were collected according to their correspondent mass 
peaks. However, there are some challenges associated with this purification 
technique, including product solubility, mass change between starting material and 
product, and peptide sequence length. 
 
As mentioned earlier, most of the linear peptides synthesised in this project were not 
readily soluble in aqueous solution, and neither were their cyclic versions. Therefore, 
the reaction mixtures from air oxidation reactions usually required filtration before 
injecting into the LCMS column. Then large dilutions using different ratios of 
MeOH and H2O (LCMS eluting solvents) were carried out in order to dissolve as 
much peptide as possible and eluents with a high percentage of MeOH (20-50%) 
were often used. 
 
The disulfide bridge is formed between two thiol groups of cysteine residues in the 
same peptide sequence. Therefore, the mass difference between the starting material 
and the product is only 2 units. It was found that the linear peptide and its 
corresponding cyclic peptide often had similar retention times. Hence, it was difficult 
to confirm whether an oxidation reaction was completed by LCMS (ESI), 
particularly for compounds having Mw > 2000, for which the !!!  or !!!  ion was 
usually observed instead of M+ or M- ions. 
 
Finally, for peptides with sequences longer than 20 amino acids, e.g. A-B loop 2, 
some difficult amide bond couplings were required to form the linear peptide and 
consequently it was difficult even to generate a high yield of the desired linear 
Chapter 1 
 28 
product from the peptide synthesiser. In addition, the LCMS profiles from the 
reaction mixtures were typically broad peaks. Therefore, the products obtained 
following purification were frequently less homogeneous than for shorter sequences, 
and also gave lower yields. Interestingly, similar problems were encountered to form 
the disulfide link between the two single linear chains of Ro25-9612 4 and Ro25-
9960 5; see for example the LCMS profile of Ro25-9612 4 (Figure 29). 
 
Figure 29: The LCMS profile of Ro25-9612 4. 
 
3) Synthetic Results: 
Despite these difficulties, all selected peptidic inhibitors were successfully 
synthesised and characterised by observation of their corresponding molecular 
weight and retention time using LCMS analyses (Table 3). 
Entry Peptide Mw (Expected) Mw-H (ES-) Rt (min) Yield (%) 
1 IGE07 1 1747.03 1747.8 11.9 7 
2 A-B Loop 2 2366.80 1184.4 (!!! ! 12.6 5 
3 C-C’ Loop 3 1566.80 1567.8 9.9 8 
4 Ro25-9612 4 2356.76 
1177.80 & 
1177.54 (!!! ! 8.31 & 8.67 2 
5 Ro25-9960 5 2158.50 1078.44 (!!! ! 8.13 2 
6 Fc"RI C-Region 
Mimic 6 1090.27 1088.79 8.93 7 
7 retro-Fc"RI C-
Region Mimic 7 
1090.27 1088.66 9.52 40 
 
Table 3: Characterisation table of peptidic antagonists for 1st phase development. 
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Yields obtained after purifications were low except that of retro-Fc"RI C-Region 
Mimic Y116-D123 peptide 7 (entry 7). The molecular weights of all peptidic 
inhibitors found using LCMS analyses correspond well with their expected values 
although for compounds having Mw>2000, the !!!  or !!!  ion was usually observed 
instead of M+ or M- ions (e.g. entries 1-5). 
 
To simplify nomenclature issues, Fc"RI C-Region Mimic Y116-D123 peptide 6 will 
henceforth be referred to as BM3110-Am and retro-Fc"RI C-Region Mimic Y116-
D123 peptide 7 will be referred to as BM1149-Am. 
 
1.2.1.2. ELISA Results 
With all the purified peptides in hand, ELISA was firstly used for testing their 
biological activity. All results obtained from ELISA were interpreted using the 
Grafit118 programme (Table 4). 
Entry Peptide IC50/ µM 
1 IGE07 1 N.I. 
2 A-B Loop 2 N.I. 
3 C-C’ Cyclo-L-262 Loop 3 N.I. 
4 Ro25-9612 4 N.I. 
5 Ro25-9960 5 N.I. 
6 BM3110-Am 6 N.I. 
7 BM1149-Am 7 102±13 51±8 
 
Table 4: ELISA results of selected peptidic inhibitors for 1st phase development. 
(‘N.I.’ = no inhibition) 
 
Only BM1149-Am 7, which mimics the binding epitope of the receptor, showed 
some activity in the ELISA; whereas BM3110-Am 6 and all literature reported 
peptidic inhibitors showed no activity against the IgE-Fc"RI interaction. Concerning 
the issues with reported peptidic inhibitors, they were submitted to our collaborators’ 
lab for further testing using the SPR assay and the !-hexosaminidase release assay. 
In the meantime, BM1149-Am 7 was carried forward for 2nd phase development. 
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1.2.2. 2nd Phase: Development of Peptidic Inhibitors 
1.2.2.1. Peptidic Inhibitors Selection Process 
Inspired by the results obtained above, we set out to investigate a small library of 
monomeric and dimeric peptides based on Ro25-9960 5 with both natural and retro-
sequences (Figure 30). 
 
Figure 30: Peptides designed for 2nd phase peptidic inhibitor development. 
 
By definition, linear peptides contain end groups and so simply reversing the peptide 
sequence does not maintain the structural equivalence to its natural counterparts. 
Thus, retro-linear peptides usually suffer from so-called end group problems, which 
are not an issue for a cyclic peptide.119 There are many different ways to solve these 
end group problems. The most common and simplest way is to modify peptides with 
protected end groups, i.e. amidate the carboxyl terminal or acylate the amino 
terminal, or amidate the carboxyl terminal and acylate the amino terminal (Figure 
31).120 
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C-Terminal Amidation N-Terminal Acylation 
C-Terminal Amidation  
& N-Terminal Acylation 
Figure 31: End group protection methods. 
 
Using this end group protection strategy, the natural and retro-sequences of both 
monomeric and dimeric structures were synthesised and tested in ELISA (Table 5). 
Entry Description IC50/ µM Simplified Name 
1 
Fc"RI C-Region 
Mimic 
(Monomer) 
free N- & C- 1626±33 BM3110 10 
2 N-Ac N.I. Ac-BM3110 11 
3 C-Am N.I. BM3110-Am 6 
4 N-Ac & C-Am N.I. Ac-BM3110-Am 12 
5 
retro-Fc"RI C-
Region Mimic 
(Monomer) 
free N- & C- 69±8 85±6 BM1149 13 
6 N-Ac 142±9 131±11 Ac-BM1149 14 
7 C-Am 102±13 51±8 BM1149-Am 7 
8 N-Ac & C-Am 335±46 967±64 Ac-BM1149-Am 15 
9 Fc"RI C-Region 
Mimic (Dimer) 
C-Am N.I. Ro25-9612 4 
10 free N- & C- ( (?
11 Fc"RI C-Region 
Mimic (Dimer) 
C-Am N.I. Ro25-9960 5 
12 free N- & C- 443±22 BM3108B 16 
13 retro-Fc"RI C-
Region Mimic 
(Dimer) 
C-Am N.I. BM3085A 8 
14 free N- & C- 544±53 BM3109A 17 
15 retro-Fc"RI C-
Region Mimic 
(Dimer) 
C-Am N.I. BM3085B 9 
16 free N- & C- 605±67 BM3109B 18 
 
Table 5: ELISA results of peptidic inhibitors for 2nd phase development. 
(‘N.I.’ = no inhibition; ‘(’ = peptidic inhibitor was not synthesised) 
 
As described in section 1.2.1.1, Ro25-9612 4 and Ro25-9960 5 (entries 9 & 11) 
suffered from some purification problems where their LCMS profiles showed as 
merged multiplets and were only obtained in 90% and 92% purities respectively. 
This was also the case for their free termini analogues (entries 10 & 12). Indeed, the 
analogue of Ro25-9960 with both termini free could not be purified, hence, no 
sample was tested in ELISA (entry 10). 
 
When comparing the ELISA results, half of the dimeric analogues 4, 5, 8 and 9 
showed no activities (entries 9, 11, 13 & 15) whereas the other three dimeric 
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analogues 12, 16 and 18 showed poor activities (IC50s ~ 400 µM, entries 12, 14 & 
16). As for all monomeric analogues, retro-monomers 13, 14, 7 and 15 in general 
showed reasonable IC50 values (entries 5-8) whereas their natural counterparts 10, 
11, 6 and 12 showed essentially no activities (IC50 > 1000 µM, entries 1-4).  
 
Overall, the retro-monomeric peptides 13, 14, 7 and 15 showed the best results 
among those compounds tested and the IC50 values were reproducible (entries 5-8). 
Among these retro-monomers, protection of both N- and C-termini 15 seemed to 
reduce the IC50 values significantly (entry 8), whereas the IC50 value of the peptide 
without any protection 13 (entry 5) had a comparable value to the N-terminus 
acylated 14 (entry 6) and C-terminus amidated 7 (entry 7) analogues. Therefore, the 
retro-monomeric C-terminus amidated analogue 7 (BM1149-Am) was taken forward 
for further studies. 
 
1.2.2.2. Structure-Activity Relationship (SAR) 
To study the SAR of BM1149-Am 7, two series of experiments were carried out: 
firstly, an alanine scan was performed in which each amino acid in the sequence is 
replaced with alanine; and secondly, truncation of the peptide was explored by 
removing amino acids in the sequence one by one starting from each end. 
 
1) Alanine Scan Analogues:  
Alanine being the smallest chiral amino acid with an inert methyl functional group, is 
often used to replace amino acids one by one in a peptide sequence in order to 
determine the contribution of specific residues to the peptide’s function. Eight 
alanine scan peptides were therefore synthesised to determine the relative importance 
of residues along the BM1149-Am 7 peptide sequence (Figure 32). 
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Figure 32: Alanine scan analogues of BM1149-Am 7 designed for structural-activity 
relationship study. 
 
All alanine scan analogues were successfully synthesised and tested by ELISA. The 
‘IC50 factor’ was calculated from averaged IC50 values with BM1149-Am 7 as 
reference (i.e. !"#$%& ! !!!"!"!#$%"!!!"!"#"!"$%", rounded to the nearest whole number) (Table 
6). 
Entry Peptide IC50/ µM IC50 Factor 
1 BM1149-Am 7 102±13 51±8 1 
2 [D1A] BM1149-Am 19 654±62 ( 8 
3 [K2A] BM1149-Am 20 43±4 182±24 1.5 
4 [Y3A] BM1149-Am 21 413±55 309±79 5 
5 [Y4A] BM1149-Am 22 308±21 259±27 4 
6 [I5A] BM1149-Am 23 311±42 1367±188 11 
7 [V6A] BM1149-Am 24 1400±79 570±80 13 
8 [K7A] BM1149-Am 25 99±9 90±15 1 
9 [Y8A] BM1149-Am 26 6.3±0.6 11.8±1.1 0.1 
 
Table 6: ELISA results of alanine scan analogues of BM1149-Am 7 for structure-activity 
relationship study.  
(‘(’ = ELISA results were not repeated) 
 
It was concluded that residues Ile5 (entry 6) and Val6 (entry 7) are the most 
important ones to maintain the peptide activity, with increases of 11-fold and 13-fold 
in IC50 values respectively. Just next to them, Tyr3 (entry 4) and Tyr4 (entry 5) also 
showed increases of 5-fold and 4-fold in IC50 values respectively, which indicated 
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that these four residues in the middle of the peptide sequence are the key structural 
epitope. 
 
The two positively charged Lys residues – Lys2 and Lys7 (entries 3 and 8) at either 
end of the peptide sequence did not appear to contribute significantly to the IC50 
value. However, replacement of the negatively charged aspartic acid Asp1 gave a 8-
fold increase in IC50 (entry 2), which could suggest a salt bridge at the binding 
interface. 
 
Surprisingly, the Y8A mutant 26 (entry 9) improved the IC50 by 10-fold. This 
suggests that one of the three aromatic residues in the peptide sequence could 
probably be removed via peptide truncation. 
 
2) Truncated analogues: 
Next, truncated analogues of BM1149-Am 7 were investigated. Six truncated 
peptides were designed by systematically removing the flanking residues of the 
original peptide, BM1149-Am 7 (Figure 33). 
 
Figure 33: Truncated analogues of BM1149-Am 7 designed for structural-activity relationship 
study. 
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All the truncated analogues were successfully synthesised and tested in ELISA with 
repeats (Table 7).  
Entry Peptide IC50/ µM 
1 BM1149-Am 7 102±13 51±8 
2 [)1] BM1149-Am 27 N.I. N.I. 
3 [)1,2] BM1149-Am 28 N.I. N.I. 
4 [)1,2,3] BM1149-Am 29 N.I. N.I. 
5 [)8] BM1149-Am 30 802±77 211±34 
6 [)7,8] BM1149-Am 31 2420±248 2376±196 
7 [)6,7,8] BM1149-Am 32 928±106 341±32 
 
Table 7: ELISA results of truncated analogues of BM1149-Am 7 for structural-activity 
relationship study. 
(‘N.I.’ = no inhibition) 
 
The ELISA results suggested that removal of residues in general reduced the peptide 
activity. This could mean that the original 8-mer monomer BM1149-Am 7 has the 
optimal length for it to be active due to the relatively flat surface found at this PPI. 
 
A few interesting observations from this truncation series also confirmed some 
results from the alanine scan series: 1) residues Lys2 and Lys7 are not important to 
peptide activities, whereas Asp1 is essential to maintain the activity; 2) Tyr3 is 
important to activity in both analogues; 3) replacing Tyr8 with Ala improved the 
activity, but removal of an amino acid at 8th position is detrimental to activity, which 
suggests a possible small hydrophobic pocket to fit the amino acid at position 8. 
 
3) Solubility Issues:  
Before carrying out further modifications to improve peptide activities, solubility 
issues were noted for this series of monomeric peptidic inhibitors, i.e. most peptides 
either formed precipitates or gels during ELISA. Although 100% DMSO was 
generally used to dissolve peptides into stock solutions before diluting down slowly 
to 5% DMSO (which is usually used in ELISA) with PBS buffer for the assay, as 
soon as any aqueous buffer was added, precipitation was observed. For some 
peptides, e.g. [Y8A] BM1149-Am 26, gel formation was observed in 100% DMSO 
and addition of PBS buffer did not break down these aggregates. 
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Peptide solubility is sequence dependent. Peptides containing 50% to 75% 
hydrophobic residues may be insoluble or only partially soluble in aqueous 
solutions.121 For this series of monomeric peptides, five out of eight residues are 
hydrophobic (Tyr ( 2, Ile, Val and Tyr/Ala). Gel formation is usually believed to be 
due to intermolecular hydrogen bonding networks between peptide molecules in 
concentrated solutions. In the case of [Y8A] BM1149 26, the peptide was first 
dissolved into high mM concentration as a stock solution before being used in a 
titration ELISA. 
 
Many strategies have been reported to overcome problems with peptide solubility 
and aggregation.122 One relatively straightforward strategy to solubilise the peptides 
without modifying the peptide sequences is simply to select an appropriate solvent 
that can effectively dissolve the peptide, which is compatible with the ELISA and 
does not react with or promote degradation of the peptides. 
 
Therefore, three water miscible solvents (MeOH, EtOH and MeCN) were tested 
firstly with ELISA controls only. With control tests at different percentage of solvent 
in PBS buffer (2%, 5% and 10%), all solvents were suitable to use in the ELISAs and 
no loss of activity was observed. Therefore, 5% solvent was chosen for inhibitor 
testing as done with DMSO (Table 8). 
Entry Solvent 
IC50/ µM 
BM1149 13 BM149-Am 7 [Y8A] BM1149-Am 26 
1 DMSO* 
Insoluble 
69±8 
85±6 
Gel 
102±13 
51±8 
Gel 
6.3±0.6 
11.8±1.1 
2 MeOH 
Insoluble 
64±7 
Gel 
224±60 
Gel 
13±4 
3 EtOH 
Insoluble 
43±16 
Insoluble 
203±24 
Insoluble 
5.2±1.4 
4 MeCN 
Insoluble 
129±23 
Insoluble 
580±66 
Insoluble 
11.2±2.2 
 
Table 8: Solvent investigations to solubilise peptides in ELISA. 
[‘insoluble’ = a suspension formed when 100% DMSO was added to a peptide; then the PBS buffer 
was added to make up a 5% DMSO conc.; ‘gel’ = a jelly-like material formed when a solution of 
peptide in 100% DMSO was added into the PBS buffer to make up a 5% DMSO conc.; ‘*’ = IC50 
values obtained in 5% DMSO are listed here for comparison (cf. entries 5 and 7 in Table 5, and entry 
9 in Table 6)] 
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However, when 5% solvents were used to dissolve up all three chosen peptides 13, 7 
and 26 (which had typical solubility issues), solubility problems remained although 
reasonably consistent ELISA results were obtained in all four solvents. 
 
Sometimes, for hydrophobic sequences, solubility can be imposed by addition of a 
charged amino acid to the original peptide sequence without significant loss of 
activity.123 Two analogues of [Y8A] BM1149-Am with additional Arg residues 33 & 
34 were therefore synthesised, with one having the additional Arg residue at the N-
terminus and the other having this residue at the C-terminus (Figure 34). 
 
Figure 34: Analogues of [Y8A] BM1149-Am containing N- and C-terminal Arg residues to help 
improve solubility. 
 
To our delight, both peptides were soluble even in 100% PBS buffer. However, 
BM3135A 33 gave no inhibition in the ELISA, possibly due to disrupting the 
structural activity near the Asp1 position. On the other hand, BM3131B 34, while 
less soluble than BM3135A 33, gave comparable results to that of BM1149-Am 7 in 
the ELISA. This suggests that the addition of arginine did not interfere with the 
activity of the peptide when the charged amino acid was installed at the C-terminus, 
but also significantly improved the solubility of peptide. 
 
1.2.3. Results from The SPR and The !-Hexosaminidase Release Assays 
As described above, ELISA was performed for all the peptidic inhibitors synthesised 
in this project due to it being relatively straightforward to perform and already 
having optimised conditions. However, some literature-reported peptidic inhibitors 
showed no activity in the ELISA assay (Table 4, section 1.2.1.2). This demonstrates 
a disadvantage of pursing just one type of assay for the development of inhibitors. 
Furthermore, the biggest downfall of ELISA is that the assay cannot provide a 
definitive answer as to which protein partner the peptidic inhibitor binds to.  
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So far the investigation towards the development of a peptidic inhibitor for the 
inhibition of IgE-Fc"RI interaction led on to a retro-Fc"RI C-region mimic Y116-
D123 peptide 7 (AKA: BM1149-Am) and one of its alanine-scan analogues 26 
([Y8A] BM1149-Am) as the most promising leads. Although these two peptidic 
inhibitors are mimics of an epitope of Fc"RI, as retro-mers their binding partners 
may differ from their natural counterparts. 
 
For further evaluation, all peptides synthesised were delivered to our collaborators at 
King’s College London for analysis in SPR and !-hexosaminidase release assays. 
Due to time constraints, full analyses of all peptidic inhibitors were not completed. 
The results are shown below along with the results obtained from ELISA for 
comparison (Table 9). 
Entry Peptide 
IC50/ µM 
SPR 
(compet.) 
SPR 
(direct) 
!-
Hexosaminidase 
(1 h at 250 µM) 
ELISA for 
comparison 
1 IGE07 1 1.23±0.03 17 68% N.I. 
2 A-B 2 N.I. N.I. 0% (at 50 µM) N.I. 
3 C-C’ 3 N.I. N.I. 0% N.I. 
4 BM3109A 17 ( ( 12% 544±53 
5 BM3109B 18 ( ( 67% 605±67 
6 BM1149-Am 7 ( 
178.1 
(#Fc"RI); 
140.1 
(IgE-Fc) 
( 102±13 51±8* 
7 
[Y8A] 
BM1149-
Am 26 
( N.I. ( 6.3±0.6 11.8±1.1* 
 
Table 9: Results obtained from SPR and !-hexosaminidase release assays of some peptidic 
antagonists developed. 
(‘N.I.’ = no inhibition; ‘(’ = assays not run; ‘*’ = repeated ELISA under the same conditions) 
 
Among the re-synthesised literature peptidic inhibitors, IGE07 1 (entry 1) showed 
comparable IC50 values to these reported, but neither the A-B loop peptide 2 (entry 
2) nor the C-C’ cyclo-L-262 loop peptide 3 (entry 3) showed any activity.  
 
Among peptidic inhibitors developed from the Y116-D123 epitope of the Fc"RI C-
region, the two retro-dimers BM3109A 17 and BM3109B 18 (entries 4 & 5) showed 
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activities in both the !-hexosaminidase release assay and the ELISA assay tested. 
However, the IC50 values obtained from the ELISA suggested that they had 
comparable activities, but the !-hexosaminidase release assay suggested them to be 
significantly different from one another. 
 
IC50 values obtained from the SPR assay for BM1149-Am 7 (entry 6) showed 
comparable results to those from ELISA. However, this direct binding assay also 
gave comparable results against both protein partners. This either indicates that 
BM1149-Am 7 binds to both IgE and Fc"RI or suggests that BM1149-Am 7 binds 
non-specifically. However, for [Y8A] BM1149-Am 26 (entry 7), due to its 
insolubility (as mentioned in section 1.2.2.2), no readable signal was detected using 
the direct SPR assay, nor could the !-hexosaminidase release assay be performed. 
 
1.3. Conclusions and Future Work 
1.3.1. Conclusions 
The main aim of this part of the project was to identify new peptidic inhibitors of the 
PPI between IgE and Fc"RI and to carry out kinetic binding and structural-activity 
studies on these peptidic inhibitors. 
 
To achieve the aim and objectives set out, five literature peptidic inhibitors were 
successfully re-synthesised as starting points, they were IGE07 1, A-B loop peptide 
2, C-C’ cyclo-L-262 loop peptide 3, Ro25-9612 6 and Ro25-9960 7. However, only 
IGE07 1 showed comparable activity in direct SPR assay as reported. The others did 
not show any activity. 
 
From the study of literature peptidic inhibitors, a retro-#Fc"RI C-region mimic 
peptidic inhibitor 7 was developed and named BM1149-Am. ELISA showed its IC50 
value to be 77±11 µM (av.) although direct SPR assay suggested that this peptidic 
inhibitor could bind to both IgE:Fc and #Fc"RI proteins. 
 
Nevertheless, SAR studies of BM1149-Am 7 were carried out using alanine-scan and 
truncation techniques. The key structural epitope within the sequence of BM1149-
Am 7 was identified as Tyr-Tyr-Ile-Val and one of the alanine-scan analogues, 
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[Y8A] BM1149-Am 26 showed a 10-fold improved IC50 value in ELISA as 
compared to that of BM1149-Am 7. However, further studies of [Y8A] BM1149-Am 
26 using other types of assays were not conclusive due to solubility issues. 
 
1.3.2. Future Work 
Various avenues of research appear promising for future work, including to: 1) 
improve the solubility of the peptidic inhibitors in aqueous solutions; 2) use 
appropriate additional assays for testing the lead peptidic inhibitors; 3) improve the 
activity of the peptidic inhibitors, paying particular attention to key residues 
identified by SAR studies, for example, positions Tyr3 and Tyr4 in BM1149-Am 
peptide 7. These are considered in more detail below. 
 
1) To Improve the Solubility of Peptidic Inhibitors in Aqueous Solutions: 
To improve the solubility of peptidic inhibitors with their activities maintained, a 
spacer could be incorporated between the main peptide sequence (e.g. [Y8A] 
BM1149-Am 26) and a charged amino acid (e.g. an arginine residue) to separate the 
additional amino acid from the active epitope (Figure 35).  
 
Figure 35: Structure of a proposed new peptide incorporating an Arg residue and a spacer to 
improve solubility. 
 
The solubility could hopefully therefore be improved by the charged side-chain, 
without interfering with the key active epitope in order to maintain activity. At the 
same time, just like the Arg residue, the spacer itself must not interfere with the 
activity of the peptide. Incorporation of a spacer between a short peptide and an 
arginine residue, e.g. a bifunctional poly(ethylene glycol) (PEG) spacer, could be 
considered (Figure 36).  
 
Figure 36: Structure of a proposed new peptide incorporating a bifunctional PEG spacer 
between the Arg residue and the peptide sequence. 
 
PEG units have been shown to improve the solubility of peptides and proteins,124 
particularly, hydrophobic peptides, where the hydrophilic PEG is likely to reduce the 
lipophilicity of the peptide, thereby increasing its solubility in an aqueous 
H
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environment. Furthermore, various lengths of PEG spacers developed for both solid 
and liquid phase synthesis are available commercially, which allows tailoring of the 
distance between the Arg residue and the peptide. 
 
The large number of PEG linkers incorporating different lengths, degrees of 
branching and chemical design available commercially means that there is likely to 
be a PEG linker suited to this application, although the quality of PEG linkers from 
commercial suppliers can be variable,125 and self-synthesis may be preferred. 
 
2) To Use Appropriate Type(s) of Assays: 
The ELISA chosen for initial testing of peptidic inhibitors requires large amounts of 
materials including both proteins and peptidic inhibitors and includes time-
consuming and labour-intensive procedures. Consequently, it would be advantageous 
to develop new assays. To this end, an electrochemiluminescence (ECL) base assay 
is being considered. ECL as suggested in the name, detects signal from an 
electrochemiluminescent reaction (Figure 37).126-128 
 
Figure 37: Mechanism of detection via ECL (Figure is adapted from references 126-128). 
 
ECL requires three key components: 1) a charged species capable of generating 
chemiluminescence to label the immobilised protein (e.g. #Fc"RI). Ruthenium tris-
(2,2’-bipyridyl) dichloride, which chelates to protein as [Ru(bpy)3]2+, is usually a 
good choice. 2) A detection buffer containing tripropylamine (TPA), which is used 
as a co-oxidant. 3) An analyser used to detect electrochemiluminescence that 
contains an in-built electrode. The electrode oxidises Ru2+ to Ru3+, and TPA to 
TPA+!, which deprotonates to TPA!. This radical species TPA! excites Ru3+ to Ru2+*, 
which generates luminephore at 620 nm. 
[Ru(bpy)3]2+[Ru(bpy)3]3+
[Ru(bpy)3]2+*
TPATPA+•
TPA•H
+
Photo at
620 nm
e- e-Electrode
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To illustrate the key difference between ELISA and ECL, the last steps where 
detectable signals are generated are compared in the figure below (Figure 38). 
  
Figure 38: Comparison of the last step in both ELISA and ECL assays. 
 
In contrast to ELISA, ECL does not require multi-washing steps, this cuts down the 
amount of time-consumed to perform the assay. It also uses smaller amount of 
IgE:Fc, #Fc"RI and peptidic inhibitors.  
 
All types of assay techniques used for testing peptidic inhibitors discussed here have 
advantages and disadvantages (Table 10). 
Assay Type Advantages Disadvantages 
ELISA 
• Easy to perform; 
• Highly sensitive. 
• Multi-washing steps; 
• Identify the binding partner ! 
• Measure the release of 
inflammatory mediators ! 
ECL 
• Highly sensitive; 
• Conc. range down to pM; 
• No multi-washing steps; 
• Identify the binding partner ! 
• Measure the release of 
inflammatory mediators ! 
SPR 
• Real time IC50 
measurements; 
• Able to identify binding 
partner. 
• Too sensitive in solution; 
• The sensor surface deteriorates 
with re-use; 
• Measure the release of 
inflammatory mediators ! 
!-Hexos-
aminidase 
• Homogeneous; 
• Real time cell 
sensitisation & activation. 
• Use of cultured cells; 
• Time consuming; 
• Danger of contamination; 
• Measure for direct binding ! 
 
Table 10: Advantages and disadvantages of the four assay techniques discussed. 
 
The choice of immunoassay for the development of inhibitors should be a 
combination of a few different types of assays, not just one single type. ECL is easy 
to perform, so may be a good candidate as a front line assay to identify lead 
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compounds. SPR is good for identifying the protein partner of the inhibitor, so it 
could be used to eliminate compounds, which binds non-specifically. The !-
hexosaminidase release assay is a functional assay, which can be used to measure 
whether inflammatory mediator release is actually reduced, or any potential risk 
towards anaphylaxis. 
 
3) To Improve the Activity of Peptidic Inhibitors at Key Residues: 
As mentioned in the introduction, PPIs generally have flat binding surfaces. 
However, many studies have highlighted the frequent occurrence of Trp, Tyr and 
Arg residues in hotspot and core regions, which reflects the ability of their side 
chains to participate in hydrophobic interactions, van der Waals interactions, 
hydrogen bonding and polar !-interactions.10,11,56 As identified by the SAR studies on 
BM1149-Am, both Tyr3 and Tyr4 are within the key epitope. Therefore, 
modifications of either or both of these Tyr residues into biaryl functionality could 
allow the peptide to fit deeper into its binding pocket (Figure 39). 
 
Figure 39: Structures of proposed biaryl derivatives of [Y8A] BM1149-Am 26. 
 
However, incorporation of a biaryl unit into [Y8A] BM1149-Am 26 may exacerbate 
the solubility issues, which prevent it currently being analysed in SPR and !-
hexosaminidase release assays. If the modified peptide is more hydrophobic, and/or 
allows for more *-* interactions, then this could increase aggregations between 
peptide molecules and decrease solubility. Therefore, trial and error will play a part 
in developing improved binders via this approach.  
 
Nevertheless, modification of residues like Phe and Tyr into biaryl derivatives is of 
great interest. A study towards modification of this type of residue via germylation is 
discussed in Chapter 2. 
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Chapter 2. Towards Aryl Germane-Based Synthetic 
Mutagenesis of Peptides 
2.1. Introduction 
2.1.1. Synthetic Mutagenesis of Aromatic Amino Acids 
Peptides are natural messenger molecules of the human body and hence excellent 
lead compounds for the initiation of drug discovery research. However, the use of 
unmodified native peptides as therapeutic drugs has been hindered by their 
unfavourable pharmacological properties, such as poor stability and poor oral 
availability.105 
 
Many strategies for the incorporation of chemical modifications into peptide 
scaffolds have been used to install conformational constraints that could improve 
oral absorption, metabolic stability or functional specificity. Among the different 
strategies, manipulations of the side-chains of peptide sequences are being 
increasingly investigated. Synthetic mutagenesis of aromatic amino acids (AAAs), in 
particular phenylalanine (Phe) and tyrosine (Tyr), to introduce biaryl functionality 
are of great interest as many studies have highlighted these two AAAs as being 
important structural elements in protein-protein interactions (PPI). 
 
Thirty years ago, Evans et al. introduced the concept of ‘privileged structures’,129 the 
idea being that some generic scaffolds are preferred substructures for binding to very 
different proteins. Using NMR-based screening, two independent studies led by 
Fesik130 and Krimm131 both showed that the biaryl scaffold is such a preferred 
structure, which can fit into a wide variety of protein binding pockets. It was 
hypothesised that this is not only because of the biaryl group’s aromatic and 
hydrophobic nature but also its size and shape that facilitates binding. In fact, biaryl 
motifs are often found in drugs in a wide number of therapeutic areas (Figure 
40).17,132,133 
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Flurbiprofen®134 
Non-Steroidal  
Anti-Inflammatory Drug 
 
Valsartan®135 
Antihypertensive Drug 
Brequinar®132 
Immunosuppressant 
 
A-349821133 
Histamine H3 Receptor Antagonist 
 
ABT-73717 
Bcl-2, Bcl-XL and Bcl-w Inhibitor 
Figure 40: Biaryl motifs in marketed drugs or drug candidates. 
 
2.1.2. Synthetic Approaches towards Mutagenesis 
There are two main synthetic mutagenesis approaches to incorporate a biaryl motif 
into a peptide side-chain: one being the building block approach – i.e. the use of 
modified AAAs as building blocks for peptide synthesis; the other being the 
postsynthetic approach – i.e. the modification of AAAs within a preformed peptide 
sequence (Scheme 3). 
 
Scheme 3: Two synthetic approaches to incorporate biaryl motifs into peptides. 
 
The postsynthetic approach is considered a more convenient method than the 
building block approach as it can easily produce a library of compounds in a parallel 
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fashion. In this way, the modifications of peptides can avoid the use of preformed 
amino acid building blocks and a linear synthesis for every analogue, which can 
potentially speed up structural-activity relationship (SAR) studies in peptide 
chemistry. However, the building block approach is still widely in use as not all 
structures are amenable to postsynthetic approaches, mainly due to the instability of 
peptides and proteins being modified in organic chemical reactions. 
 
Some recent literature examples where modifications of Phe and/or Tyr using 
postsynthetic approach are summarised below: 
1) Modifications on preformed peptides: 
Barluenga et al. reported the modifications of 4-iodophenylalaine (4-IPhe) and 3,5-
diiodotyrosine of side-chain unprotected peptides using the Suzuki-Miyaura cross-
coupling reaction. The best conditions used Pd(OAc)2 as catalyst, TPPTS as ligand, 
K3PO4 as base, and H2O as solvent at 50 °C for 3-24 h (Scheme 4).136  
 
Reagents and conditions: (i) IPy2BF4 (2.5 eq.), H2O; (ii) ArBF3K (5 eq.), Pd(OAc)2 (10 mol%), 
TPPTS (30 mol%), K3PO4 (15 eq.), H2O, 50 °C, 24 h. 
Scheme 4: Barluenga’s AAA modification on side-chain unprotected peptide in aqueous 
media.136 
 
The iodination and arylation of AAAs could also be achieved in a one-pot reaction. 
However, variable percentage conversions were observed for 4-IPhe containing 
peptides. In the case of 3,5-diiodotyrosine, both mono- and di-cross-coupling 
products were obtained.  
 
Fournier et al. developed a strategy for the modification of 4-IPhe on solid-phase 
supported peptides via the Suzuki-Miyaura cross-coupling reaction. The best results 
were obtained where Pd(PPh3)4 was used as catalyst, K3PO4 as base, and DMF as 
solvent at 50-80 °C for 20 h (Scheme 5).137  
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Reagents and conditions: (i) ArB(OH)2 (3 eq.), Pd(PPh3)4 or PdCl2(PPh3)2 (10 mol%), K3PO4 or 
Na2CO3 (3 eq.), DMF, 50-80 °C, 20 h. 
Scheme 5: Fournier’s AAA modification on solid phase supported peptides.137 
 
Various functionalised aryl, heteroaryl and alkenyl boronic acids were investigated, 
however, a high variability in the conversion rate was observed. An Fmoc-protecting 
group was not compatible with the reaction conditions, although reactive amino acids 
such as methionine (Met), cysteine (Cys), histidine (His) and tryptophan (Trp) were 
untouched. 
 
2) Modifications on proteins: 
Davis et al. developed an efficient catalyst for aqueous Suzuki-Miyaura cross-
coupling to aromatic functionalities on subtilisin Bacillus lentus mutant S156C 
protein. The reaction was carried out using preformed Pd-pyrimidine as catalyst in 
phosphate buffer (pH 8.0) at 37 oC for 30-60 min (Scheme 6).138 
 
Reagents and conditions: ArB(OH)2 (500 eq.), Pd-cat. (50 eq.), pH 8.0 phosphate, 37 °C, 30 min. 
Scheme 6: Davis’ modification of aromatic functionality on subtilisin Bacillus lentus mutant 
S156C protein.138 
 
The reaction conditions were first optimised on simple AAA derivatives such as 4-
iodophenylalanine and 3,5-diiodotyrosine as well as 4-iodobenzyl cysteine (Pic). 
Various boronic acid substrates were tested on the Pic-modified protein, with >95% 
conversions being achieved for all. 
 
Hamachi et al. reported mild aqueous conditions for the Suzuki coupling reaction to 
modify 4-iodophenylalanine on the WW domain of Pin1 protein. The best conditions 
found used Na2PdCl4 as reagent and glycerol as an additive at 40 °C for 18-20 h 
(Scheme 7).139 
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Reagents and conditions: ArB(OH)2 (3 eq.), Na2PdCl4 (1 eq.), glycerol (50% v/v), H2O, 40 °C, 
18-20 h. 
Scheme 7: Hamachi’s modification of aromatic functionality on WW domain of Pin1 Protein.139 
 
However, the exact reaction conditions seemed to be substrate specific; for the three 
proteins tested, different percentages of glycerol were required to give 65-90% yields 
calculated from HPLC peak areas. Only four aryl boronic acids were investigated in 
this study.  
 
As seen from the four examples above, the most widely employed approach to 
prepare biaryl AA motifs involves a Suzuki coupling strategy. However, none of the 
examples prepared the boron containing AAAs from their corresponding iodinated 
AAAs via Miyaura’s palladium catalysed borylation.140 This is largely due to issues 
regarding the compatibility of the reaction conditions required for borylation and AA 
chemistry. For example, racemisation of the #-carbon has been documented for both 
iodophenylalanine and iodotyrosine.141,142 Furthermore, some borylated AA 
derivatives produced have been shown to be difficult to purify and prone to 
degradation.142,143 
 
2.1.3. Biaryl Cross-Coupling Reactions 
The basis of biaryl AA formation comes from biaryl cross-coupling reactions. 
Transition metal catalysed cross-coupling reactions have been developed and applied 
to the synthesis of a wide range of biaryls for several decades. 
 
2.1.3.1. Fundamental Biaryl Cross-Coupling Reactions 
The Ullman reaction dates from 1901, when Ullmann reported the first biaryl 
formation. Two equivalents of aryl halide were treated with stoichiometric amounts 
of Cu at high temperature (>200 °C) to yield a symmetrical biaryl (Scheme 8).144  
 
Scheme 8: Biaryl formation via the Ullmann reaction.144 
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Unsymmetrical biaryl formation is possible under modified reaction conditions. 
However, there are several drawbacks: the product yields are usually dependent on 
the nature of substituents; excess amounts of one of the aryl halides is used in order 
to favour the unsymmetrical selectivity; and there are difficulties in product 
separation from the homocoupling by-product, the dehalogenation by-product, and 
excess aryl halide starting materials.145 
 
The Negishi reaction occurs between aryl halides and organozinc, aluminium and 
zirconium reagents. This cross-coupling reaction involves the use of Pd or Ni as 
catalyst (Scheme 9).146 
 
Scheme 9: Biaryl formation via the Negishi reaction.146 
 
The Negishi reaction has been applied frequently to solid-phase organic synthesis 
(SPOS). However, the formation of homocoupling and dehalogenation by-products 
from the reaction are often observed due to its complicated transmetalation step.147 
Additionally, the organozincs used are moisture sensitive. The combination of these 
two factors seriously limits the development of the Negishi reaction for AAA 
functionalisation.  
 
The Kumada-Corriu reaction involves direct cross-coupling between aryl halides 
and Grignard reagents. The reaction conditions are similar to those of the Negishi 
reaction, but avoid the additional step required to convert the Grignard reagents to 
organozinc compounds (Scheme 10).148,149  
 
Scheme 10: Biaryl formation via the Kumada-Corriu reaction.148,149 
 
However, the Grignard reagents are also moisture sensitive and have narrow 
functional group tolerance.  
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The Suzuki reaction is a cross-coupling reaction between aryl halides and 
organoboranes catalysed by Pd(0) species. (Scheme 11).150 
 
Scheme 11: Biaryl formation via the Suzuki reaction.150 
 
The Suzuki reaction is widely used because the organoborane starting materials are 
non-hazardous and many are commercially available. However, the major drawbacks 
of the Suzuki reaction are the homo-coupling products, which in many cases cause 
difficulties for purification of the desired products, and the preparation and 
purification of customised organoboranes for coupling purposes is often 
tedious.151,152 
 
The Stille reaction is the Pd-catalysed cross-coupling reaction between aryl halides 
and organostannanes (Scheme 12).153  
 
Scheme 12: Biaryl formation via the Stille reaction.153 
 
The advantage of this process lies in the stability of organostannanes to both 
moisture and air, its tolerance to various functional groups and its use in SPOS. 
However, due to organostannanes’ reactive nature, they are very labile towards 
strong nucleophiles and organolithium. Therefore, the organostannane functionality 
can only be installed immediately prior to the coupling step within a long synthetic 
route. Furthermore, the toxicity of organostannanes and tin-containing by-products 
often limits the Stille coupling from being used for the preparation of bioactive 
intermediates or proteins.154  
 
The Hiyama reaction is the Pd-catalysed cross-coupling reaction between aryl 
halides and organosilanes (Scheme 13).155  
 
Scheme 13: Biaryl formation via the Hiyama reaction.155 
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The Hiyama reaction can be regarded as a variant of the Stille reaction that utilises a 
non-toxic metal partner. However, due to organosilanes’ less reactive nature 
compared to organostannanes, tetravalent organosilanes are often resistant to 
transmetalation. Therefore, nucleophilic promoters like F- or OH- are invariably 
required to achieve the required reactivity.156  
 
2.1.3.2. Organogermanes in Biaryl Cross-Coupling Reactions 
Silicon (Si), germanium (Ge) and tin (Sn) are all group 14 elements. However, 
considerably less work has been reported on the formation of biaryls via cross-
coupling reactions with organogermanes compared to those of organosilanes and 
organostannanes (see above). This is probably because of two major reasons – the 
higher cost of Ge materials (due to Ge metal’s low abundance on the earth) and the 
lower reactivity of organogermanes. 
 
As listed below, Ge is situated in the group between Si and Sn in the periodic table. 
However, Ge is more electronegative than Si or Sn (Table 11).157 
Element 
(Group 14) Electron Configuration 
Electronegativity157 
(Pauling scale) 
C [He] 2s2 2p2 2.55 
Si [Ne] 3s2 3p2 1.90 
Ge [Ar] 3d10 4s2 4p2 2.01 
Sn [Kr] 4d10 5s2 5p2 1.96 
Pb [Xe] 5d10 6s2 6p2 2.33 
 
Table 11: Electron configurations and electronegativities of the group 14 elements. 
 
This is a result of d-block contraction (also known as scandide contraction), the 
effect of having a full shell of 3d electrons which cannot shield efficiently the 
increasing nuclear charge on the 4th period elements and in turn means that the outer 
valence electrons are more strongly attracted by the nucleus.158,159 Hence Ge’s 
relatively high electronegativity. In fact, Ge is the closest in electronegativity to C 
amongst the group 14 elements. Therefore, C-Ge bonds are less polarised than C-Si 
and C-Sn bonds, which is reflected in the low reactivity of organogermanes. 
 
On the other hand, the low polarity of C-Ge bonds also result in organogermanes 
having better stability towards strongly nucleophilic and basic conditions. This 
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means that organogermanes are more able to survive multistep chemical 
transformations than organosilanes or organostannanes. Combined with their low-
toxicity,160,161 organogermanes are therefore potentially attractive precursors for 
biaryl cross-coupling reactions. 
 
1) Literature Examples of Biaryl Cross-coupling via Organogermanes: 
In 1996, Kosugi et al. reported the first example of a Pd(0)-catalysed cross-coupling 
reaction using an organogermane and an aryl bromide to obtain a biaryl compound 
(Scheme 14).162  
 
Reagents and conditions: (i) Pd2(dba)3!CHCl3 (1 mol%), P(2-tol)3 (4 mol%), THF, 120 °C, 24 h. 
Scheme 14: Kosugi’s biaryl synthesis from phenylcarbagermatrane.162 
 
After heating at 120 °C for 24 h in a sealed glass ampoule, the reaction was complete 
and gave the desired product in 85% yield. It was suggested that the cross-coupling 
product was promoted by the transannular coordination of nitrogen to germanium, 
which rendered the germanium pre-activated to transmetalation. 
 
Since Kosugi’s biaryl synthesis from phenylgermane, milder cross-coupling 
conditions have been reported using various activating reagents. For example, 
Oshima et al. reported the use of TBAF (>4 eq.) in conjunction with aryl tri-(2-
furyl)germanes to yield a hypervalent organogermane species – [ArGe(OH)F]-, 
which participated in rapid transmetalation from germanium to palladium (Scheme 
15).163 
 
Reagents and conditions: (i) ArX (1.2 eq.), Pd2(dba)3!CHCl3 (1 mol%), P(2-furyl)3 (2 mol%),  
TBAF (4 eq.), NMP, 100 °C, 5-10 h. 
Scheme 15: Oshima’s biaryl synthesis from aryl tri-(2-furyl)germanes.163 
 
On the other hand, Fugami and Kosugi reported the use of NaOH (>8 eq.) in 
conjunction with aryl trichlorogermanes to yield again a hypervalent organogermane 
species – Nan[ArGe(OH)3+n] (n=1 or 2). It was hypothesised that the excess base 
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drove the reversible formation of the active hypervalent species to a certain extent 
(Scheme 16).164 
 
Reagents and conditions: (i) ArGeCl3 (1.2 eq.), Pd(OAc)2 (5 mol%), NaOH (9.6 eq.),  
1,4-dioxane/H2O, 100 °C, 0.5-1.5 h. 
Scheme 16: Fugami and Kosugi’s biaryl synthesis from aryl trichlorogermanes.164 
 
This type of biaryl cross-coupling reaction of organogemanes and aryl halides is now 
often referred to as the germyl-Stille cross-coupling reaction. 
 
2) Prior Work in Our Group on Biaryl Cross-Coupling Using Organogermanes: 
The germyl-Stille cross-coupling reaction has been intensively studied in our group 
for the past decade. Gripton (Spivey group, 1999-2004) found that alkyl(4-
tolyl)dichlorogermane was reactive for cross-coupling reactions whereas trialkyl(4-
tolyl)germane and dialkyl(4-tolyl)chlorogermane were unreactive (Scheme 17).165,166 
  
Reagents and conditions: (i) NaOH (6 eq.), THF, rt, 4 h; (ii) ArBr (1 eq.), Pd(OAc)2 (5 mol%),  
PPh3 (10 mol%), 66 °C, 24 h. 
Scheme 17: Gripton’s discovery of the effect of halogen substituents on germanium in cross-
coupling.165,166 
 
After some systematic investigation, optimisation of the reaction conditions was 
achieved. Gripton then explored the syntheses of various biaryls with isolated yields 
ranging from 28% to 79% (Scheme 18).165,166 
 
Reagents and conditions: Method A: (i) NaOH (6 eq.), THF, rt, 4 h; (ii) ArBr (1 eq.), Pd(OAc)2 (5 
mol%), PPh3 (10 mol%), 66 °C, 24 h; Method B: (i) KF (6 eq.), DMF, rt, 3 h; (ii) ArBr (1 eq.), 
PdCl2(MeCN)2 (5 mol%), dppp (5 mol%), 120 °C, 24 h. 
Scheme 18: Cross-coupling of arylalkyldichlorogermanes and aryl bromides.165,166  
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Hannah (Spivey group, 2002-2006) found that more electronegative atoms at Ge 
gave higher yields of cross-coupling products when comparing the reaction with 
dihydroxygermane to the reaction with a 1:1 mixture of difluoroalkylarylgermane 
and dichloroalkylarylgermane (Scheme 19).165,167 
 
Reagents and conditions: PdCl2(MeCN)2 (10 mol%), dppp (15 mol%), KF (6 eq.), DMF, 120 °C,  
16 h. 
Scheme 19: Hannah’s use of dihydroxy and difluoro germanes for cross-coupling.165,167 
 
Consequently, a photooxidation process was developed by Hannah to access 
difluorogermanes. The photooxidation process could not only be used with the 
ethoxy ethyl ether germyl linker, but was also compatible with a fluorous-tagged 
germyl linker although the yields of final products were poor. Hannah also found that 
this difluorogermane could not be purified by chromatography, but could be directly 
subjected to the cross-coupling reaction (Scheme 20).165,167 
 
Reagents and conditions: (i) h+, Pyrex tube, Cu(BF4)2 (2 eq.), MeOH/MeCN (3:1), rt, 40 min; (ii) 
ArBr (1.1 eq.), PdCl2(MeCN)2 (10 mol%), dppp (15 mol%), KF (6.7 eq.), DMF, 120 °C, 12 h. 
Scheme 20: Hannah's 'one-pot' photooxidation and cross-coupling reaction.165,167 
 
Tseng (Spivey group, 2005-2009) then optimised the reaction conditions to give an 
overall yield of 96% over the two-step photoactivation/cross-coupling process. The 
new reaction conditions used CuI as a co-catalyst to enhance the rate of reaction 
(Scheme 21).165,168 
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Reagents and conditions: (i) h+, Pyrex tube, Cu(BF4)2 (2 (?4 eq.), MeOH/MeCN (3:1), 2 h; (ii) ArBr 
(1 eq.), PdCl2(MeCN)2 (10 mol%), P(2-Tol)3 (15 mol%), TBAF!3H2O (2.7 eq.), CuI (1 eq.), DMF, 
120 °C, 16 h. 
Scheme 21: Photoxoidation of bis(2-naphthylmethylgermane) followed by cross-coupling with 
3,5-bis(trifluoromethyl)bromobenzene.165,168 
 
In particular, the new conditions explored the ‘copper effect’, which was discovered 
by Marino to enhance the rate of Stille reactions.169 Tseng envisaged that the germyl-
Stille reaction could also be facilitated by an analogous copper effect.165,168 Indeed, 
the use of CuI as a co-catalyst significantly improved the product yield (96% cf. 42% 
shown in Scheme 20).  
 
Tseng then explored the scope of aryl substrates with both electron-donating and 
electron-withdrawing groups (Scheme 22).168,170  
 
Reagents and conditions: (i) h+, Pyrex tube, Cu(BF4)2 (2 (?4 eq.), MeOH/MeCN (3:1), 2 h; (ii) ArBr 
(1 eq.), PdCl2(MeCN)2 (10 mol%), P(2-Tol)3 (15 mol%), TBAF!3H2O (2.7 eq.), CuI (1 eq.), DMF, 
120 °C, 16 h. 
Scheme 22: Tseng’s photooxidation of fluorous-tagged arylgermanes followed by cross-coupling 
with aryl bromides.168,170 
 
These fluorous-tagged arylgermanes display exceptional levels of stability towards 
bases and nucleophiles and allow for purification using fluorous SPE,171-173 making 
them particularly attractive for parallel synthesis of high value biaryls as was 
exemplified by Tseng’s synthesis of the agrochemical fungicide Boscalid®.168,170 
 
2.1.4. Arylgermanes as Precursors for Biaryl Formation 
As outlined above, a robust method has been developed for Pd(0)-catalysed synthesis 
of biaryls using arylgermanes. Prior to the biaryl cross-coupling reactions, 
arylgermanes need to be prepared just as do the arylsilanes and arylstannanes used in 
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Hiyama and Stille cross-coupling reactions respectively. However, only a handful of 
literature reports detail methods for germylations of aryl substrates; this is in contrast 
to the vast number of silylation and stannylation procedures available. 
 
1) Germylation by Transmetalation: 
In 1925, Morgan and Drew reported the first synthesis of phenylgermanes where 
GeCl4 was treated with a large excess of Grignard reagent. Four different arylated 
products were identified with yields between 22 and 37% (Scheme 23).174 
 
Reagents and conditions: (i) PhMgBr (xs.), Et2O, ), 2 h. 
Scheme 23: Germylation via reaction of GeCl4 with a Grignard reagent.174 
 
In the same paper, a digermane compound – Ph3Ge-GePh3, was prepared by heating 
Ph3GeBr with excess ‘molecular’ Na (Scheme 24). 174 
 
Reagents and Conditions: (i) molecular Na (xs.), xylene (anhydrous), ), 2 h. 
Scheme 24: Digermane formation from a triarylgermanium bromide using ‘molecular’ Na.174 
 
In 1949, Johnson and Nebergall reported an improved procedure in the preparation 
of GePh4 from GeCl4, which resulted an isolated yield of 90% (Scheme 25).175 
 
Reagents and conditions: (i) PhLi (xs.), Et2O (anhydrous) " C6H12, reflux, 2 h. 
Scheme 25: Germylation from Ph3GeBr using phenyl lithium.175 
 
In 1960s, Eaborn summarised 3 different procedures, which had been reported for 
the synthesis of phenylgermanes: from aryl lithium compounds; from Grignard 
reagents; and by Wurtz-Fittig synthesis.176 All reactions gave moderate to good 
yields for various substituted aryls. However, it was in general difficult to control the 
chemoselectivity of germylation. Either various degrees of GePhn (n = 1-3) were 
identified or tetraphenylgermane was prepared. 
 
Ge
4
BrGe
3
Br2Ge
2
Br3Ge
GeCl4 + + +
Yield = 40% Yield = 25%
i
Ge Ge
BrGe
3
2 !
3 3
i
Yield = 24%
GeCl4
Gei
Yield = 90%
4
Chapter 2 
 57 
As described above, classically, arylgermanes have been synthesised from 
corresponding aryl halide via aryl lithium compounds or the Grignard reagents. This 
method, however, is limited to arenes, which lack base-sensitive functional groups, 
which is clearly not suitable for AAAs. 
 
2) Pd-catalysed Germylation: 
When developing a germylation process that can be applied to AAA modifications to 
biaryl functionalities, the formation of aryllithium/Grignard reagents can be difficult 
for certain classes of aromatic compound because of self-condensation, the presence 
of reactive functional groups or the possibility of racemisation/epimerisation. This 
limits the choice of aromatic library precursor and hence the range of the consequent 
solid phase syntheses. Therefore, transition-metal-catalysed conditions are favoured. 
 
In 1976, Eaborn reported the first Pd(0)-catalysed germylation of digermane and aryl 
halides. At an elevated temperature (140-180 °C) after 90 h, desired ArGeEt3 was 
obtained in 28-35% yield along with a substantial amount of biaryls as 
homocoupling products (Scheme 26).177 
 
Reagents and conditions: (i) Pd(PPh3)4 (0.6 mol%), mesitylene/toluene, sealed ampoule, 140-180 °C, 
90 h. 
Scheme 26: The first Pd(0)-catalysed germylation reaction, as reported by Eaborn.177 
 
In 2002, Oshima et al. reported the Pd(0)-catalysed cross-coupling reaction of 
germanium hydride and aryl halides. Mild reaction conditions were explored in this 
case, where DMF was used as solvent at rt and the reactions mostly completed 
within 2 h (Scheme 27).163 
 
Reagents and conditions: (i) ArI (1.2 eq.), Pd(OAc)2 (5 mol%), dppf (5 mol%), Cs2CO3 (1.1 eq.), 
DMF, rt. 
Scheme 27: Germylation with tri-(2-furyl)germane by Oshima.163 
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Oshima’s study into the electronic nature of tri(2-furyl)germane indicates that the 
germyl hydride is particularly acidic in this system, which leads to the formation of 
the trifuryl germyl anion and consequently successful germylation. However, the 
formation of a trialkylgermyl anion is less favoured under the same conditions, 
which suggests the uniqueness of the tri(2-furyl)germane substrates (see section 
2.1.5.2 for more details). 
 
3) Prior Work in Our Group on Germylation: 
The germylation of aryl halides has also been studied by previous members of the 
Spivey group. Jones (Spivey group, 2000-2004) developed a method for the Pd-
catalysed germylation of aryl iodide with a germyl hydride linker.178 Jones’ 
conditions for the germylation of 4-iodoanisole with germyl hydride were adapted 
from the silylation conditions of DeShong179 (Scheme 28). 
  
Reagents and conditions: (i) ArI (0.5 eq.), Pd2dba3 (5 mol%), P(tBu2)biph (20 mol%), iPr2NEt (3 eq.), 
NMP, rt, 16 h. 
Scheme 28: Jones' germylation conditions using a germyl hydride.178 
 
After a screen of catalysts, ligands, bases and solvents, Jones found that the best 
conditions were Pd2dba3 as catalyst, P(tBu)2biph or P(o-Tol)3 as ligand and iPr2NEt 
or Et3N as the base in enolisable solvents (i.e. NMP or DMA). However, the scope of 
germylation was restricted to electron rich aryl iodides; aryl bromides did not give 
any product. 
 
In an attempt to improve the germylation conditions, Martin (Spivey Group, 2004-
2008)180 adapted the silylation conditions of Yamanoi181 where Pd(tBu3P)2 was used 
as catalyst and K3PO4 as additive. Due to the high cost of Pd(tBu3P)2, an in situ 
version of Pd(tBu3P)2 was prepared by mixing Pd2dba3 and P(tBu)3 following Fu’s 
procedures182 (Scheme 29).  
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Reagents and conditions: (i) GeH (2 eq.), Pd2dba3 (1.5 mol%), P(tBu)3 (6 mol%), K3PO4 (3 eq.), 
NMP, rt, 19 h. 
Scheme 29: Martin's germylation conditions using a germyl hydride.180 
 
In Martin’s case, phenyl nonaflate was chosen as reaction partner due to its high 
stability and reactivity over the triflate equivalent.183,184 However, the conditions 
generated a mixture of products with an overall yield of 35%. But the same 
conditions were repeated with aryl iodides and the product yields were comparable to 
those of Jones. Again the electron rich aryls gave better yields whilst aryl bromides 
showed no reaction. 
 
Although neither Jones’ nor Martin’s conditions were fully optimised for a range of 
aryl iodide substrates, they are transferrable to germyl hydride with a fluorous-tagged 
linker, Warren (Spivey group, 2007-2008) successfully employed Jones’ conditions 
for germylation reactions of 4-iodoanisole (Scheme 30).185 
 
Reagents and conditions: (i) ArI (0.5 eq.), Pd2dba3 (5 mol%), P(tBu2)biph (20 mol%), iPr2NEt (3 eq.), 
NMP, rt, 16 h. 
Scheme 30: Warren's germylation reactions of aryl iodide with fluorous-tagged germyl 
hydride.185 
 
However, an attempt to use the same conditions for germylation of a 4-
iodophenylalanine (4-IPhe) derivative gave only starting materials back (Scheme 
31). 
 
Reagents and conditions: (i) ArI (0.5 eq.), Pd2dba3 (5 mol%), P(tBu2)biph (20 mol%), iPr2NEt (3 eq.), 
NMP, rt, 16 h. 
Scheme 31: Warren's attempted of germylation of a 4-iodophenylalanine derivative with a 
fluorous-tagged germyl hydride.185 
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Pisaneschi (Spivey group, 2006-current) also attempted to transfer Jones’ conditions 
to a 6-iodo-DOPA (6-IDOPA) derivative but only starting materials were recovered 
(Scheme 32).186 
 
Reagents and conditions: (i) ArI (0.5 eq.), Pd2dba3 (5 mol%), P(tBu2)biph (20 mol%), iPr2NEt (3 eq.), 
NMP, rt, 16 h. 
Scheme 32: Pisaneschi's attempted of germylation of a 6-iodo-DOPA derivative with a germyl 
hydride.186 
 
Both Warren and Pisaneschi then went on to test Murata’s conditions, which were 
developed for Rh-catalysed silylations of aryl iodide.187 However, under these 
conditions only traces of the desired products were identified by MS. Yamanoi and 
Nishihara’s conditions developed for Rh-catalysed silylation of aryl iodides188,189 and 
Oshima’s conditions developed for Pd-catalysed germylation of aryl iodides with tri-
(2-furyl)germane163 were also tested by Pisaneschi with no improvement in outcome 
(Scheme 33). 
  
Reagents and Conditions: Method A (Murata): R3GeH (2 eq.), Rh(acac)(cod) or 
[Rh(cod)(MeCN)2]BF4 (3 mol%), DABCO (5 eq.), DMF, rt-80 oC, 16 h; Method B (Yamanoi and 
Nishihara): R3GeH (1 eq.), ArI (0.5 eq.), [Rh(COD)2]BF4 (5 mol%), K3PO4 (1.5 eq.), NMP, rt, 2-7 d; 
Method C (Oshima): R3GeH (1 eq.), Pd(OAc)2 (5 mol%), dppf (5 mol%), Cs2CO3 (1.1 eq.), DMF, rt, 
16 h. 
Scheme 33: Warren's185 and Pisaneschi's186 attempts at germylation using Murata's, Yamanoi 
and Nishihara's, and Oshima's conditions. 
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Key findings from these investigations using germyl hydrides are summarised below 
(Table 12). 
Entry 
Key Findings 
Conditions Adapted 
  
Jones178 
• e-rich aryl " 
• ArI " 
• ArBr ! 
-- 
DeShong179 
+ degassed NMP 
Martin180 
• e-rich aryl " 
• ArI " 
• ArBr ! 
• ArNf ! 
-- Yamanoi181 
Warren185 -- 
• e-rich " 
• ArI " 
• I-Phe ! 
Jones178 
Murata187 
Pisaneschi186 • I-DOPA ! -- 
Jones178 
Murata187 
Yamanoi & 
Nishihara188,189 
Oshima163 
 
Jones: Aryl iodide (0.5 eq.), Pd2dba3 (5 mol%), P(tBu2)biph (20 mol%), iPr2NEt (3 eq.), NMP, rt, 16 
h; Martin: GeH (2 eq.), Pd2dba3 (1.5 mol%), P(tBu)3 (6 mol%), K3PO4 (3 eq.), NMP, rt, 19 h; Murata: 
GeH (2 eq.), Rh(acac)(cod) or [Rh(cod)(MeCN)2]BF4 (3 mol%), DABCO (5 eq.), DMF, rt-80 oC, 16 
h; Yamanoi and Nishihara: ArI (0.5 eq.), [Rh(COD)2]BF4 (5 mol%), K3PO4 (1.5 eq.), NMP, rt, 2-7 d; 
Oshima: Pd(OAc)2 (5 mol%), dppf (5 mol%), Cs2CO3 (1.1 eq.), DMF, rt, 16 h. 
Table 12: Germylations of aryl derivatives by previous group members.  
(‘"’ = reaction proceeded; ‘!’ = no reaction observed; ‘--‘ = no reaction attempted) 
 
Jones’ original conditions were compatible with both the ethoxy ethyl ether germyl 
hydride and the fluorous-tagged germyl hydride and gave reproducible results. 
However, these conditions worked better with electron-rich aryl iodides than 
electron-deficient ones. Also, with more complicated molecules such as 4-IPhe and 
6-IDOPA, no desired products were formed. In summary, there is as yet no standard 
germylation procedure that can be applied to a wide range of aryl substrates. 
 
2.1.5. Germyl Hydrides vs Bimetallogermanes as Germylation Precursors 
The afore mentioned research focussed on the use of germyl hydrides as germylation 
precursors. To compare this with the analogous silylation and stannylation reactions, 
O
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Chapter 2 
 62 
silyl hydrides and stannyl hydrides are not the only precursors; both bimetallosilanes 
and bimetallostannanes respectively have been frequently reported in the literature. 
These bimetallo substrates include disilane,177,190-195 distannanes177,196,197 and silyl-
stannanes.196,198 It would therefore seem plausible that bimetallogermanes would 
afford an alternative route to Ge-Ar bond formation. 
 
Germylation using bimetallogermanes is less well-studied, and very few examples 
have been reported with the use of digermanes.177,199 But due to the high cost of 
germanium starting materials,200 the use of digermane substrates in germylation 
reactions is not economical since half the reagent is not coupled. Therefore, a hetero-
bimetallogermane species would be preferred (Figure 41). 
 
Figure 41: The structure of a hetero-bimetallogermane for potential germylation of aryl 
substrates. 
 
Clearly, for the germylation of aryl substrates, the germyl portion of the molecule 
would need to be readily transmetalated whereas the other metal portion would need 
to act as a non-transferrable or ‘dummy’ partner. 
 
2.1.5.1. The Proposed Catalytic Cycle 
As a group 14 element situated in-between Si and Sn, a generic catalytic cycle for 
palladium catalysed aryl germylation could be envisaged to resemble those 
postulated for silylation and stannylation (Figure 42).153 
 
Figure 42: A proposed catalytic cycle for aryl germylation using digermanes or germyl 
hydrides.  
(Cycle A is the proposed route for the formation of by-product; Cycle B is the propose route for the 
formation of desired product) 
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The standard catalytic cycle involves: 1) insertion of the active zerovalent palladium 
[Pd(0)] oxidatively into the aryl-halogen bond; 2) the resultant Pd(II) species 
undergoing transmetalation with the germyl hydride or the bimetallogermane; and 
then 3) reductive elimination releasing the aryl germane as the desired product, 
which regenerates Pd(0) to the catalytic cycle. Transmetalation is usually considered 
as the rate determining step among these three key steps.  
 
As drawn in the catalytic cycle above, there are two ‘transmetalation’ possibilities, 
cycle B results in formation of a germanium-aryl bond; whereas cycle A could result 
in either transmetalation of the ‘dummy’ metal partner or reduction of the aryl halide 
to the corresponding hydrocarbon as side-product depending whether a 
bimetallogermane or a germyl hydride was employed respectively. Therefore, 
selective transmetalation is important no matter whether bimetallogermane or germyl 
hydride is involved. 
 
Many factors could contribute to the results of transmetalation, which could be 
divided into two major areas: 1) the reaction substrates, i.e. the nature of the metal 
centre, and the steric and electronic properties of the substituents attached to the 
metal; 2) the reaction conditions including the choice of catalysts, ligands, solvents, 
additives and bases. Due to the complexity of factors involving different reaction 
conditions, sections below are focused on the factors of reaction substrates, which in 
the case of germylation are the germyl hydride and the bimetallogermane. 
 
2.1.5.2. The Ge-H bond in germyl hydrides 
Comparing the electronegativities of the group 14 elements (C: 2.55; Si: 1.90; Ge: 
2.01; Sn: 1.96; Pb: 2.33) to that of hydrogen (H: 2.20) on Pauling’s scale, Si, Ge and 
Sn are all less electronegative than hydrogen.157 Therefore within Si-H, Ge-H and 
Sn-H bonds, the partial negative charge resides on hydrogen, i.e. M,+-H,-. Hence the 
silanes, germanes and stannanes are regarded as hydride donors. However, 
transmetalation is usually considered as taking place by nucleophilic attack by the 
metal unit in question on palladium; to selectively transfer the metal partner rather 
than hydride in this particular step when using a metal hydride, requires the M-H 
bond polarity to be M,--H,+. This can be achieved by modulating the electronic 
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properties of the substituents attached to the metal, as discovered by Oshima in the 
case of tri-(2-furyl)germane.163,201 
 
In an investigation of nucleophilic addition of tri(2-furyl)germane to aldehydes, 
Oshima and co-workers found that only a catalytic amount of potassium tert-
butoxide (tBuOK) was needed to abstract a proton from tri(2-furyl)germane.201 This 
showed that tri(2-furyl)germane did not behave like an R3Ge,+-H,- species, as often 
seen in the case of trialkylgermyl hydride, which requires a stoichiometric amount of 
butyllithium (BuLi) or even tert-butyllithium (tBuLi) in the presence of TMEDA in 
THF for deprotonation (Scheme 34).  
 
Reagents and conditions: (i) RCOH (1.2 eq.), tBuOK (10 mol%), THF, 0 °C, 10 min;  
(ii) tBuLi (1 eq.), TMEDA, THF. 
Scheme 34: Oshima’s deprotonation of tri-(2-furyl)germane using catalytic tBuOK.201 
 
After some DFT calculations on tri-(2-furyl)germane [(2-furyl)3GeH], 
triphenylgermane (Ph3GeH), trimethylgermane (Me3GeH) and their corresponding 
germyl anions, Oshima et al. found that the acidity of the proton is in the order of (2-
furyl)3GeH>Ph3GeH>Me3GeH.201 This suggested that the furyl group has an 
electron-withdrawing character, which resulted in the Ge-H of tri-(2-furyl)germane 
being the most protic among all. This electron-withdrawing character of tri-(2-
furyl)germane could also be seen in the case of germylation of aryl halides described 
in section 2.1.4.163 
 
2.1.5.3. The Ge-M bond in hetero-bimetallogermane 
Comparing the electronegativities of group 14 elements,157 any hetero-
bimetallogermanes (silyl germanes or stannyl germanes) would have a polarised Ge-
M bond towards Ge, i.e. the partial negative charge resides on Ge (Table 13). 
Element (Electronegativity) 
Element (Electronegativity) 
Si (1.90) Ge (2.01) Sn (1.96) 
Si (1.90) Si-Si Si,+-Ge,- Si,+-Sn,- 
Ge (2.01) -- Ge-Ge Ge,--Sn,+ 
Sn (1.96) -- -- Sn-Sn 
 
Table 13: Hypothetical M-M' bond polarity according to elemental electronegativities.157 
R3GeH
ii R3GeLiO GeH3
+
nC5H11H
O i
O Ge3 nC5H11
O
cf.
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However, as mentioned in section 2.1.5.1, the factors affecting transmetalation of 
one metal over another in a hetero-bimetallo system also depend on both the steric 
and electronic properties of the substituents attached to that metal. Some literature 
reported hetero-bimetallo group 14 systems illustrate this: 
1) Reactions of aryl halides with silylstannanes: 
Eaborn and co-workers were the first to report a Pd(0)-catalysed silylation using a 
hetero-bimetallo group 14 system with an aryl halide.196 Arylsilane products were 
formed in the presence of Pd(PPh3)4 catalyst; no arylstannanes were observed 
(Scheme 35). 
 
Reagents and conditions: (i) ArBr (0.5 eq.), PdBr2(PPh3)2 (0.65 mol%), Toluene, 115 °C, 15 h. 
Scheme 35: Eaborn’s silylation using a stannyl silane substrate.196 
 
The outcome of reaction seems to contradict the bond polarity argument presented 
above, however, comparing the substituents of both metal centres in this reaction, the 
butyl (Bu) substituents of Sn are obviously much bulkier than the methyl (Me) 
substituents of Si, which could account for the exclusive silyl transmetalation here. 
 
One decade later, Shibasaki re-investigated the several selectivity of Pd(0)-catalysed 
transmetalation of silyl stannanes. In this procedure, a mixture of compounds was 
obtained including arylstannane, arylsilane, reduced aryl and biaryl products 
(Scheme 36).198 
 
Reagents and conditions: (i) PdCl2(PPh3)2 (1.3 mol%), HMPA, 80 °C, 5 h. 
Scheme 36: Shibasahi's reaction of a silylstannane with an aryl halide.198 
 
Although the arylstannane was obtained in a marginal excess to the arylsilane; the 
reduced aryl (28%) and biaryl (8%) were also generated as side-products. By 
protonolysis and reaction with the arylpalladium bromide respectively, the 
arylstannane was shown to be the precursor of both by-products. Therefore, the 
Bu3Sn SiMe3 +
Br
R
R = 4-Me
R = 4-Cl
R = 4-OMe
i Me3Si
R
Yield: 
60%
34%
50%
Br
COOBn
Bu3Sn SiMe3 +
i Bu3Sn
COOBn
Me3Si
COOBn
Yield = 36% Yield = 20%
+
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major product from this reaction was the arylstannane. This is in direct contrast to 
Eaborn’s results and demonstrates that the inherent polarity and steric demand of the 
hetero-bimetallo group 14 reagent is not the only factor influencing the 
transmetalation and that presumably to the solvent and ligands on palladium also 
play a decisive role. 
 
2) Reactions of allyl halides and acyl halides with bimetallogermanes: 
Although the germylation of aryl halides with hetero-bimetallogermanes has not 
been reported, the germylation of allyl halides and acyl halides with hetero-
bimetallogermanes has. 
 
In 1999, Nakano reported a Pd(0)-catalysed metallo-, regio- and stereoselective 
germylation of allyl halides with unsymmetrical silyl germanes. In all cases, the 
transmetalation process favoured allyl germanes with good yields (Scheme 37).202 
 
Reagents and conditions: (i) PhMe2GeSiMe3 (0.33-0.5 eq.), Pd(dba)2 (1-2 mol%), rt, 3-6 h. 
Scheme 37: Nakano's synthesis of allylgermanes using silyl germanes.202 
 
Nakano et al. then went on to investigate the germylations of allylic halides using 
stannyl-germanes. In all cases, allylgermane products were obtained in good yields 
in the presence of a Pd(0) catalyst (Scheme 38).203 
 
Reagents and conditions: (i) Et3GeSnBu3 (1 eq.), Pd2(dba)3•CHCl3 (1.5 mol%), rt, 17 h. 
Scheme 38: Nakano's synthesis of allygermanes using stannyl-germanes.203 
 
In contrast to the germylations using silyl germanes where allylsilanes were usually 
isolated in small amounts, allylgermanes were the exclusive products from stannyl-
germanes. Nakano anticipated the reason lies within the transmetalation step where 
the formation of the C-Ge bond is faster than that of the C-Sn bond. 
Cl GeMe2Ph SiMe3+
Yield = 70% Yield = 3%
Cl GeMe2Ph
Yield = 97% (E/Z = 95/5)
Cl PhMe2Ge
Yield = 82%Cl
GeMe2Ph
i
i
i
Br GeEt3
Yield = 83%
i
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Yamamoto studied the Pd(0)-catalysed reaction of unsymmetrical disilanes, 
digermanes and silyl germanes with benzoyl chloride to give acyl silanes/germanes 
(Scheme 39).204 
 
Reagents and conditions: (i) PhCOCl (2.2 eq.), [(-3-C3H5)PdCl]2 (5 mol%), P(OEt)3 (10 mol%),  
110 °C, 4.5-5.5 h. 
Scheme 39: Yamamoto's Pd-catalysed reaction of Si- and Ge-based bimetallo reagents with 
benzoyl chloride.204 
 
These results led Yamamoto to postulate a relative reactivity order for the different 
metal groups involved (Table 14).204 
Metal Groups PhMe2Ge-R Me3Ge-R PhMe2Si-R Me3Si-R 
Relative Rates 42.0 5.4 2.6 1.0 
 
Table 14: The relative reactivity towards transmetalation of silyl and germyl groups within 
group 14 bimetallo reagents as proposed by Yamamoto.204 
 
Yamamoto proposed that due to the electrophilic nature of the Pd(II) intermediate, 
the rate determining factor for the transmetalation step was the ability of the 
transferring metal centre to bear a partial negative charge, which influences its 
chance of bonding to palladium and consequently undergoing benzoylation. 
Unsurprisingly, the more electronegative germanium benzoylates faster than does 
silicon. An R group such as phenyl (Ph) can also stabilise a partial negative charge, 
and hence facilitate the transmetalation. 
 
In summary, all of the evidence above suggests that selective transmetalation of a 
hetero-bimetallogermane substrate with a ‘dummy’ metal partner should be possible.  
O
GeMe3
O
SiMe3
O
SiMe2Ph
O
SiMe3
O
GeMe3
O
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2.1.6. Aims and objectives: 
The overall aim of this part of the project was to develop a germylation protocol 
suitable as a new synthetic mutagenesis method for functionalisation of AAA 
derivatives to allow the resulting germyl-AAAs to be subsequently modified into 
libraries of biaryl AAs containing peptidic inhibitors (Scheme 40).  
 
Scheme 40: The overall plan to incorporate a germyl residue in a peptide sequence to build up a 
library of biaryl functionalised peptidic inhibitor. 
 
The main objectives were:  
Step 1: 
• To prepare suitable hetero-bimetallo germanes for this germylation 
procedure. In particular, it was planned to introduce ‘dummy’ metals 
possessing substituents of different bulkiness in order to investigate the 
effects of steric hindrance on rates of transmetalation; 
• To employ simple aryl halides to optimise the germylation conditions; 
• To transfer the optimised germylation conditions to a range of aryl substrates 
so as to map out the scope and limitations of the method; 
• To transfer the optimised germylation conditions to 4-iodophenylalanine and 
6-iodo-DOPA; 
Step 2: 
• To use SPPS to make a germyl residue containing a peptide, e.g. 
[Y8A]BM1149-Am at Tyr3 or Tyr4 (see section 1.3.2).  
Step 3: 
• To build up a library of biaryl incorporated peptides to allow more diversified 
SAR studies. 
 
COOHH2N
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H
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Peptide Sequence
O H
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O
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R3Ge-SiR'3
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I
COOHH2N
R3Ge
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2.1.7. Choice of Starting Points for the Germylation Reactions 
1) The Germyl Linker: 
Both an ethoxy ethyl ether germyl linker and a fluorous-tagged germyl linker have 
been used extensively in the group. The ethoxy ethyl ether germyl linker was used to 
model a PEG-type resin bound linker, whereas the fluorous-tagged germyl linker was 
designed to be employed directly in fluorous synthesis (Figure 43). 
 
Figure 43: Germyl linkers used previously in the Spivey group. 
 
Germylated aryl compounds were envisaged to be developed as precursors towards 
modification of AAAs like Phe and Tyr to give biaryl derivatives. Modification of 
AAAs in solution phase as well as in solid phase would be desirable. However, to aid 
development, solution conditions were explored initially, using the fluorous-tagged 
germyl linker rather than the ethoxy ethyl ether germyl linker.  
 
It was also decided to initially explore the use of a silyl rather than a stannyl 
‘dummy’ partner because of the toxicity of stannyl compounds. Hence, the initial 
bimetallogermane substrate for the study of germylation of aryl iodides was 
envisioned to be a silyl germane (Figure 44). 
 
Figure 44: Silyl germane substrate proposed for the germylation of aryl iodides. 
 
The synthesis of silyl germanes is known in the literature and is usually performed 
by addition of silyl halide to a lithiated germane (R3GeLi).205-208 This method had 
been used previously by Jones for the syntheses of four ethoxyl ethyl ether silyl 
germanes (Scheme 41).178 
 
Reagents and conditions: (i) tBuLi (3 eq.), TMEDA (3.3 eq.), THF, -10 °C, 1 h; 
(ii) RCl (3 eq.), rt, 16 h. 
Scheme 41: Jones' syntheses of silyl germanes.178 
O
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2) The Model Aryl Substrate: 
It was decided to employ 4-iodotoluene as a model system for 4-IPhe and 1-
iodoveratrole and 4-iodoanisole as models for 6-IDOPA in the studies (Figure 45). 
 
Figure 45: 4-Iodophenylalanine and its model structure 4-iodotoluene; 6-iodo-DOPA and its 
model structure 1-iodoveratrole or 4-iodoanisole. 
 
It was also decided to employ aryl iodides in the model system, not aryl chlorides or 
aryl bromides. This is due to two reasons: 1) aryl chlorides are generally unreactive 
towards any cross-coupling reactions, activation of aryl chlorides209 is usually 
required; 2) aryl bromides has been reported as unreactive in the literature with 
group 14 metal hydrides.163,181,210 Jones178 and Martin180 also observed no formation 
of desired product when aryl bromides were investigated in their studies. 
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2.2. Results and Discussions 
2.2.1. Synthesis of Silyl Germane 
The first priority was to synthesise the silyl germane precursor. Before transferring 
Jones’ conditions (see section 2.1.7 above) to fluorous-tagged germyl hydride, the 
germyl hydride 42 needed to be synthesised following the route developed by 
Hannah and Tseng (Scheme 42).167,168 
 
Scheme 42: Hannah and Tseng’s synthetic route towards germyl hydride 42.167,168 
 
The detailed syntheses of all intermediates are described in sections 2.2.1.1-2.2.1.5. 
 
2.2.1.1. Synthesis of trichlorogermane 
The first key intermediate in the overall synthesis towards germyl hydride 42 is 
trichlorogermane 37. This was prepared from commercially available 
germanium(IV) chloride 35 in 2 steps (Scheme 43).167 
 
Reagents and conditions: (i) TMDS (1 eq.), 1,4-dioxane, 100 °C, 3 h;  
(ii) 1H,1H,2H,2H-perfluorodecyl iodide (1 eq.), 1,4-dioxane, 150 °C, 24 h. 
Scheme 43: Synthesis of trichlorogermane 37 from commercially available germanium(IV) 
chloride 35 in 2 steps. 
 
Firstly, a solution of germanium(IV) chloride 35 and tetramethyldisiloxane (TMDS) 
was heated to 100 °C in 1,4-dioxane for 3 h to yield germanium(II) chloride!1,4-
dioxane 36. This dichlorogermylene(II) complex 36 was then treated with 1H2,2H2-
perfluorodecyl iodide. Upon heating for a further 24 h, insertion of 
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dichlorogermylene into the carbon-iodine bond occurred readily and afforded the 
desired trichlorogermane product 37 in 91% yield. 
 
2.2.1.2. Synthesis of dichlorogermane 
The second key intermediate in the overall synthesis towards germyl hydride 42 is 
dichlorogermane 39. This was prepared from trichlorogermane 37 in 2 steps (Scheme 
44).167 
 
Reagents and conditions: (i) 4-bromoanisole (5 eq.), nBuLi (6 eq.), THF, -78 °C " rt, 16 h; 
(ii) conc. HCl (ex.), CH2Cl2, rt, 5 h. 
Scheme 44: Synthesis of dichlorogermane 39 from trichlorogermane 37.167 
 
Trichlorogermane 37 was treated with lithiated 4-bromoanisole at -78 °C to give the 
tris-4-anisylgermane 38, which on dissolution in conc. HCl gave dichlorogermane 
39. Both intermediates 38 and 39 were used in the following syntheses without 
further purification. 
 
To confirm the formation of these intermediates, a small portion of each was purified 
using Kugelrohr distillation. Analyses by 1H NMR spectroscopy and by MS were in 
agreement with the expected structures.167  
 
2.2.1.3. Synthesis of bis(naphthalen-2-ylmethyl)germane 
The next key step is the formation of bis(naphthalen-2-ylmethyl)germane 40 via a 
Grignard reaction. Bis(naphthalen-2-ylmethyl)germane 40 was synthesised by the 
reaction of crude dichlorogermane 39 with 2-naphthymethyl Grignard reagent, which 
was generated in situ from 2-bromomethylnaphthalene and magnesium turnings 
(Scheme 45).167  
 
Reagents and conditions: (i) Mg turnings (6 eq.), 2-bromomethylnaphthalene (5 eq.), Et2O, 0 °C " rt, 
2.5 h. 
Scheme 45: Synthesis of bis(naphthalen-2-ylmethyl)germane 40 from dichlorogermane 39.167 
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The reaction was monitored by TLC and found to be complete after 2.5 h. The 
desired product 40 was purified using flash chromatography (FC) to remove any 
excess reagent left after work-up and any anisole by-product carried through from 
previous steps and then passed through a fluorous SPE cartridge in small batches to 
remove bi-2-methylnaphthalene homocoupling by-product 43 (Figure 46). These 
purification steps afforded clean desired product 40 in 88% yield. 
 
Figure 46: Bi-2-methylnaphthalene 43 ' a homocoupling by-product from the Grignard 
reaction. 
 
Purification to remove the homocoupling by-product 43 was the time-consuming 
process for this reaction. It was found that purification of the crude material by FC 
chromatography alone could not remove by-product 43 because this by-product has 
the same Rf value as desired product 40. Therefore, further purification using a 
fluorous SPE (F-SPE) chromatography was required (50-100% v/v MeCN/H2O or 
30-70% v/v THF/H2O).168 Even after all these purification methods, not all of the by-
product 43 could be removed as determined by 1H NMR spectroscopic analysis, but 
a 99% purity of the desired product 40 could be obtained, which was determined by 
the ratio of proton peaks at , 3.28 ppm (CH2NP of by-product 43) and , 2.79 ppm 
(GeCH2NP of desired product 40) in the 1H NMR spectrum. 
 
2.2.1.4. Synthesis of germyl hydride 
Germyl hydride 42 was then synthesised from bis(naphthalen-2-ylmethyl)germane 
40 via bromogermane 41 in 2 steps (Scheme 46).168 
 
Reagents and conditions: (i) conc. HBr (ex.), CH2Cl2, rt, 19 h; (ii) LiEt3BH (1.5 eq.), THF, 0 °C " rt, 
16 h. 
Scheme 46: Synthesis of germyl hydride 42 from bis(naphthalen-2-ylmethyl)germane 40 via 
bromogermane intermediate 41.168 
 
Bromogermane 41 was obtained from bis(naphthalen-2-ylmethyl)germane 40 by 
vigorous stirring in CH2Cl2 and conc. HBr (48 wt%) at rt overnight. Purification to 
43
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remove the anisole by-product by Kugelrohr distillation afforded the desired product 
41 quantitatively. 
 
Addition of LiEt3BH to a solution of bromogermane 41 in THF afforded germyl 
hydride 42 after stirring at rt overnight. Purification of germyl hydride 42 by passing 
through a small plug of flash silica gave in the desired product 42 in 85% yield. 
 
2.2.1.5. Synthesis of Silyl Germane 
The first silyl germane selected for synthesis was TBS-germane 44. This compound 
was chosen as starting point due to the availability of TBS-Cl. Jones’ conditions 
were used for its preparation (Scheme 47).178 
 
Reagents and conditions: (i) TMEDA (3.3 eq.), tBuLi (3 eq.), THF, -78 °C, 10 min;  
(ii) TBSCl (3 eq.), THF, -78 °C " rt, 16 h. 
Scheme 47: Synthesis of silyl germane 44 from germyl hydride 42 using conditions developed by 
Jones.178 
 
Germyl hydride 42 was first deprotonated by tBuLi in THF at -78 °C. TBSCl was 
then added and the reaction mixture was allowed to warm up to rt slowly. The 
reaction was monitored by TLC and found to be complete after stirring over 16 h.  
 
Purification of crude silyl germane 44 gave the product with yields varying from 
38% to 55%. The moderate yields were believed to be due to the instability of the 
silyl germane 44 on silica gel during purification. However, addition of Et3N (1%) in 
the eluting solvent or replacing SiO2 with neutral Al2O3 did not help to improve the 
product yield. This issue was not further investigated at this stage. The optimisation 
of the synthesis of silyl germanes is addressed later in section 2.2.2.5. 
 
2.2.2. Germylation of Aryl Halides 
2.2.2.1. Conditions Previously Applied by Jones and Martin 
Before testing the germylation of aryl iodides with silyl germane 44 using conditions 
previously applied by members of the group, the authentic tolyl germane product 45 
was synthesised using a Grignard reaction analogous to that used for the synthesis of 
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bis(naphthalen-2-ylmethyl)germane 40.167,168 This authentic germyl toluene product 
45 was to be used in TLC analyses against reaction mixture to monitor the progress 
of reactions and 1H NMR spectroscopic analyses to verify the components in 
reaction mixtures (Scheme 48). 
 
Reagents and conditions: (i) Mg turnings (6 eq.), 4-bromotoluene (5 eq.), Et2O, rt, 16 h. 
Scheme 48: Synthesis of germyl toluene 45.167,168 
 
With the silyl germane precursor 44 and the authentic tolyl germane product 45 in 
hand, the conditions of Jones’ and Martin’s which were developed for germylation 
using germyl hydrides were tested (Table 15). 
 
Reagents and Conditions: Method A (Jones): 4-iodotoluene (1 eq.), Pd2(dba)3 (5 mol%), P(tBu)2diph 
(20 mol%), iPr2NEt (3 eq.), 1,4-dioxane;178 Method B (Martin): 4-iodotoluene (1 eq.), Pd2(dba)3 (1.5 
mol%), P(tBu)3 (6 mol%), K3PO4 (3 eq.), LiCl (3 eq.), 1,4-dioxane.180 
Entry Method F- (5 eq.) Temp Outcome 
1 A CsF rt S.M. recovered 
2 B KF rt S.M. recovered 
3 A CsF 100 °C S.M. recovered 
4 B KF 100 °C S.M. recovered 
5 A - 100 °C S.M. recovered 
6 B - 100 °C S.M. recovered 
 
Table 15: Attempted germylation of 4-iodotoluene with silyl germane 44 using Jones’ and 
Martin’s conditions.178,180  
(‘-‘ = no fluoride was added; ‘S.M.’ = starting material) 
 
Although the silyl component of the silyl germane substrate 44 was anticipated to act 
as a ‘dummy’ partner in the germylation of the iodotoluene, there is a possibility that 
the transmetalation would lead to the unwanted silylation (cf. the bimetallo catalytic 
cycle in section 2.1.5.1). As discussed in section 2.1.5.3, both Nakano and 
Yamamoto proved experimentally that the cross-coupling reactions using silyl 
germane substrates favoured the germame counterpart, but small proportions of silyl 
by-products (<10%) were isolated.202-204 Therefore, fluoride (F-) was introduced into 
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Jones’ and Martin’s conditions because it was hoped that F- would display better 
affinity for silicon than germanium,211 and by rendering the Si centre hypervalent 
make the Ge more susceptible to transmetalation. 
 
For the first set of reactions, CsF and KF were added into reactions using Jones’ and 
Martin’s conditions respectively (entries 1-2). However, only starting materials were 
recovered. For the second set of reactions, elevated reaction temperature was used 
along with addition of CsF or KF to encourage the rate of reaction under thermal 
conditions (entries 3-4). Again only starting materials were recovered. 
 
2.2.2.2. Analysis of Conditions Developed for Bimetallo Group 14 Compounds 
1) Summary of literature conditions developed for bimetallo group 14 compounds: 
Given the lack of success adopting conditions previously optimised in the group for 
germylation with germyl hydrides, it was decided to screen some literature 
conditions developed for silylations, germylations and stannylations using disilanes, 
digermanes and distannanes respectively. These conditions surveyed are summarised 
in Table 16.  
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Pd Source References R3M-MR3 Features 
Ph(PPh3)4 
Matsumoto190-
192 
Me3Si-SiMe3  • Sealed tube; 
• High reaction temperature; 
• Long reaction time. Eaborn177 
Me3Sn-SnMe3 
Bu3Sn-SnBu3 
Et3Ge-GeEt3 
Kosugi197 Bu3Sn-SnBu3 
• Low to moderate yields. 
Valliant212 
[Rf(CH2)2]3Sn-
Sn[(CH2)2Rf]3 
Goossen194 Me3Si-SiMe3 
• DMPU as solvent; 
• Different conditions for e-rich 
& e-deficient ArBr. 
PdCl2/PdBr2 
+ PPh3 or 
PO Lig.*  
Eaborn196 Me3Sn-SnMe3 • See details above 
Shibasaki198 Bu3SnSnMe3 
• HMPA as solvent; 
• Low yields; 
• R’ = CO2Bn only 
Shirakawa193 Me3Si-SiMe3 
• Different conditions for e-rich 
& e-deficient ArX (X = Cl, 
Br). 
Pd2dba3 
+ biph Lig.* 
Buchwald213 Me3Si-SiMe3 
• Moderate to high yields; 
• H2O as additive, i.e. not 
moisture sensitive; 
• Similar to Jones’ and Martin’s 
conditions. 
 
Table 16: A survey of published conditions developed for silylation, germylation and 
stannylation using bimetallo group 14 compounds. 
[*PO Lig. = (o-C6H4-OH)PPh2; biph Lig. = (biph)PCy2 or (Me2N-biph)PtBu2] 
 
A protocol, which would not require harsh experimental procedures and would be 
successful for a wide range of aryl halide substrates irrespective of electronic 
properties, would be ideal. Only Buchwald’s conditions appeared to meet these 
requirements albeit for silylation using Me3Si-SiMe3.213 
 
2) Attempted germylation using Buchwald’s conditions: 
Buchwald’s conditions were developed for the silylation of aryl chlorides with 
hexamethyldisilane.213 These conditions were employed for the germylation of 4-
iodotoluene with silyl germane 44 (Table 17). 
R3M MR3 +
X
R'
R3M
R'
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Reagents and conditions: (i) 4-iodotoluene (1eq.), Pd2(dba)3 (1.5 mol%), P(Cy)2diph (4.5 mol%),  
H2O (2 eq.), 1,4-dioxane.213 
Entry Base (5 eq.) Temp Outcome 
1 KF 100 °C  S.M. recovered 
2 KF rt S.M. recovered 
3 - 100 °C S.M. recovered 
 
Table 17: Attempted germylation of 4-iodotoluene with silyl germane 44 using Buchwald’s 
conditions.213 
(‘-’ = no fluoride was added; ‘S.M.’ = starting material) 
 
Buchwald et al. found that for electron-rich aryl chlorides, the combination of KF as 
base and 1,4-dioxane as solvent was the most suitable condition, whereas for 
electron-deficient systems, LiOAc was used as the base and DMF was the solvent.213 
In Buchwald’s silylation procedure, two equivalents of water were required to pre-
activate the catalyst.214 
 
The exact conditions reported by Buchwald for electron-rich aryl systems were 
applied (entry 1). Modifications of reaction conditions were also attempted (entries 
2-3). However, with or without KF, at rt or at elevated temperature, only starting 
materials were recovered. 
 
2.2.2.3. Conditions Previously Applied by Warren and Pisaneschi 
Yamanoi and Nishihara’s188,189 and Murata’s187 conditions were developed for the 
Rh-catalysed silylation of iodoarenes with silyl hydrides, whereas Oshima’s163 
conditions were reported for Pd(0)-catalysed germylation of aryl iodides with tri(2-
furyl)germane. When adapted by Warren185 and Pisaneschi186 for the germylation of 
4-iodophenylalanine (4-IPhe) and 6-iodo-DOPA (6-IDOPA) respectively with 
germyl hydride, only traces of desired products were identified by MS analyses and 
no optimisation studies were attempted.  
 
The conditions of Yamanoi and Nishihara, Murata and Oshima were therefore re-
investigated for the germylation of 4-iodotoluene with silyl germane 44 (Table 18). 
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Reagents and conditions: Method A (Yamanoi and Nishihara): 4-iodotoluene (0.5 eq.), [Rh(cod)2]BF4 
(5 mol%), K3PO4 (1.5 eq.), NMP;188,189 Method B (Murata): 4-iodotoluene (0.5 eq.), 
[Rh(cod)(MeCN)2]BF4 (1.5 mol%), DABCO (2.5 eq.), DMF;187 Method C (Oshima):  
4-iodotoluene (1.2 eq.), Pd(OAc)2 (5 mol%), dppf (5 mol%), Cs2CO3 (1.1 eq.), DMF.163 
Entry Cond. Temp T/d Outcome  
1 A rt 2-7 Trace 
2 B 80 °C 2-7 Trace 
3 C rt 2-7 9% (isolated yield) 
 
Table 18: Attempted germylation of 4-iodotoluene with silyl germane 44 using Yamanoi and 
Nishihara's, Murata's and Oshima's conditions.163,187-189 
 
All reactions were observed to form the desired product 45 although starting material 
44 remained, as judged by TLC analyses. For Yamanoi and Nishihara’s and Murata’s 
conditions, only trace amounts of the desired product 45 were identified by MS (EI) 
analyses. For Oshima’s conditions, both 1H NMR and MS (EI) analyses confirmed 
the presence of desired germyl toluene product 45. However, on separation using 
plate TLC (PLC) techniques, the isolated yield of the germyl toluene product 45 was 
only 9%. 
 
During separation of germyl toluene 45 from reaction mixture where Oshima’s 
conditions were applied, a digermoxane by-product 46 was identified as the major 
contributor to the mass loss (Figure 47). 
  
Figure 47: Digermoxane by-product 46 isolated from reaction mixture corresponding to entry 3, 
Table 18. 
 
Digermoxanes can be formed in quantitative yields by treatment of germyl hydrides 
with Pd(0)-catalysts when exposed to air (i.e. oxygen) within an hour even in the 
absence of an aqueous work-up.178 This suggested that the digermoxane 46 obtained 
from the germylation reactions using Oshima’s conditions, could be formed by 
reaction with oxygen in the reaction mixture. Alternatively, germanium hydroxide 
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could form on hydrolysis of the silyl group during work-up, which could then 
undergo dimerisation to form the digermoxane by-product 46. In order to avoid the 
possible formation of digermoxane 46 in the reaction process, all subsequent 
reactions used degassed solvents. 
 
2.2.2.4. Attempted Optimisation of Oshima’s Conditions 
1) Temperature and catalyst and ligand loading effects: 
Further optimisation of Oshima’s conditions was then undertaken. Approaches 
including elevating the reaction temperature and increasing the catalyst and ligand 
loading were explored first (Table 19). 
  
Reagents and conditions: (i) Pd(OAc)2, dppf, Cs2CO3 (1.1 eq.), DMF.163 
Entry Cat. (mol%) Lig. (mol%) Temp T/d Outcome  (Isolated Yield) 
1 5 5 rt 2-7 9% 
2 5 5 40 °C"100 °C 3-7 3% 
3 10 10 rt"100 °C 3-7 2% 
 
Table 19: Attempted optimisation of Oshima's conditions for germylation of 4-iodotoluene with 
silyl germane 44. 
[Grey shading (entry 1): the reaction using the original conditions of Oshima is listed again here for 
comparison (cf. entry 3 in Table 18)] 
 
Firstly, an elevated reaction temperature (40 °C) was introduced. However, no 
desired product was observed by TLC analysis for 3 days (entry 2). In a parallel 
reaction, double amount of catalyst and ligand loadings were employed while the 
reaction temperature was kept at rt. But no desired product 45 was observed by TLC 
analysis for 3 days (entry 3). Both reactions were then brought to 100 °C, but this 
encouraged the formation of the ditolyl by-product 47, which was confirmed by 1H 
NMR and MS (EI) analyses. Again, the digermoxane by-product 46 was isolated 
from both reactions. However, this by-product 46 was not initially observed by TLC 
analysis, or 1H NMR spectroscopic analysis of the crude reaction mixture before 
aqueous work-up. This suggested that majority of the silyl germane starting material 
44 was untouched during the reaction, which then formed digermoxane by-product 
46 upon aqueous work-up.  
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In order to improve upon the Oshima’s conditions, ligand and additive effects were 
investigated next. Ligand bite angle effects are often associated with the 
transmetalation step in metal-catalysed C-C and C-X bond formation.215,216 
Additives, which have high affinity to silicon, could facilitate the Si-Ge bond 
cleavage.217,218 
 
2) Ligand bite angle effects: 
Casey and Whiteker were the first to define the ‘natural bite angle’ concept as the 
preferred chelation angle determined by the ligand backbone.219 The calculation of 
the natural bite angle "n usually applies to a diphosphine ligand. It requires a 
hypothetical metal atom, which does not have any angular preferences, to fix the 
ligand from free movement (Figure 48). 
 
Figure 48: The natural bite angle is defined by the preferred angle of the diphosphine ligand 
backbone chelating to a hypothetical metal atom.219 
 
Two reviews by van Leeuwen et al. in the past decade discussed the ligand bite angle 
effects of diphosphine ligands in metal-catalysed C-C and C-X bond forming cross-
coupling reactions.215,216 Although no direct examples of silylation, germylation or 
stannylation were listed, the overall conclusion is that wider bite angle bidentate 
phosphine ligands are more readily able to associate and dissociate from the metal 
centre, thereby, enhancing all steps in the catalytic cycle particularly the 
transmetalation step. 
 
For example, in a study on the effect of the bite angle of chelating diphosphines on 
the activity and selectivity in the Pd-catalysed cross-coupling reaction of 2-
butylmagnesium chloride with bromobenzene, dppp, dppf, DPEphos and Xantphos 
were chosen for comparison (Table 20).220 
 
PR P R
!n
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 Reagents and conditions: (i) Pd(Cl2)(Lig) (1 mol%), 2-butylmagnesium chloride (2 eq.), Et2O, 20 °C. 
Ligand !n/deg. TOF Reaction Time/h % A % B % C 
dppp 91 nd 24 69 31 nd 
dppb 98 nd 8 51 25 nd 
dppf 96 79 2 95 2 3 
DPEphos 103 181 2 98 1 1 
Xantphos 111 24 16 41 19 40 
 
Table 20: van Leeuwen's study on the effect of the bite angle of chelating diphosphines on the 
activity and selectivity in the Pd-catalysed cross-coupling reaction of 2-butylmagnesium chloride 
with bromobenzene.220 
(‘nd’ = not determined; TOF = turnover frequency, determined after 5 min of reaction time; TOF unit: 
mol.(mol of Pd)-1.h-1) 
 
Among all ligands tested, DPEphos was suggested as having the optimum P-Pd-P 
angle of ca. 103o, which allows the reaction to complete in the fastest time with the 
highest yield.220 With a larger bite angle and more rigid structure, Xantphos is likely 
to distort the Pd coordination to tetrahedral, which decreased the rate of reaction. 
 
To find the optimum ligand for the germylation of 4-iodotoluene with silyl germane 
44, a ligand screen was investigated (Table 21). 
 
Reagents and conditions: (i) Pd(OAc)2 (5 mol%), Lig. (5 mol%), Cs2CO3 (1.1 eq.), DMF, rt.163 
Entry Cat. Lig. !n /deg T/d Outcome  
1 Pd(OAc)2 dppf 96 2-7 9% (isolated yield) 
2  PdCl2(dppf) - 96 3 Trace 
3 Pd(OAc)2 dppp 91 7 S.M. recovered 
4 PdCl2(dppp) - 91 7 S.M. recovered 
5 Pd(OAc)2 dppb 98 7 S.M. recovered 
6  Pd(OAc)2 DPEphos 101 3 Trace 
7  Pd(OAc)2 Xantphos 111 3 Trace 
 
Table 21: Ligand screen for the germylation of 4-iodotoluene with TBS germane 44 using 
Oshima's conditions.163 
[Grey shading (entry 1): the reaction using the original conditions of Oshima is listed again here for 
comparison (cf. entry 3 in Table 18); ‘-’ = no extra ligand was added; ‘S.M.’ = starting material) 
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No difference was observed whether a PdCl2(dppf) catalyst was used or a mixture of 
Pd(OAc)2 catalyst and dppf ligand was used (entries 1-2). This showed that a ligand-
complexed catalyst had no clear advantage over in situ complexed mixture of 
catalyst and ligand. 
 
When diphosphine ligands with smaller bite angles were applied, i.e. dppp, dppb and 
a ligand complexed Pd-catalyst [PdCl2(dppp)], no formation of either desired product 
45 or ditolyl by-product 47 was observed by TLC analysis; only starting materials 44 
were recovered after 7 days (entries 3-5). The diphosphine ligands with bigger bite 
angles were then investigated, i.e. Xantphos and its more flexible congener 
DPEphos, however, only trace amounts of desired product 45 were observed by MS 
(EI) and 1H NMR analyses (entries 6 & 7). This indicated that the bite angles of 
ligands have no significant effects on the germylation reaction of 4-iodotoluene with 
silyl germane 44. 
 
3) Additive effects: 
Organosilanes are often considered as unreactive cross-coupling partners due to the 
small electronegativity difference between C and Si.217,218 The use of fluoride as a 
nucleophilic promoter opened up possibilities for cross-coupling reactions with 
silicon-based compounds. Co-ordination of fluoride allows an access to penta-
coordinated ‘silicate’ species, which have enhanced polarisation at the C-Si bond, 
hence promoting the cross-coupling reaction. 
 
Over the past two decades, fluoride-free activation of organosilanes has been 
explored. One such idea was to structurally strain the organosilane to enhance the 
Lewis acidity of the silicon by means of a siletane (Figure 49).221,222 
 
Figure 49: Denmark’s proposed strain-release activated siletanes.221,222 
 
The siletane unit was anticipated to undergo facile conversion to a hypervalent 
intermediate due to partial release of angle strain when transforming from tetrahedral 
coordination to trigonal bipyramidal coordination upon binding to a fifth ligand. It 
Si
79o Nuc- Si
Nuc
79o
Si
109o
Si
90o
cf. cf.
Reduction of ring strain
Chapter 2 
 84 
turned out that although these compounds were active for cross-coupling, their 
activity actually arose because the ring was opened to give a silanol under the 
conditions of the reaction.223 This discovery then led onto a series of heteroatom-
substituted organosilanes including silanols, siloxanes, silyl ethers and 
pyridylsilanes, with the aim of polarising the C-Si bond.217,218 These groups render 
the Si centre susceptible to hypervalency in the presence of a nucleophilic additive 
such as fluoride or hydroxide and may also allow direct co-ordination to the Pd(II) 
immediately prior to transmetalation. 
 
Hiyama found that silver(I) oxide was a very efficient non-fluoride additive for the 
coupling of aryl silanol to a variety of aryl iodides (Figure 50).224,225 
 
Figure 50: Hiyama’s proposed nucleophilic activation of Si using Ag2O as the promoter.224,225 
 
Hiyama suggested that the oxygen atom of the Ag2O acts as a nucleophile and 
activates the silicon. Then the silver atom extracts the iodide from the Ar-Pd(II)-I 
species to give a more electrophilic and reactive palladium centre. 
 
To test the effects of additives in the germylation of 4-iodotoluene with silyl 
germane 44, KF, CsF and Ag2O were investigated as additives to promote the 
cleavage of the Ge-Si bond (Table 22). 
 
Reagents and conditions: (i) Pd(OAc)2 (5 mol%), dppf (5 mol%), Cs2CO3 (1.1 eq.), DMF, rt.163 
Entry Additive T/d Outcome 
1 KF 3 Trace 
2 CsF 3 Trace 
3 Ag2O 3 Trace 
 
Table 22: Additive investigation for the germylation of 4-iodotoluene with silyl germane 44 
using Oshima's conditions. 
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Addition of CsF, KF or Ag2O did not improve the formation of the desired product 
44 (entries 1-3). As in the ligand screen, only trace amounts of desired product 45 
were observed by analyses of MS (EI) and 1H NMR spectra. This indicated that the 
additives have no significant effects on this germylation reaction of 4-iodotoluene 
with silyl germane 44. 
 
2.2.2.5. Attempted Germylation with Three Different Silyl Germanes 
1) Optimisation of silyl germane formation from germyl hydride: 
It was thought that the bulkiness of silyl counterpart in the silyl germane substrate 
could have a deleterious impact on the rate of germylation. Therefore, sterically less 
bulky silyl groups (e.g. TES and TMS) were considered.  
 
Contemporaneous with the decision to investigate these silyl germane, Oshima et al. 
published a method of synthesis of tetraorganosilanes by substitution of 
chlorotriorganosilanes with Grignard reagents using AgNO3 as a catalyst.226 In a 
subsequent paper, Oshima reported a ZnCl2!TMEDA catalyst for the same 
purpose,227 which gave comparable results but required less catalytic loading 
(Scheme 49). 
  
Reagents and conditions: Method A: TolMgBr (1.5 eq.), AgNO3 (5 mol%), THF, 20 °C, 1.5 h;226 
Method B: TolMgBr (1.5 eq.), ZnCl2!TMEDA (1 mol%), THF or 1,4-dioxane, 20 °C, 1-1.5 h.227 
Scheme 49: Oshima's AgNO3 and ZnCl2!TMEDA catalysts for the syntheses for 
tetraorganosilanes.226,227  
 
From literature studies of organoargentates and organozincates, Oshima et al. 
proposed reaction mechanisms for both the AgNO3 and ZnCl2!TMEDA catalytic 
systems (Scheme 50).226,227  
Me2PhSi Cl +
BrMg Me2PhSiMethod A/B
AgNO3 (5 mol%):
ZnCl2•TMEDA (1 mol%):
Yield: 
 92%
 77% (in THF)
 84% (in 1,4-dioxane)
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Scheme 50: Oshima’s proposed mechanisms for the synthesis of tetraorganosilanes using 
AgNO3 and ZnCl2!TMEDA as catalysts.226,227 
 
In the case of AgNO3, the organoargentate species would initially be generated in 
situ from AgNO3 with two equivalents of the Grignard reagent. Then nucleophilic 
attack of the argentate complex upon the chlorosilane would afford a silicate 
intermediate with a Si-Ag(III) bond. Reductive elimination would hence yield the 
product. At the same time, with another equivalent of the Grignard reagent, the initial 
argentate species would be regenerated. 
 
In the case of ZnCl2!TMEDA, the proposed mechanism was not as clearly defined, 
but it was indicated that the organozincate species would first be generated in situ 
from ZnCl2 with three equivalents of the Grignard reagent. This organozincate 
species would then be the active species. The role of TMEDA was not commented 
upon. 
 
Considering the similarity between Ge-Si bonds and C-Si bonds and drawing 
inspiration from these two publications,226,227 AgNO3 and ZnCl2!TMEDA complex 
were evaluated as catalysts for the syntheses of silyl germanes 44, 48 and 49 (Table 
23). 
 
Reagents and conditions: (i) TMEDA (3.3 eq.), tBuLi (3 eq.), THF, -78 °C, 10 min; (ii) No catalyst or 
AgNO3 (5 mol%) or ZnCl2!TMEDA (5 mol%), TBSCl (3 eq.), THF, -78 °C " rt, 16 h.226,227 
3 ! ArMgX
ZnCl2
Ar3ZnMgX
Ar2Zn
R3SiCl
R3SiAr
+
MgClX
ArMgX
2 ! ArMgX
AgNO3
Ar2AgMgX
R3SiCl
Si
Ag
R
R
R
Cl
ArAr
ArAg
ArMgX
R3SiAr + MgClX
C8F17
Ge
SiR3
2-Np 2-Np
C8F17
Ge
2-Np 2-Np
H
i, ii
42 SiR3 = TBS 44
SiR3 = TES 48
SiR3 = TMS 49
Chapter 2 
 87 
Entry SiR3 No catalyst AgNO3 ZnCl2!TMEDA 
1 TBS 55% 72% -- 
2 TES -- 81% 83% 
3 TMS 30% by NMR 81% 83% 
 
Table 23: Syntheses of silyl germanes 44, 48 and 49 from germyl hydride 42 in comparison of 
the conditions developed by Jones178 and Oshima.80,81 
(‘--’ = reactions were not attempted) 
 
In order to allow direct comparison with the previous reactions, all crude reaction 
mixtures were purified through neutral Al2O3. Jones’ conditions were firstly applied 
to the synthesis of silyl germanes, only 55% of desired TBS germane 44 was isolated 
whilst only 30% of TMS germane 49 was formed with germyl hydride calculated 
based on 1H NMR spectroscopic analysis. It was then found that by using either 
AgNO3 or ZnCl2!TMEDA complex as a catalyst, the yields of silyl germanes 44, 48 
and 49 had significantly improved for all the silyl units investigated (entries 1-3). 
However, the ZnCl2!TMEDA complex required a 2-step preparation procedure 
before it was used in the formation of silyl germane 44, 48 and 49, and since no 
significant improvement in product yield is observed in these reactions compared to 
those using AgNO3, the AgNO3-catalysed conditions were considered the most 
appropriate. This method was used for all subsequent reactions. 
 
2) Attempted germylation with three different silyl germanes: 
For each of the three silyl germanes 44, 48 and 49, germylation of 4-iodotoluene 
using Oshima’s conditions was again attempted (Table 24).163 
 
Reagents and conditions: Pd(OAc)2 (5 mol%), dppf (5 mol%), Cs2CO3 (1.1 eq.), DMF, rt.163 
Entry SiR3 Outcome  
1 TBS Trace 
2 TES Trace 
3 TMS Trace 
 
Table 24: Attempted germylation of 4-iodotoluene with silyl germanes 44, 48 and 49 using 
Oshima's conditions.163 
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The desired product 45 was formed in all these reactions with starting material 44, 48 
and 49 remaining as evidenced by analysis of TLC and 1H NMR spectra. However, 
only trace amounts of the desired product 45 were isolated.  
 
As it was uncertain whether the size of the silyl unit was a significant factor in the 
germylation of 4-iodotoluene, TMS germane 49 was used as the germylation 
substrate in further reactions due to its reduced steric bulk relative to the TBS 
germane 44 used previously. 
 
2.2.2.6. Attempted Germylation of 1-Iodoveratrole 
1) Synthesis of the model system of germyl DOPA: 
At this junction, it was decided to use the more electron-rich aryl iodide, 1-
iodoveratrole (one of the models for 6-iodo-DOPA) instead of 4-iodotoluene for 
further studies. 
 
Before testing the germylation of 1-iodoveratrole with silyl germanes 44, 48 and 49 
the authentic germyl veratrole product 45 was synthesised, which was then used in 
TLC analyses against reaction mixture as a control to monitor the progress of 
reactions and act as a standard in 1H NMR spectroscopic analyses for the formation 
of the desired product. The germyl veratrole 50 was successfully synthesised via 
lithium-halogen exchange of 1-bromoveratrole and transmetalation with germyl 
bromide 41 although it required several attempts (Table 25). 
 
Entry ArBr (eq.) Reaction Conditions Outcome/Yield 
1 5 Mg (6 eq.), Et2O, 0 °C " rt Ge-O-Ge dimer 
2 5 
Mg (6 eq.), AgNO3 (5 mol%), 
Et2O, 0 °C " rt 
Ge-O-Ge dimer 
3 5 nBuLi (6 eq.), THF, -78 °C " rt No reaction 
4 1.2 
tBuLi (2 eq.), 3Å MS, 
THF, -78 °C " rt 
Desired prdt. 
(88%) 
 
Table 25: Synthesis of the authentic germyl veratrole 50. 
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The Grignard reaction conditions used for the synthesis of tolyl germane 45 were 
unsuitable for the case of 1-iodoveratrole as only the digermoxane by-product 46 was 
isolated after work-up (entry 1). Inspired by Oshima’s tetraorganosilane formation 
from the corresponding Grignard reagents (see details in section 2.2.2.5), AgNO3 
was then added as a catalyst to assist the Grignard reaction (entry 2). However, only 
the digermoxane by-product 46 was obtained. 
 
It was then found that tBuLi is essential for this transformation as nBuLi was not 
sufficient (entries 3-4). Furthermore, 3Å MS were required to dry 1-bromoveratrole 
before and after its addition to the reaction mixture due to 1-bromoveratrole’s high 
boiling point, which made it difficult to remove any air and moisture absorbed via 
distillation following storage. 
 
2) Attempted germylation of 1-iodoveratrole: 
Conditions of Oshima163 and Murata187 were screened for cross-coupling reaction of 
1-iodoveratrole with TMS germane 49 (Table 26). 
 
Reagents and conditions: Method A (Oshima): 1-iodoveratrole (1.2 eq.), Pd(OAc)2 (5 mol%),  
dppf (5 mol%), Cs2CO3 (1.1 eq.), DMF, rt;163 Method B (Murata): 1-iodoveratrole (0.5 eq.), 
Rh(acac)(C2H4)2 (10 mol%), DABCO (2.5 eq.), DMF, 80 °C;187 Method C (Murata):  
1-iodoveratrole (0.5 eq.), [Rh(cod)(MeCN)2]BF4 (10 mol%), DBCO (2.5 eq.), DMF, 80 °C.187 
Entry Method Outcome 
1 A S.M. recovered 
2 B 7% (isolated yield) 
3 C Trace 
 
Table 26: Attempted germylation of 1-iodoveratrole with TMS germane 49 using Oshima’s163 
and Murata’s187 conditions. 
(‘S.M.’ = starting material) 
 
Reactions where Murata’s conditions applied were observed to form the desired 
product 50 with starting material 49 left by TLC analyses and 1H NMR spectroscopic 
analyses (entries 2-3). Conditions using Rh(acac)(C2H4)2 as catalyst showed 
promising results. However, the desired product 50 was isolated in only 7% yield. 
Therefore, an attempted optimisation of Murata’s conditions (entry 2) was carried 
out (Table 27).187 
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Reagents and conditions: (i) 1-iodoveratrole (1 eq.), Rh(acac)(C2H4)2 (10 mol%), DABCO (2.5 eq.), 
DMF, 80 °C.187 
Entry Slow Additions Outcome (1H NMR) 
1 No slow addition 
Ge-Ver: Ge-TMS: Ge-O-Ge 
(2.23: 1.00: 0) 
2 1-Iodoveratrole (3.17: 1.00: 0) 
3 TMS germane 49 (1.90: 1.00: 0) 
4 1-Iodoveratrole + Rh(acac)(C2H4)2 (1.08: 1.00: 0) 
5 TMS germane 49 + Rh(acac)(C2H4)2 (0.64: 1.00: 0) 
6 Rh(acac)(C2H4)2  (1.03: 1.00: 0.53) 
7 Rh(acac)(cod) (1.03: 1.00: 1.13) 
 
Table 27: Attempted optimisation of Murata's conditions for germylation of 1-iodoveratrole 
with TMS germane 49.187 
(‘slow addition’ = reagents were added at 0.1 mL/h using a syringe pump) 
 
It was noticed that a significant amount of material was lost during the stage of 
separating components from the reaction mixture and so the ratios between different 
components were calculated by integration of 1H NMR spectra. Firstly, the exact 
conditions of entry 2 in Table 26 were repeated (entry 1). The ratio calculated here 
between the possible germanium compounds 50, 49 and 46 was used as a reference 
for subsequent optimisation. 
 
Assuming that the transmetalation step is the rate-limiting, a set of combinations 
where slow additions of starting materials and/or catalysts via a syringe pump were 
investigated (entries 2-7). However, none of these trials increased the formation of 
desired product 50 significantly although in some cases they decreased it (entries 4-
5) or encouraged the formation of the digermoxane by-product 46 (entries 6-7). 
 
A solvent screen was also attempted for Murata’s conditions, where reactions were 
carried out in THF, toluene, acetonitrile, 1,4-dioxane, NMP, DMF, or DMA. It was 
found that only trace amounts of desired product 50 was formed in THF, toluene, 
acetonitrile or 1,4-dioxane; no reaction occurred in NMP; whereas the reaction in 
DMA gave comparable results to that of DMF. 
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2.2.2.7. Attempted Germylation Using Cu-Catalysed Conditions 
At this point in the investigation, Marder et al. reported a Cu-catalysed borylation of 
aryl halides with diboron reagents.228 Although boron is a group 13 element, biaryl 
syntheses using arylboronic esters (i.e. the Suzuki reaction) resemble those of 
arylsilanes and arylstannanes (i.e. the Hiyama reaction and the Stille reaction 
respectively, see section 2.1.3.1). The Pd-catalysed borylation protocol from diboron 
compounds (known as the Miyaura coupling)140 also has similarities to the 
preparation procedures of arylsilanes and arylstannanes from disilanes177,190-192,194,213 
and distannanes177,196-198,212 respectively (Scheme 51). 
 
Scheme 51: Palladium-catalysed borylation, silylation and stannylation from their 
corresponding diborons,140 disilanes47,82-84,87,89 and distannanes.177,196-198,212 
 
The utility of copper in cross-coupling reactions has long been recognised.144 
However, since the introduction of Pd-catalysts, copper has been somewhat 
neglected. 
 
A long list of advantages and disadvantages apply to Cu-assisted cross-coupling 
reactions.229 The key advantages are: 1) copper can easily access four oxidation 
states (from 0 to +3) whilst palladium can only access two stable oxidation states (i.e. 
0 and +2); 2) copper can transfer a single-electron in redox reaction, which allows 
copper to access radical mechanistic manifolds; 3) copper metal is 105 times cheaper 
than palladium, and the ligands often used with copper are generally cheap N or O 
ligands whereas palladium prefers more expensive phosphine ligands. 
 
The key disadvantages are: 1) most copper salts are not very soluble in organic 
solvents although this does not always appear to decisively hinder reactions where 
complete dissolution is not achieved; 2) the copper salts regenerated from the 
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catalytic cycle can bear different ligands from the initial salt added to the reaction, 
and this newly generated copper salt may not be active towards the catalytic cycle, 
which can make it difficult to develop efficient catalytic cycle; often stoichiometric 
amounts are required; and 3) the mechanism of Cu-assisted reactions is less well 
explored than Pd-catalysed ones. 
 
1) Attempted germylation using Marder’s conditions: 
Marder’s conditions were developed for the attempted germylation of 1-
iodoveratrole with TMS germane 49 (Table 28).228 
 
Reagents and conditions: Method A: Pd(OAc)2 (5 mol%), dppf (5 mol%), CsCO3 (1.1 eq.), DMF,  
16 h;163 Method B: CuI (10 mol%), nBu3P (10 mol%), KOtBu (1.5 eq.), THF, 16 h;228  
Method C: CuCl (7.5 mol%), (iPr)NHC.Cl (7.5 mol%), KOtBu (1.5 eq.), THF, 16 h.228 
Entry Method Cond. Mod. Outcome (1H NMR) 
1 A rt 9% (isolated yield)* 
2 B rt " 60 °C 
Ge-Ver: Ge-H (0.63: 1.00) 
Ge-Ver (14% isolated yield) 
3 C rt " 60 °C 
Ge-Ver: Ge-H (0.13: 1.00) 
Ge-Ver (not isolated) 
4 B 
rt " 80 °C; 
D2O quench 
Ge-Ver: Ge-H (0.34: 1.00) 
Ge-Ver (not isolated) 
5 B 
rt " 80 °C; 
DMF 
Ge-Ver: Ge-H (trace: trace) 
Ge-O-Ge dimer present 
 
Table 28: Attempted germylation of 1-iodoveratrole with TMS germane using Marder’s Cu-
catalysed conditions.228 
[Grey shading (entry 1): the germylation of 4-iodotoluene with TBS germane 44 using the original 
conditions of Oshima is listed here for comparison (cf. entry 3 in Table 18); ‘*’ = isolated yields 
obtained for tolyl germane product 45] 
 
All reactions were started at rt, however, no formation of desired product 50 was 
observed by TLC analysis after 2 h. Pleasingly all starting materials were completely 
consumed after the reaction temperature was raised to 60 or 80 °C for further 14 h 
(entries 2-5). With the combination of CuI and nBu3P, the desired product was 
isolated in 14% yield but germyl hydride 42 was also identified as a major by-
product by MS (EI) and 1H NMR analyses (entry 2). The formation of germyl 
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hydride 42 was also observed with the combination of CuCl and NHC ligand (entry 
3). 
 
Initially, the hydride/proton was thought to be delivered during aqueous work-up. 
However, a reaction where D2O was used in work-up still showed the presence of 
germyl hydride 42 (entry 4). In case trace amounts of water were present, due to the 
hygroscopic nature of DMF, fresh anhydrous DMF was used to see if this would help 
suppress the formation of germyl hydride 42. Indeed, only trace amounts of germyl 
hydride 42 were formed in these conditions; however, this reaction also failed to 
produce the desired product 50 (entry 5). 
 
3) Investigation of copper/palladium co-catalysis: 
Copper salts have also been used as additives to Pd-catalysts. For our germylation, 
the use of a stoichiometric amount of CuI in co-operation with a Pd-catalyst showed 
promising results (Table 29). 
 
Reagents and conditions: Method A: Pd(OAc)2 (5 mol%), dppf (5 mol%), CsCO3 (1.1 eq.), DMF,  
16 h;163 Method B: CuI (10 mol%), nBu3P (10 mol%), KOtBu (1.5 eq.), THF, 16 h;228 Method C: 
Pd(OAc)2 (5 mol%), dppf (5 mol%), CuI (1.1 eq.), nBu3P (1.3 eq.), base (1.5 eq.), CsCO3 (1.1 eq.), 
THF, 16 h.163,228 
Entry Method Cond. Mod. Outcome (1H NMR) 
1 A rt 9% (isolated yield)* 
2 B rt " 60 °C 
Ge-Ver: Ge-H (0.63: 1.00) 
Ge-Ver (14% isolated) 
3 C 60 °C 
Ge-Ver: Ge-H (0.29: 1.00) 
Ge-Ver (38% isolated) 
4 C 80 °C, KHMDS 
Ge-H (no presence) 
Ge-Ver (8% isolated) 
5 C 50 °C, KHMDS 
Ge-Ver: Ge-H (1.01: 1.00) 
Ge-Ver (not isolated) 
 
Table 29: Investigation of Cu-assisted Pd-catalysed conditions for germylation of 1-
iodoveratrole with TMS germane 49. 
[Grey shading: (entry 1): the germylation of 4-iodotoluene with TBS germane 44 using the original 
conditions of Oshima is listed again here for comparison (cf. entry 3 in Table 18); (entry 2): the 
reaction using the original conditions of Marder is listed again here for comparison (cf. entry 2 in 
Table 28); ‘*’ = isolated yields obtained for tolyl germane product 45] 
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When CuI was used as an additive in Pd-catalysed conditions (entry 3), the isolated 
yield of desired product 50 increased by 4-fold compared to using Oshima’s 
conditions163 (entry 1) and doubled compared to using Marder’s conditions228 (entry 
2). However, significant amounts of germyl hydride 42 were still observed. 
 
It was then speculated that the hydride/proton could be transferred from KOtBu (used 
as base), when Cu inserted into the Ge-Si bond. Unfortunately, investigations where 
KOtBu was replaced with KHMDS to eliminate the formation of germyl hydride 42 
were not conclusive (entries 4-5).  
 
It was noted in a review by Beleskaya and Cheprakov that a neighbouring oxygen 
atom may facilitate transmetalation with Cu(I) giving rise to the corresponding 
organocopper species,229 and a positive influence of bidentate and particularly 
tridentate ligands (bipyridine230,231 and terpyridine) on Cu(I) catalysed cross-coupling 
has been reported. Therefore, a series of nitrogen- and oxygen-based ligands (1-7) 
were screened in the germylation of 1-iodoveratrole with TMS germane 49 using the 
Cu-assisted Pd-catalysed conditions (Table 31). 
 
Reagents and conditions: (i) Pd(OAc)2 (5 mol%), dppf (5 mol%), CuI (1.1 eq.), ligand (1.3 eq.), 
KOtBu (1.5 eq.), CsCO3 (1.1 eq.), THF, 16 h.163,228 
 
Entry Cond. Mod. Outcome (1H NMR) 
1 60 °C Ge-Ver (38% isolated) 
2 50 °C, Lig 1 S.M. recovered 
3 50 °C, Lig 2 25% (isolated yield) 
4 50 °C, Lig 3 S.M. recovered + Trace Ge-H 
5 50 °C, Lig 4 33% (isolated yield) 
6 50 °C, Lig 5 S.M. recovered 
7 50 °C, Lig 6 S.M. recovered 
8 50 °C, Lig 7 64% (isolated yield)* 
 
Table 30: Attempted optimisation of Cu-assisted Pd-catalysed conditions for germylation of 1-
iodoveratrole with TMS germane 49. 
[Grey shading (entry 1): the reaction using the combined conditions of Oshima and Marder is listed 
again here for comparison (cf. entry 3 in Table 29); ‘*’ = irreproducible result; ‘S.M.’ = starting 
material] 
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Pyridine was chosen for its advantage of dissolving copper salts readily, which was 
also used as the solvent in this particular experiment. However, only starting material 
49 was recovered (entry 2). 
 
Next, a series of N,O- and N,N-bidentate ligands was employed (entries 3-8). In 
2001, Buchwald and co-workers reported a Cu-catalysed N-arylation of hydrazides 
where 2-picolinic acid was used as a ligand.232 This Cu-picolinic acid system was 
also useful for the O-arylation of phenols.233 It was hypothesised that the 2-picolinic 
acid could offer a planar N,O-coordination environment for the Cu metal centre 
(Figure 51).234 
 
Figure 51: Buchwald’s proposed mode of N,O-coordination by 2-picolinic acid. 
 
Inspired by this N,O-bidentate Cu-catalyst, 2-picolinic acid was chosen for the ligand 
screen (entry 3). Due to the possibility of C-H activation at C6 position, the 6-methyl 
congener was also chosen for the ligand screen (entry 4). However, 25% desired 
product 50 was isolated when Lig. 2 was used, whereas starting material 49 was 
recovered along with traces of germyl hydride 42 when Lig. 3 was used. These 
results indicated that the extra 6-methyl function could also hinder the activity of the 
Cu-ligand complex. 
 
A Cu-2-(hydroxymethyl)pyridine system has also been reported to provide a planar 
N,O-coordination environment for the metal centre.235,236 Furthermore, 2-
(hydroxymethyl)pyridine can be considered as a more flexible congener of 2-
picolinic acid (Lig. 2). This Cu complex was applied successfully in asymmetric Si-
O coupling of silanes and alcohols, although in this particular example, the Cu-
catalyst was used to deliver the 2-(hydroxymethyl)pyridine (Lig. 4) as a substrate for 
the formation of a Si-O bond.237 Again to avoid the possibility of C-H activation, a 6-
methyl congener (Lig. 4) was also investigated (entry 5), which gave comparable 
results to that of nBu3P (entry 1). 
 
N
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Among all N,N-bidentate ligands tested, 4,4’-di-tert-butyl-2.2’-bipyridine (Lig. 7) 
gave a 2-fold increase in isolated yield of the desired product 50 (entry 8). Lig. 7 
features a flexible bipyridine structure with electron donating tert-butyl substituents, 
which also aid solubility. However, the results obtained with Ligand 7 were found to 
be irreproducible.  
 
It was also interesting to find that replacement of nBu3P with bidentate ligands 
completely eliminated the formation of germyl hydride 42 (entries 3-5 & 8). 
Therefore, the best conditions found for the germylation of 1-iodoveratrole were the 
Pd-catalysed conditions developed by Oshima, but with CuI as additive and 6-
methyl-2-(hydroxymethyl)pyridine (Lig. 4) as the ligand for CuI (entry 5). 
 
4) Application of copper-assisted conditions to other aryl iodide substrates: 
These conditions were then applied to a range of aryl iodide substrates (Table 31). 
 
Reagents and conditions: (i) Pd(OAc)2 (5 mol%), dppf (5 mol%), CuI (1.1 eq.),  
6-methyl 2-pyridinemethanol (1.3 eq.), KOtBu (1.5 eq.), CsCO3 (1.1 eq.), THF, 16 h. 
 
Entry ArI Outcome 
1 1 33% (isolated yield) 
2 2 Trace 
3 3 S.M. recovered 
4 4 S.M. recovered 
5 5 S.M. recovered 
6 6 S.M. recovered 
 
Table 31: Cu-assisted Pd-catalysed conditions were applied to a range of aryl iodides (Arl1-6). 
(‘S.M.’ = starting material) 
 
Disappointingly, only 1-iodoveratrole gave comparable results to those described 
previously (entry 1). A trace amount of desired product was identified when 4-
iodoanisole was subjected to germylation (entry 2). However, none of the rest of the 
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aryl iodides gave any positive results and only starting materials were recovered 
(entries 3-6). These results indicated substrate-specific issues of the Cu-assisted Pd-
catalysed conditions developed here. 
 
2.3. Conclusion and Future Work 
2.3.1. Conclusion 
The overall aim of this part of the project was to develop a germylation protocol that 
could allow for the efficient introduction of tagged germanium groups onto AAA 
derivatives using fluorous-tagged silyl germanes 44, 48 and 49, and then use the 
resulting germyl-AAAs to build up a small library of peptides containing biaryl AAs.  
 
To achieve this aim, the germylation precursor, fluorous-tagged silyl germanes 44, 
48 and 49 was synthesised from commercially available germanium(IV) chloride 35 
in eight steps. The final step of the formation of silyl germanes 44, 48 and 49 from 
germyl hydride 42 was optimised using AgNO3 or ZnCl2!TMEDA as catalyst. Silyl 
groups possessing different bulkiness were tolerated and isolated with excellent 
yields. 
 
Conditions reported in the literature for transition metal catalysed silylation, 
stannylation and germylation of aryl halides using both metal hydride and bimetallo 
group 14 reagents were screened for their suitability for coupling these silyl germane 
44, 48 and 49 to aryl iodides. Conditions were screened against both 4-IPhe and 6-I-
DOPA model systems, i.e. 4-iodotoluene and 1-iodoveratrole respectively. Among 
all conditions screened, the germylation reaction works best with the Cu-Pd bimetal-
mediated conditions, where a N,O-bidentate ligand is required. However, attempted 
optimisation of the conditions did not give any significant improvement over the 
initially developed system. 
 
Further investigations into a range of aryl iodide substrates showed that the Cu-Pd-
mediated conditions are restricted to electron-rich aryl iodides. As similar trend in 
electron properties of aryl iodides in the cross-coupling reaction with group 14 
organo-compounds has been reported by a number of research groups, where two 
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different conditions for electron-rich and electron-deficient aryl iodide are often 
developed to overcome this issue.163,194,210,213 
 
2.3.2. Future Work 
Several avenues of future work should be considered including: 1) studying the 
mechanism of the Cu-assisted Pd-catalysed conditions; 2) developing a digermane 
precursor for the germylation process; 3) reducing the steric bulkiness of the 
germane precursors. These ideas are expanded upon below: 
 
1) Study of the mechanism of the Cu-assisted Pd-catalysed conditions: 
It is known that activated Pd(0) catalysts will insert Pd into Ar-I bonds to form Ar-
Pd(II)-I species.238 According to Oestreich et al., Cu(I) is able to complex with 2-
(hydroxymethyl)pyridine, which could coordinate to silyl hydride compounds.237 It is 
therefore hypothesised that the Cu(I) iodide salt will form a complex with the 6-
methyl-2-(hydroxymethyl)pyridine ligand as an active Cu species to facilitate the 
germylation reaction (Scheme 52). 
 
Scheme 52: Proposed mechanism by which a Cu(I)-(hydroxymethyl)pyridine complex facilitates 
transmetalation. 
 
Cu may therefore insert into the Ge-Si bond to activate the TMS germane 49. Due to 
the polarity of Ge-Si bond, the oxygen atom of the hydroxymethyl group would be 
expected to bond to the silicon centre. At the same time, the copper metal centre 
would coordinate to the germanium centre and hence facilitate the germanium 
transmetalation step in the Pd-catalysed cycle (Scheme 53). 
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Scheme 53: Proposed role of Cu-activated germane in the Pd-catalysed mechanism. 
 
NMR investigations could be used to monitor the formation/lack of formation of 
each intermediate proposed in the catalytic cycle. Computational experiments would 
also likely prove a useful tool for the study of this reaction mechanism and could 
help understand the associated transitions states and energy profiles. However, NMR 
studies could be difficult to carry out with insoluble copper salts capable of 
switching between four possible oxidation states. In general, Cu-mediated reactions 
are poorly understood and catalytic cycles in the literature are often no more than 
speculation. The difficulties are compounded due to the accessibility of odd-electron 
states of copper, which means that radical mechanisms could also be possible in 
these reactions. 
 
2) Development of a digermane precursor: 
As described in section 2.1.5.3, only a handful of hetero-bimetallo group 14 
compounds have been reported for cross-coupling reactions and these show low to 
moderate yields of products. On the other hand, homo-bimetallo group 14 
compounds have been more frequently explored, particularly disilanes and 
distannanes. The development of a digermane compound may therefore offer a 
solution to the problem of developing an efficient and general method for 
germylation of AAAs. 
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Jones previously synthesised a symmetrical digermane with an ethoxy ethyl ether 
linker 52 but did not carry out germylation reactions with it. However, the fluorous-
tagged equivalent of digermane 53 could be too bulky particularly with the 
bis(methylnaphthyl) groups. An asymmetric digermane system such as 54 may 
overcome this problem but would require the 2nd germane unit to act as the ‘dummy’ 
partner (Figure 52). 
 
Figure 52: Proposed symmetric and asymmetric digermanes with ethoxy ethyl ether linker or 
fluorous-tag. 
 
Of course, germanium compounds are expensive compared to silicon and tin 
compounds and therefore to use one as the ‘dummy’ partner is wasteful and non-
atom-economic. Additionally, it is difficult to predict at this stage whether the 
desired fluorous-tagged germanium unit would be favoured for transmetalation over 
the ‘dummy’ germanium unit. 
 
3) Reduction of steric bulkiness of germane precursors: 
It is conceivable that the steric bulkiness of the germanium unit within the silyl 
germanes studied this far could be preventing efficient germylation. Investigation of 
the silyl unit was carried out during the project, but no significant difference was 
observed with different silyl groups (TMS, TES and TBS). Therefore, reduction of 
the steric bulkiness of the germanium unit counterpart should be investigated next. 
 
The current germanium unit contains two bulky 2-methylnaphthyl groups in order to 
allow subsequent photo-oxidation prior to Ar-Ar cross-coupling (see section 2.1.3.2 
for details).166-168 
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Simply removing either or both of the 2-methylnaphthyl groups would prevent 
subsequent Ar-Ar cross-coupling reactions, however, it is possible that the 
tetrahydrobenzogermole containing molecule 56 would be functionally equivalent 
whilst presenting a reduced steric demand and increase atom economy (Figure 53).  
 
Figure 53: Proposed tetrahydrobenzogermole system 56 with reduced steric demand. 
 
The constrained germane structure 56 could facilitate the transmetalation step in the 
germylation reaction whilst retaining the photo-oxidative susceptibility required for 
subsequent cross-coupling. 
 
It can be envisioned that the chemistry for preparing such a molecule could be 
developed using a silicon-based model 57 (Scheme 54). 
 
Reagents and conditions: (i) HCl (36%, 2.5 eq.), CH2O (35%, 2.5 eq.), HCl gas,  
1,4-dioxane (10 fold), 0 °C " 40 °C.239,240 
Scheme 54: Proposed synthesis of tetrahydrobenzosilole 57. 
 
Once an efficient and general procedure for germylation of aromatic halides with a 
germanium group suitable for subsequent germyl-Stille type cross-coupling is 
developed, then myriads of possibilities open up for the use of this type of compound 
in the synthetic mutagenesis of AAAs in peptides and proteins. 
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Overall Conclusion 
The overall aim of the project was to identify new peptidic inhibitor leads which 
would be able to inhibit the PPI between IgE and Fc"RI. Upon finding a promising 
lead candidate, the aim was to develop a germylation protocol suitable as a new 
synthetic mutagenesis method for functionalisation of AAA derivatives to allow the 
resulting germyl-AAAs to be incorporated into the lead peptide to enable synthesis 
of modified libraries of biaryl AA containing peptidic inhibitors, hopefully having 
improved affinity. 
 
From kinetic binding and structure-activity studies, a retro-#Fc"RI C-region mimic 
peptidic inhibitor 26 (named [Y8A] BM1149-Am) was developed, which had an IC50 
value of 9.1±0.9 µM (av.). For future work, study of the mode of action of this lead 
peptide by running additional immuno assays, by carrying out protein NMR studies, 
and by X-ray co-crystal structure determination will be the next milestones towards a 
new generation of more potent inhibitors.  
 
Silyl germanes, the precursors towards germyl-AAAs were successfully synthesised 
from commercially available germanium(IV) chloride in eight steps. Screens of 
conditions found that Cu-mediated Pd(0)-catalysed conditions were the most 
promising. For future work, a general procedure for germylation of aromatic halides 
will enable development of a new methodology for the synthetic mutagenesis of 
AAAs in peptides and proteins. 
 
Recent advances in peptide synthesis and their structural modification have opened a 
new era of potential peptide therapeutics. With ever more peptides with ‘drug-like’ 
properties entering clinical studies, studies into the development of peptidic 
inhibitors and new methods as carried out in this project will hopefully contribute to 
a new and exciting anti-allergic drug, which targets the PPI between IgE-Fc"RI, in a 
not too distant future. 
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Chapter 3. Experimental 
3.1. Syntheses of Peptidic Inhibitors 
3.1.1. Materials 
All general laboratory chemicals obtained from chemical suppliers (Merck 
Chemicals UK or Sigma Aldrich UK) were used without further purification. 
Peptides were synthesised using a ResPep SL peptide synthesiser (Intavis, Koeln, 
Germany). The purification of crude peptides was performed on a LC-MS mass 
directed auto purification system (Waters, Massachusetts, USA) equipped with a 
2998 Photodiode Array (detection at 200-600 nm) and a 3100 mass spectrometer 
with ESI. The following elution method (gradient of H2O and MeOH): 0-10 min 5-
98% MeOH, 10-12 min 98% MeOH, 12-13 min 98-5% MeOH, 13-17 min 5% 
MeOH was used. Solvents used for the method were supplemented with 0.1% FA 
and were degassed with helium. 
 
Solid Phase Resins: Both preloaded Wang resin and rink amide resin were 
purchased from Novabiochem UK. The resin substitution ratios were as follows: 
Fmoc-Cys(Trt)-Wang: 0.65 mmol/g; Fmoc-CysD(Trt)-Wang: 0.44 mmol/g; Fmoc-
Met-Wang: 0.75 mmol/g; Fmoc-Ile-Wang: 0.63 mmol/g; Fmoc-Tyr(tBu)-Wang: 0.63 
mmol/g; Fmoc-Val-Wang: 0.65 mmol/g; rink amide: 0.71 mmol/g). 
 
Amino Acids: N-!-9-Fluorenylmethoxycarbonyl (N-!-Fmoc) protected amino acids 
were obtained from Merck Chemicals UK with the following side chain protecting 
groups: Arg(Pbf), Asn(Trt), Asp(tBu), Cys(Trt), CysD(Acm), Glu(tBu), His(Trt), 
Lys(Boc), Ser(tBu), Thr(tBu), Trp(Boc), Tyr(tBu). 
 
Reagents: Peptide synthesis grade N,N-dimethylformamide (DMF) and 20% 
piperidine (v/v) in DMF were purchased from National Diagnostics USA. Acetic 
anhydride, 2-(1H-benzotriazole-1-yl)-1,1,3,3-tetramethylaminium 
hexafluorophosphate (HBTU), tert-butylmethylether (TBME), ethanedithiol (EDT), 
N-methylmorpholine (NMM), trifuoroacetic acid (TFA), and 
trimethylsilylisopropane (TIPS) were reagent grade from Sigma Aldrich UK. Formic 
acid (FA) was analytical grade from Sigma Aldrich. MeOH used for HPLC-MS was 
LCMS grade from VWR UK. 
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3.1.2. General Procedures for the Preparation of Peptidic Inhibitors 
3.1.2.1. Solid Phase Peptide Synthesis (SPPS) 
All peptides were synthesised using a standard Fmoc-protected SPPS method.241 
Resin preloaded with appropriate amino acid or rink amide resin (20 µmol per well) 
was swelled in DMF for 15 min and then the N-terminal Fmoc protecting group was 
deprotected with 20% piperidine (v/v) in DMF (3 ( 10 min). The resin was washed 
with CH2Cl2 (2 () and DMF (6 (). N-Fmoc protected amino acid (5 eq., 0.5 M 
solution in NMP) were activated in separate vials with HBTU (5.5 eq.) and NMM 
(5.5 eq.). Activated amino acids were added to the resins and allowed to couple for 
35 min (3 (). The peptides were capped using a solution of 2% acetic anhydride (v/v) 
in NMP (5 min). The resins were then washed with CH2Cl2 (2 () and DMF (6 (). 
The cycle of deprotection, washing, amino acid coupling, capping and washing was 
repeated for each amino acid in the peptide sequence. After the final amino acid 
coupling, the N-terminal Fmoc group was cleaved using 20% piperidine (v/v) in 
DMF. Finally, the resins were washed with DMF (3 () and CH2Cl2 (3 (). The 
peptides were then placed in syringes fitted with a fritter. Resin-bound peptides were 
washed with MeOH (3 () and Et2O (3 () and were dried in vacuum desiccator 
overnight. 
 
3.1.2.2. Deprotection and Cleavage from Resin 
Side chain deprotection and cleavage of the peptide from the resin were done by 
adding 2 mL of TFA mixture (A: 95% TFA, 2.5% H2O, 2.5% TIS; or B: 94% TFA, 
2.5% H2O, 2.5% TIS, 1% EDT for Cys- and/or Met-containing peptides) to dry 
resin-bound peptide and agitated on an orbital shaker at room temperature for 2 h. 
The filtered mixture was precipitated from ice-cold TBME (10 mL) and centrifuged 
at 4000 rmp for 15 min at 4 °C. The supernatant discarded and the remaining peptide 
washed with a fresh aliquot of TBME. The process was repeated twice to ensure 
complete removal of all organic impurities. The crude peptides were dried in a 
desiccator to yield off-white solids. 
 
3.1.2.3. Peptide Purification 
Peptide analysis and purification were performed on Gilson RP-HPLC or Waters 
LC-MS system with the elution methods described in section 3.1.1. Pure fractions 
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were combined. MeCN or MeOH in the fractions was removed in vacuo. The peptide 
was then obtained as a white solid after lyophilisation on a Christ Alpha 2-4 freeze 
dryer (Osterode am Harz Germany).  
 
3.1.2.4. Formation of Cyclic Peptides via Air-Oxidation117 
The linear peptide was dissolved in DMSO (4 mL/1 mg linear peptide, 20%, with 5% 
AcOH in H2O, pH = 3-8). Oxygen gas was bubbled into the reaction mixture for 30 
min before the resultant mixture was left stirring vigorously under an oxygen balloon 
at rt for 16 h. To confirm the completion of the oxidation reaction, a sample of the 
crude reaction mixture was analysed by analytical LC-MS. The reaction mixture was 
then purified by Gilson RP-HPLC or Waters LC-MS system as described in section 
3.1.2.3. Pure fractions were combined and lyophilised to yield the desired cyclic 
peptide. 
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3.1.3. Characterisation Data of Peptidic Inhibitors 
*See appendices for HPLC and LC-MS diagrams of purified peptidic inhibitors. 
3.1.3.1. Literature Reported Peptidic Inhibitors 
Entry Mw (Expected) Mw-H (ES-) Rt (min) Yields (%) 
IGE07 1 1747.03 1747.8 11.9 7 
A-B Loop 2 2366.80 1184.4 (!!! ! 12.6 5 
C-C’ Cyclo-L-262 Loop 3 1566.80 1567.8 9.9 8 
 
Table 32: Characterisation data of literature reported peptidic inhibitors. 
 
3.1.3.2. Fc#RI C-Region Mimic Y116-D123 Peptidic Inhibitors 
Name Description Mw (Expected) 
Mw-H  
(from ES-) 
Rt 
(min) 
Yields 
(%) 
BM3110 10 
Fc"RI C-
Region Mimic 
(Monomer) 
1091.26 1089.91 9.23 12 
Ac-BM3110 11 1133.29 1131.74 10.37 9 
BM3110-Am 6 1090.27 1088.79 8.93 7 
Ac-BM3110-
Am 12 1132.31 1130.78 10.03 15 
BM1149 13 
retro-Fc"RI 
C-Region 
Mimic 
(Monomer) 
1091.26 1089.68 9.44 46 
Ac-BM1149 14 1090.27 1088.66 9.52 40 
BM1149-Am 7 1133.29 1131.74 10.55 41 
Ac-BM1149-
Am 15 1132.31 1130.71 9.83 23 
Ro25-9612 4 
Fc"RI C-
Region Mimic 
(Dimer) 
2356.76 
1177.80 & 
1177.54 (!!! ! 8.31 & 8.67 2 
Ro25-9960 5 Fc"RI C-
Region Mimic 
(Dimer) 
2158.50 1078.44 (!!! ! 8.13 2 
BM3108B 16 2160.47 1079.20 (!!! ! 7.97 4 
BM3085A 8 retro-Fc"RI 
C-Region 
Mimic 
(Dimer) 
2825.30 1178.15 (!!! ! 10.70 18 
BM3109A 17 2356.76 
1166.54, 
1177.60 & 
1177.28 (!!! ! 
9.29, 
9.41 & 
10.31 
3 
BM3085B 9 retro-Fc"RI 
C-Region 
Mimic 
(Dimer) 
2160.47 1079.18 (!!! ! 10.42 15 
BM3109B 18 2158.50 1077.73 (!!! ! 9.44 3 
 
Table 33: Characterisation data of Fc#RI C-region mimic Y116-D123 peptidic inhibitors.  
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3.1.3.3. Alanine-Scan Analogues of BM1149-Am 7 
Entry Mw (Expected) Mw-H (ES-) Rt (min) Yields (%) 
[D1A] BM1149-Am 19 1046.26 1044.68 9.44 9 
[K2A] BM1149-Am 20 1033.18 1031.5 9.59 12 
[Y3A] BM1149-Am 21 998.18 996.6 7.68 10 
[Y4A] BM1149-Am 22 998.18 996.6 8.16 16 
[I5A] BM1149-Am 23 1048.19 1046.6 7.70 19 
[V6A] BM1149-Am 24 1062.22 1060.5 8.05 18 
[K7A] BM1149-Am 25 1033.18 1031.5 9.52 24 
[Y8A] BM1149-Am 26 998.16 996.74 7.34 8 
 
Table 34: Characterisation data of alanine-scan analogues of BM1149-Am 7. 
(This series of peptidic inhibitors was synthesised under the help of Teng, an exchange student from 
Nanyang University of Singapore, Sep2010 to Jan 2011) 
 
3.1.3.4. Truncated Analogues of BM1149-Am 7 
Entry Mw (Expected) Mw-H (ES-) Rt (min) Yields (%) 
["1] BM1149-Am 27 975.18 973.70 8.51 17 
["1,2] BM1149-Am 28 847.01 845.56 8.80 15 
["1,2,3] BM1149-Am 29 683.84 682.54 8.39 13 
["8] BM1149-Am 30 927.10 925.63 8.39 17 
["7,8] BM1149-Am 31 798.93 797.56 8.90 25 
["6,7,8] BM1149-Am 32 699.79 698.55 8.10 46 
 
Table 35: Characterisation data of truncated analogues of BM1149-Am 7. 
 
3.1.3.5. Arg-Addition Analogues of BM1149-Am 7 
Entry Mw (Expected) Mw-H (ES-) Rt (min) Yields (%) 
BM3135A 33 1154.36 1153.95 7.69 17 
BM3135B 34 1154.36 1152.86 7.30 26 
 
Table 36: Characterisation data of arg-addition analogues of BM1149-Am 7.  
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3.1.4. General Procedures for ELISA Assay 
3.1.4.1. Materials and Methods 
Reagents and Materials: Phosphate buffered saline (PBS) tablets were purchased 
from Oxoid Ltd., tween-20 and bovine serum albumin (BSA) were purchased from 
Sigma Life Sciences, biotinylated anti-IgE was purchased from Vector Laboratories, 
streptavidin-horse radish peroxidase conjugate was purchased from Biosource 
International Inc., stable peroxide buffer (10 () was purchased from Thermo 
Scientific, o-phenylenediamine dihydrochloride (OPD) and Rose Bengal (RB) were 
purchased from Sigma-Aldrich, alpha-gamma protein (AG) is a chimeric construct of 
the #-chain of Fc"RI fused to the Fc region of IgG,242 IgE-Fc protein (Fc) is the C"2-
4 region of IgE,243 and both AG and Fc were kindly provided by our collaborators at 
King’s College London, ELISA plate used was the P96 Maxisorp NUNC 
immunoplate purchased from Nalgene Europe Ltd. 
 
PBS Solution: PBS tablets (20) were dissolved in deionised water (2 L). 
 
PBS-Tween (PBS-T) Solution: Tween-20 (1 mL) was dissolved in PBS (1 L) to 
make the PBS-T solution (0.1% v/v). 
 
Carbonate Buffer: NaHCO3 (3.8 g) and Na2CO3 (1.92 g) were dissolved in 
deionised water (1 L) to make the carbonate buffer (pH 9.6). 
 
Peroxide Buffer: Stable peroxide buffer (1 mL) was added to deionised water (9 
mL). 
 
Peptide Preparation: The peptides were made up into stock solution in DMSO (100 
mM). The stock solution was then diluted with PBS (5 mM, 5% DMSO). 
 
ELISA Plate Coating: The plates were coated with AG receptor protein (100 µL, 2 
µg mL-1) in aqueous carbonate buffer for 14 h at 4 °C. The plates were then washed 
with PBS-Tween 20 (3 ( 300 µL, 0.1% v/v, 5 min) to remove residual AG receptor 
protein and unbound sites were then blocked by incubation with a solution of BSA in 
PBS (300 µL, 2% v/v) for 1 h at 37 °C. 
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3.1.4.2. ELISA Procedures 
ELISA Controls:  
Control IgE-Fc (nM) PBS/ µL DMSO (% v/v) 
IgE-Fc (Fc) 33 100 0 
IgE-Fc-DMSO (FcD) 33 110 5 
Rose Bengal (RB) (10 µM) 33 110 5 
Alpha-Gamma (AG) (10 µg/mL) 33 110 5 
PBS (P) 0 110 5 
Water (W) 0 110 (water) 5 
 
Table 37: Preparation of ELISA controls. 
 
ELISA Testing: 
The ELISA plates were washed with PBS-T (3 ( 300 µL, 0.1% v/v, 5 min) and pre-
mixed solutions of the IgE:Fc protein (33 nM in PBS) and the peptide were added, 
the wells thoroughly stirred, and the plates incubated for 1 h at 37 °C. The final 
concentration of DMSO in all the wells was 5% v/v. The plates were then washed 
with PBS-T (3 ( 300 µL, 0.1% v/v, with the first wash taking ~30 min cf. 5 min in 
normal washes to ensure removal of DMSO). Bound IgE-Fc was detected by 
incubation with biotinylated anti-IgE (1/5000 dilution in 1% v/v BSA in PBS) for 1 h 
at 37 °C followed by washing with PBS-T (3 ( 300 µL, 0.1% v/v, 5 min) and then 
further incubation with streptavidin-HRP (1/5000 dilution in 1% v/v BSA in PBS) 
and washing with PBS alone (3 ( 300 µL, 0.1% v/v, 5 min). A solution of OPD (50 
%L, 0.2 mg mL-1 in peroxide buffer) was added to the plates and after 4 min at rt in 
the dark the enzyme reaction was halted by addition of an aqueous solution of HCl 
(50 µL, 3 M). Absorbance detection of the plates was then performed at 492 nm 
using an ELISA plate reader (Titertek Multiskan).  
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3.1.5. IC50 Values of Peptidic Inhibitors 
All results obtained from ELISA were interpreted using the GraFit programme.118 
3.1.5.1. Literature Reported Peptidic Inhibitors 
Peptide IC50/ µM 
IGE07 1 N.I. 
A-B Loop 2 N.I. 
C-C’ Cyclo-L-262 Loop 3 N.I. 
 
Table 38: IC50 values of literature reported peptidic inhibitors. 
(‘N.I.’ = no inhibition) 
 
3.1.5.2. Fc#RI C-Region Mimic Y116-D123 Peptidic Inhibitors 
Name Description IC50/ µM 
BM3110 10 
Fc"RI C-Region Mimic 
(Monomer) 
free N- & C- 1626±33 
Ac-BM3110 11 N-Ac N.I. 
BM3110-Am 6 C-Am N.I. 
Ac-BM3110-Am 12 N-Ac & C-Am N.I. 
BM1149 13 
retro-Fc"RI C-Region 
Mimic (Monomer) 
free N- & C- 69±8 85±6 
Ac-BM1149 14 N-Ac 142±9 131±11 
BM1149-Am 7 C-Am 102±13 51±8 
Ac-BM1149-Am 15 N-Ac & C-Am 335±46 967±64 
Ro25-9612 4 Fc"RI C-Region Mimic (Dimer) C-Am N.I. 
Ro25-9960 5 Fc"RI C-Region Mimic 
(Dimer) 
C-Am N.I. 
BM3108B 16 free N- & C- 433±22 
BM3085A 8 retro-Fc"RI C-Region 
Mimi (Dimer) 
C-Am N.I. 
BM3109A 17 free N- & C- 544±53 
BM3085B 9 retro-Fc"RI C-Region 
Mimic (Dimer) 
C-Am N.I. 
BM3109B 18 free N- & C- 605±67 
 
Table 39: IC50 values of Fc#RI C-Region Mimic Y116-D123 Peptidic Inhibitors. 
(‘N.I.’ = no inhibition) 
 
3.1.5.3. Alanine-Scan Analogues of BM1149-Am 7 
Peptide IC50/ µM 
[D1A] BM1149-Am 19 654±62 ( 
[K2A] BM1149-Am 20 43±4 182±24 
[Y3A] BM1149-Am 21 413±55 309±79 
[Y4A] BM1149-Am 22 308±21 259±27 
[I5A] BM1149-Am 23 311±42 1367±188 
[V6A] BM1149-Am 24 1400±79 570±80 
[K7A] BM1149-Am 25 99±9 90±15 
[Y8A] BM1149-Am 26 6.3±0.6 11.8±1.1 
 
Table 40: IC50 values of alanine-scan analogues of BM1149-Am 7. (‘(’ = assays not run) 
Chapter 3 
 111 
3.1.5.4. Truncated Analogues of BM1149-Am 7 
Peptide IC50/ µM 
["1] BM1149-Am 27 N.I. N.I. 
["1,2] BM1149-Am 28 N.I. N.I. 
["1,2,3] BM1149-Am 29 N.I. N.I. 
["8] BM1149-Am 30 802±77 211±34 
["7,8] BM1149-Am 31 2420±248 2376±196 
["6,7,8] BM1149-Am 32 928±106 341±32 
 
Table 41: IC50 values of truncated analogues of BM149-Am 7. 
(‘N.I.’ = no inhibition) 
 
3.1.5.5. Solvent Investigations to Solubilise Peptidic Inhibitors 
Solvent 
IC50/ µM 
BM1149 13 BM149-Am 7 [Y8A] BM1149-Am 26 
DMSO* 
Insoluble 
69±8 
85±6 
Gel 
102±13 
51±8 
Gel 
6.3±0.6 
11.8±1.1 
MeOH 
Insoluble 
64±7 
Gel 
224±60 
Gel 
13±4 
EtOH 
Insoluble 
43±16 
Insoluble 
203±24 
Insoluble 
5.2±1.4 
MeCN 
Insoluble 
129±23 
Insoluble 
580±66 
Insoluble 
11.2±2.2 
 
Table 42: IC50 values from solvent investigations to solubilise peptidic inhibitors in ELISA. 
[‘insoluble’ = a suspension formed when 100% DMSO was added to a peptide; then the PBS buffer 
was added to make up a 5% DMSO conc.; ‘gel’ = a jelly-like material formed when a solution of 
peptide in 100% DMSO was added into the PBS buffer to make up a 5% DMSO conc.; ‘*’ = IC50 
values obtained in 5% DMSO are listed here for comparison (cf. entry 5 and 7 in Table 5, and entry 9 
in Table 6)] 
 
3.1.5.6. Arg-Addition Analogues of BM1149-Am 
Peptide IC50/ µM 
BM3135A 33 N.I. 
BM3135B 34 164±21 
 
Table 43: IC50 values of arg-addition analogues of BM1149-Am. 
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3.1.5.7. The SPR and The !-Hexosaminidase Release Assays 
The competitive SPR assay and the !-hexosaminidase assay were carried out by Dr 
Balvinder Dhaliwal (King’s College London); the direct SPR assay was carried out 
by Dr Fabienne Saab (King’s College London). 
 
Peptidic 
Inhibitor 
IC50/ µM 
SPR 
(compet.) 
SPR 
(direct) 
!-
Hexosaminidase 
(1 h at 250 µM) 
ELISA for 
comparison 
IGE07 1 1.23±0.03 17 68% N.I. 
A-B 2 N.I. N.I. 0% (at 50 µM) N.I. 
C-C’ 3 N.I. N.I. 0% N.I. 
BM3109A 17 ( ( 12% 544±53 
BM3109B 18 ( ( 67% 605±67 
BM1149-Am 
7 ( 
178.1 
(#Fc"RI); 
140.1  
(IgE-Fc) 
( 102±13 51±8 
[Y8A] 
BM1149-Am 
26 
( N.I. ( 6.3±0.6 11.8±1.1 
 
Table 44: IC50 values from the SPR and the !-hexosaminidase release assays. 
(‘N.I.’ = no inhibition; ‘(’ = assays not run) 
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3.2. Germanium Chemistry 
3.2.1. General Directions 
Solvents and reagents: CH2Cl2, THF and Et2O were dried and deoxygenated with a 
Pure-Solv 400 solvent purification system (Innovative Inc., USA). The moisture 
content of the solvents was monitored by Karl Fischer coulometric titration (Mettler-
Toledo DL90). TMSCl was distilled from CaH2 under N2. All other reagents were 
used as commercially supplied unless otherwise stated and handled in accordance 
with COSHH regulations.  
 
Chromatography: Flash chromatography was performed on Silica gel (Merck 
Kieselgel 60 F254 230-400 mesh) according to the method of W. C. Still.244 PLC was 
performed on glass backed silica plates (200 x 200 x 1 mm, 60 F254). TLC was 
performed on aluminium backed plates pre-coated with silica (Merck 0.2 mm, 60 
F254) which was developed using standard visualising agents: UV fluorescence (254 
nm and 365 nm) and KMnO4(aq)/).  
 
Melting points: These were determined on a Khofler hot stage and are uncorrected. 
 
Infra-red spectra: These were recorded as thin films or as solids on PerkinElmer 
Spectrum 100 Series spectrometer. Only selected absorbances (#max) are reported. 
 
1H NMR spectra: These were recorded at 400 MHz on BrukerAV-400 instrument. 
Chemical shifts ($H) are quoted in parts per million (ppm) as referenced to the 
appropriate residual solvent peak, with the abbreviation s, d, t, q and m denoting 
singlet, doublet, triplet, quartet and multiplet respectively. Broad signals are assigned 
as br. Coupling constants (J) are reported to the nearest 0.5 Hz. All spectra were 
compared with reference spectra of authentic products and reagents when available. 
 
13C NMR spectra: These were recorded at 100.6 MHz on Bruker AV-400 
instrument. Chemical shifts ($C) are quoted in ppm to the appropriate solvent peak 
and are assigned as s, d, t, and q, for C, CH, CH2, and CH3 respectively. Degenerate 
peaks are prefixed by the number of carbons. The 13C signals for the Rf-tag were 
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assigned by running a partially 13C[19F] decoupled spectrum in the cases of Rf-tagged 
germanes. 
 
19F NMR spectra: There were recorded at 376 MHz on Bruker-DRX 400, AV-400 
instruments respectively. Chemical shifts ($F) are quoted in ppm as referenced to 
CCl3F.  
 
Mass Spectra: Low resolution and high-resolution spectra (m/z) were recorded on a 
VG Platform II (EI and CI) or VG AutoSpec (EI, CI, FAB) spectrometers, with only 
molecular ions (M+), and major peaks being reported with intensities quoted as 
percentages of the base peak. Molecular weights are calculated using 74Ge, 35Cl and 
79Br isotopes. HRMS values are valid to ±5 ppm.  
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3.2.2. Synthesis towards Germyl Silane 
3.2.2.1. Preparation of Precursors towards the Synthesis of Germyl Silane 
 
Germanium (II) chloride 1,4-dioxane (GeCl2!C4H8O2) complex 36245 
 
 
A stirred solution of germanium(IV) chloride 35 (5.0 g, 23.32 mmol) and 
tetramethyldisiloxane (TMDS) (3.13 g, 23.32 mmol, 4 mL) in degassed 1,4-dioxane 
(5 mL) was heated at 100 °C overnight. After cooling to 0 °C, the suspended white 
needles were isolated by filtration, and then washed with cold CHCl3 (3 ( 10 mL). 
After drying under vacuum, germanium (II) chloride 1,4-dioxane complex 36 was 
obtained as white needles (3.78 g, 70%). m/z. (EI+) (rel. intensity) 144 [M(GeCl2)+, 
39], 109 (60), 88 (100), 58 (65). 
 
Trichloro-(3,3,4,4,5,5,6,6,7,7,8,8,9,9,10,10,10-heptadecafluorodecyl)germane 
37170 
 
 
1H,1H,2H,2H-Perfluorodecyl iodide (15.00 g, 26.13 mmol) and germanium (II) 
chloride 1,4-dioxane complex 36 (6.00 g, 26.13 mmol) were heated in a Carius tube 
at 150 °C for 24 h. After cooling to rt, the reaction mixture was diluted with CH2Cl2 
(50 mL) and added H2O (50 mL) dropwise. The resulting white precipitate was 
collected by filtration, washed with H2O (2 ( 50 mL) then CH2Cl2 (2 ( 50 mL) and 
dried under suction. The dried precipitate was stirred in conc. HCl (50 mL, 37% w/v) 
for 16 h and then extracted with CH2Cl2 (6 ( 50 mL). The combined organic extracts 
were dried over MgSO4 and concentrated in vacuo to give trichlorogermane 37 as a 
red solid (14.97 g, 91%).170 1H NMR (400 MHz; CDCl3): , 2.22–2.26 (m, 2H, 
CH2CH2Ge), 2.44–2.57 (m, 2H, CH2CH2Ge); m/z. (EI+) (rel. intensity) 591 [(M-Cl)+, 
11], 574 [(M-F-Cl)+, 62], 555 [(M-2Cl)+, 57], 409 [(M-C8F17)+, 39], 109 (100).  
GeCl2
O
O
•
Chemical Formula: C4H8Cl2GeO2
Exact Mass: 231.91
Molecular Weight: 231.65
C8F17
GeCl3
Chemical Formula: C10H4Cl3F17Ge
Exact Mass: 625.83
Molecular Weight: 626.11
Chapter 3 
 116 
(3,3,4,4,5,5,6,6,7,7,8,8,9,9,10,10,10-Heptadecafluorodecyl)-tris-(4-
methoxyphenyl) germane 38170 
 
 
To a solution of 4-bromoanisole (15 mL, 120 mmol) in THF (50 mL) was added 
nBuLi (57.5 mL, 144 mmol, 2.5 M) dropwise at -78 °C. The resulting mixture was 
stirred for 30 min and then added to a solution of trichlorogermane 37 (14.97 g, 23.9 
mmol) in THF (50 mL) at -78 °C. The resulting reaction mixture was slowly warmed 
up to rt and stirred overnight. THF was removed in vacuo before the reaction mixture 
was diluted with Et2O (50 mL) and washed with water (2 ( 20 mL). The combined 
organic extracts were dried over MgSO4 and concentrated in vacuo to give crude tris-
para-anisylgermane 38 as brown oil. A sample of the crude tris-para-anisylgermane 
38 was purified by Kugelrohr distillation (125 °C/0.1 mmHg).170 1H NMR (400 
MHz; CDCl3): , 1.67–1.71 (m, 2H, CH2CH2Ge), 2.23–2.27 (m, 2H, CH2CH2Ge), 
3.86 (s, 9H, 3 ( ArOCH3), 7.00 (d, J = 8.4 Hz, 6H, ArH), 7.43 (d, J = 8.8 Hz, 6H, 
ArH); m/z. (CI+) (rel. intensity) 841 (M+, 1), 735 [(M-Ar)+, 100], 702 (60), 395 [(M-
C8F17)+, 16]. 
  
C8F17
Ge Chemical Formula: C31H25F17GeO3
Exact Mass: 842.07
Molecular Weight: 841.14OMe 3
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Dichloro-(3,3,4,4,5,5,6,6,7,7,8,8,9,9,10,10,10-heptadecafluorodecyl)-(4-methoxy-
phenyl)germane 39170 
 
 
To a solution of crude tris-para-anisylgermane 38 in CH2Cl2 (100 mL) was added 
conc. HCl (100 mL, 37% w/v). The reaction mixture was stirred for 5 h and was then 
extracted with CH2Cl2 (100 mL) and washed with H2O (2 x 100 mL). The combined 
organic extracts were dried over anhydrous MgSO4 and concentrated in vacuo to 
give crude dichlorogermane 39 as a brown oil. A sample of crude dichlorogermane 
39 was purified by Kugelrohr distillation (125 °C/0.1 mmHg).170 1H NMR (400 
MHz; CDCl3): , 1.93–1.97 (m, 2H, CH2CH2Ge), 2.47–2.52 (m, 2H, CH2CH2Ge), 
3.88 (s, 3H, 3 ( ArOCH3), 7.06 (d, J = 8.0 Hz, 2H, ArH), 7.63 (d, J = 8.0 Hz, 2H, 
ArH); m/z. (CI+) (rel. intensity) 716 [(M+NH4)+, 5], 698 (M+, 100), 680 [(M-F)+, 83], 
630 [(M-CF3)+, 19], 268 (63), 243 (62). 
  
Ge
OMe
Cl Cl
C8F17
Chemical Formula: C17H11Cl2F17GeO
Exact Mass: 697.91
Molecular Weight: 697.79
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(3,3,4,4,5,5,6,6,7,7,8,8,9,9,10,10,10-Heptadecafluorodecyl)-(4-methoxyphenyl) 
bisnaphthalen-2-ylmethylgermane 40170 
 
 
To oven dried magnesium turnings (1.04 g, 42.96 mmol) in Et2O (20 mL) was added 
a solution of 2-bromomethylnaphthalene (7.92 g, 35.8 mmol) in Et2O (30 mL) to 
initiate Grignard reagent formation. To this mixture was added a solution of crude 
dichlorogermane 39 (5.00 g, 7.16 mmol) in Et2O (30 mL) dropwise and the resulting 
mixture stirred for 2.5 h. The reaction mixture was extracted with Et2O (50 mL), 
washed with water (2 ( 20 mL), and was dried over MgSO4, then concentrated in 
vacuo to give crude bis(naphthalenylmethyl)germane 40. Purification by FC 
(petrol/EtOAc, 98:2 to 90:10), followed by F-SPE chromatography was required (50-
100% v/v MeCN/H2O or 30-70% v/v THF/H2O) gave bis(naphthylmethyl)germane 
40 as a yellow oil (3.00 g, 88%).170 Rf 0.35 (petrol/EtOAc, 20:1); 1H NMR (400 
MHz; CDCl3): , 1.22–1.26 (m, 2H, CH2CH2Ge), 1.88–2.01 (m, 2H, CH2CH2Ge), 
2.79 (s, 4H, 2 ( GeCH2Np), 3.91 (s, 3H, OCH3), 7.01 (d, J = 8.4 Hz, 2H, ArH), 7.16 
(dd, J = 8.4, 1.6 Hz, 2H, ArH), 7.34 (d, J = 8.4 Hz, 2H, ArH), 7.45 (s, 2H, ArH), 
7.47–7.55 (m, 4H, ArH), 7.72 (d, J = 8.0 Hz, 2H, ArH), 7.77 (d, J = 8.4 Hz, 2H, 
ArH), 7.87 (d, J = 7.6 Hz, 2H, ArH); m/z. (CI+) (rel. intensity) 928 [(M+NH4)+, 59], 
910 (M+, 2), 820 (100), 440 (10), 141 (37). 
  
Chemical Formula: C39H29F17GeO
Exact Mass: 910.12
Molecular Weight: 909.26
C8F17
Ge
OMe
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Bromo-(3,3,4,4,5,5,6,6,7,7,8,8,9,9,10,10,10-heptadecafluorodecyl)bisnaphthalen-
2-ylmethylgermane 41170 
 
 
To a solution of bis(naphthylmethyl)germane 40 (1.00 g, 1.10 mmol) in CH2Cl2 (10 
mL) was added a solution of conc. HBr (10 mL, 48% wt.). The resulting biphasic 
reaction mixture was stirred at rt overnight, extracted with CH2Cl2 (20 mL) and 
washed with H2O (3 ( 20 mL). The combined organic extracts were dried over 
MgSO4 and evaporated in vacuo. Purification by Kugelrohr distillation (125 °C/0.1 
mmHg) gave bromogermane 41 as a brown amorphous solid (0.96 g, 99%).170 1H 
NMR (400 MHz; CDCl3): , 1.29–1.34 (m, 2H, CH2CH2Ge), 1.89–2.02 (m, 2H, 
CH2CH2Ge), 3.01 (dd, J = 13.2, 5.6 Hz, 4H, 2 ( GeCH2Np), 7.23 (dd, J = 8.6, 1.6 
Hz, 2H, ArH), 7.44–7.50 (m, 6H, ArH), 7.69 (d, J = 7.6 Hz, 2H, ArH), 7.78 (d, J = 
8.4 Hz, 2H, ArH), 7.82 (d, J = 7.2 Hz, 2H, ArH); m/z. (EI+) (rel. intensity) 882 (M+, 
50), 741 [(M-Np)+, 1], 141 (100). 
  
Chemical Formula: C32H22BrF17Ge
Exact Mass: 881.98
Molecular Weight: 882.03
C8F17
Ge Br
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(3,3,4,4,5,5,6,6,7,7,8,8,9,9,10,10,10-Heptadecafluorodecyl)bisnaphthalen-2-yl-
methylgermylhydride 42246 
 
 
To a solution of bromogermane 41 (0.900 g, 1.02 mmol) in THF (10.0 mL) was 
added a solution of LiEt3BH (1.56 mL, 1.53 mmol, 1 M) at 0 °C. The resulting 
reaction mixture was stirred at rt overnight. A sat. solution of NaHCO3 (10 mL) was 
added and the mixture was then extracted with Et2O (3 ( 20 mL). The combined 
organic extracts were dried over MgSO4 and evaporated in vacuo. Purification by FC 
(EtOAc/Hexane, 50:50) gave germyl hydride 42 as a white amorphous solid (0.697 
g, 85%).246 Rf 0.50 (EtOAc/Hexane, 10:90); 1H NMR (400 MHz; CDCl3): , 1.03–
1.08 (m, 2H, CH2CH2Ge), 1.86–1.99 (m, 2H, CH2CH2Ge), 2.59 (ddt, J = 12.8, 6.0, 
2.8 Hz, 4H, 2 ( GeCH2Np), 4.30 (s, 1H, GeH), 7.19 (dd, J = 8.4, 1.6 Hz, 2H, ArH), 
7.40–7.48 (m, 6H, ArH), 7.69 (d, J = 7.6 Hz, 2H, ArH), 7.75 (d, J = 8.4 Hz, 2H, 
ArH), 7.80 (d, J = 8.0 Hz, 2H, ArH); m/z. (EI+) (rel. intensity) 804 (M+, 58), 663 
[(M-Np)+, 7], 531 (7), 215 (42), 141 (100).  
Chemical Formula: C32H23F17Ge
Exact Mass: 804.07
Molecular Weight: 803.14
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3.2.2.2. General Methods for the Synthesis of Germyl Silanes 
 
Method A (Jones’s conditions178): to a solution of germyl hydride 42 (1 eq.) in THF 
was added TMEDA (3.3 eq.) at -78 °C followed by addition of tBuLi (3 eq., 1.5 M) 
dropwise. The resulting mixture was stirred at -78 °C for 10 min and transferred to a 
-78 °C solution of silyl chloride (3 eq.) in THF was added. The resulting reaction 
mixture was slowly warmed up to rt and stirred for 16 h. A sat. solution of NH4Cl 
was added and the mixture was then extracted with Et2O (3 (). The combined 
organic extracts were dried over MgSO4 and evaporated in vacuo. Purification by FC 
(EtOAc/hexane, 5:95) gave pure silyl germane. 
 
Method B (Oshima’s conditions226): to a solution of germyl hydride 42 (1 eq.) in 
THF was added TMEDA (3.3 eq.) at -78 °C followed by addition of tBuLi (3 eq., 1.6 
M) dropwise. The resulting mixture was stirred at -78 °C for 10 min and transferred 
to a -78 °C solution of silyl chloride (3 eq.) and AgNO3 (10 mol% of silyl chloride) 
in THF was added. The resulting reaction mixture was slowly warmed up to rt and 
stirred for 16 h. A sat. solution of NH4Cl was added and the mixture was then 
extracted with Et2O (3 (). The combined organic extracts were dried over MgSO4 
and evaporated in vacuo. Purification by FC (neutral Al2O3, EtOAc/hexane, 5:95) 
gave pure silyl germane.  
 
Method C (Oshima’s method227): to a solution of germyl hydride 42 (1 eq.) in THF 
was added TMEDA (3.3 eq.) at -78 °C followed by addition of tBuLi (3 eq., 1.6 M) 
dropwise. The resulting mixture was stirred at -78 °C for 10 min and transferred to a 
-78 °C solution of silyl chloride (3 eq.) and ZnCl2!TMEDA (10 mol% of silyl 
chloride) in THF was added. The resulting reaction mixture was slowly warmed up 
to rt and stirred for 16 h. A sat. solution of NH4Cl was added and the mixture was 
then extracted with Et2O (3 (). The combined organic extracts were dried over 
MgSO4 and evaporated in vacuo. Purification by FC (neutral Al2O3, EtOAc/hexane, 
5:95) gave pure silyl germane.  
R3SiCl
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(3,3,4,4,5,5,6,6,7,7,8,8,9,9,10,10,10-Heptadecafluorodecyl)bisnaphthalen-2-yl-
methylgermyl tert-butyldimethylsilane 44 
 
 
Using Method A: germyl hydride 42 (0.200 g, 0.250 mmol). TMEDA (0.12 mL, 
0.830 mmol), tBuLi (0.50 mL, 0.750 mmol, 1.5 M), TBSCl (0.113 g, 0.750 mmol) in 
THF (5.0 mL) were employed. The resulting reaction mixture was slowly warmed up 
to rt and stirred for 16 h. Purification by FC (EtOAc/hexane, 5:95) gave TBS 
germane 44 as a yellow oil (0.125 g, 48%). Rf 0.53 (Et2O/petrol, 5:95); 1H NMR 
(400 MHz; CDCl3): , 0.08 (s, 6H, 2 ( CH3Si), 0.98 (s, 9H, C(CH3)3Si), 1.02–1.06 
(m, 2H, CH2CH2Ge), 1.76–1.89 (m, 2H, CH2CH2Ge), 2.61 (s, 4H, 2 ( GeCH2Np), 
7.14 (dd, J = 8.4, 1.6 Hz, 2H, ArH), 7.37–7.45 (m, 6H, ArH), 7.62 (d, J = 8.0 Hz, 
2H, ArH), 7.71 (d, J = 8.4 Hz, 2H, ArH), 7.79 (d, J = 7.6 Hz, 2H, ArH); 13C NMR 
(100 MHz; CDCl3) , -4.4 (q), 3.5 (t), 23.0 (2t), 27.3 (t), 27.5 (t), 108.2 (s), 110.2 (s), 
110.6 (3s), 110.9 (s), 111.0 (s), 117.8 (s), 124.6 (2d), 125.4 (2d), 126.0 (2d), 126.9 
(2d), 127.5 (2d), 127.6 (2d), 128.0 (2d), 131.1 (2s), 133.8 (2s), 138.1 (2s); 19F NMR 
(376 MHz; CDCl3) , -126.1 (s, 2F), -123.8 (s, 2F), -122.7 (s, 2F), -121.9 (m, 6F), -
116.7 (m, 2F), -80.7 (t, J = 10.1 Hz, 3F, (CF2)6CF2CF3]; IR/max (neat) 3054 (w), 2987 
(w) 1599 (C=C), 1507 (w), 1202 (m), 1144 (m), 817 (m), 744 (m) cm-1; m/z (EI+) 
(rel. intensity) 918 [(M+H)+, 21)], 860 (26), 777 [(M-Np)+, 46], 349 (75), 215 (41), 
141 (100); HRMS (EI+) calcd. for C38H37F1774GeSi (M+H)+ 918.1605, found 
918.1608 () 0.3 ppm). 
 
Using Method B: germyl hydride 42 (0.100 g, 0.125 mmol), TMEDA (0.06 mL, 
0.411 mmol), tBuLi (0.23 mL, 0.374 mmol, 1.6 M), TBSCl (0.056 g, 0.374 mmol) 
and AgNO3 (6.46 mg, 0.038 mmol) in THF (5.0 mL) was employed. Purification by 
FC (neutral Al2O3, EtOAc/hexane, 5:95) gave TBS germane 44 as a yellow oil (0.084 
g, 74%). Analytical data as shown above. 
  
Chemical Formula: C38H37F17GeSi
Exact Mass: 918.16
Molecular Weight: 917.40
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(3,3,4,4,5,5,6,6,7,7,8,8,9,9,10,10,10-Heptadecafluorodecyl)bisnaphthalen-2-yl-
methylgermyl triethylsilane 48 
 
 
Using Method B: germyl hydride 42 (0.050 g, 0.062 mmol), TMEDA (0.03 mL, 
0.205 mmol), tBuLi (0.13 mL, 0.186 mmol, 1.6 M), TESCl (0.029 g, 0.187 mmol) 
and AgNO3 (3.23 mg, 0.019 mmol) in THF (2.0 mL) was employed. Purification by 
FC (neutral Al2O3, EtOAc/hexane, 5:95) gave TES germane 49 as a yellow oil (0.051 
g, 89%). Rf 0.55 (Et2O/petrol, 5:95); 1H NMR (400 MHz; CDCl3): , 0.66 (q, J = 7.6 
Hz, 6H, 3 ( CH2Si), 0.92 (t, J = 8.0 Hz, 9H, 3 ( CH3CH2Si), 1.01–1.06 (m, 2H, 
CH2CH2Ge), 1.84–1.97 (m, 2H, CH2CH2Ge), 2.58 (d, J = 12.8 Hz, 2H, GeCH2Np), 
2.62 (d, J = 12.4 Hz, 2H, GeCH2Np), 7.16 (dd, J = 8.4, 1.6 Hz, 2H, ArH), 7.39–7.47 
(m, 6H, ArH), 7.66 (d, J = 7.6 Hz, 2H, ArH), 7.74 (d, J = 8.4 Hz, 2H, ArH), 7.80 (d, 
J = 8.0 Hz, 2H, ArH); 13C NMR (100 MHz; CDCl3) , 3.3 (t), 4.4 (3q), 8.2 (3t), 23.1 
(2t), 27.4 (2t), 108.3 (s), 108.4 (s), 110.2 (s), 110.7 (s), 110.7 (s), 111.1 (s), 111.2 (s), 
117.9 (s), 124.6 (2d), 125.2 (2d), 126.1 (2d), 126.9 (2d), 127.4 (2d), 127.6 (2d), 
128.0 (2d), 131.1 (2s), 133.8 (2s), 138.3 (2s); 19F NMR (376 MHz; CDCl3) , -126.1 
(s, 2F), -123.6 (s, 2F), -122.7 (s, 2F), -121.9 (m, 6F), -116.5 (m, 2F), -80.7 (t, J = 
10.0 Hz, 3F, (CF2)6CF2CF3]; IR/max (neat) 3054 (w), 2987 (w), 1598 (C=C), 1507 
(w), 1439 (w), 1239 (m), 1202 (m), 1145 (m), 838 (m), 818 (m), 704 (m) cm-1; m/z 
(EI+) (rel. intensity) 918 [(M+H)+, 3], 777 [(M-Np)+, 58], 349 (49), 321 (47), 215 
(74), 141 (100); HRMS (EI+) calcd. for C38H37F1774GeSi (M+H)+ 918.1605, found 
918.1602 (? -0.3 ppm).  
 
Using method C: germyl hydride 42 (0.050 g, 0.062 mmol), TMEDA (0.03 mL, 
0.205 mmol), tBuLi (0.13 mL, 0.186 mmol, 1.6 M), TESCl (0.029 g, 0.187 mmol) 
and ZnCl2!TMEDA (6 µL, 0.019 mmol) in THF (2.0 mL) was employed. 
Purification by FC (neutral Al2O3, EtOAc/hexane, 5:95) gave TES germane 48 as a 
yellow oil (0.048 g, 83%). Analytical data as shown above. 
  
Chemical Formula: C38H37F17GeSi
Exact Mass: 918.16
Molecular Weight: 917.40
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 (3,3,4,4,5,5,6,6,7,7,8,8,9,9,10,10,10-Heptadecafluorodecyl)bisnaphthalen-2-yl-
methylgermyl trimethylsilane 49 
 
 
Using Method B: germyl hydride 42 (0.050 g, 0.062 mmol), TMEDA (0.03 mL, 
0.205 mmol), tBuLi (0.13 mL, 0.186 mmol, 1.6 M), TMSCl (0.03 mL, 0.187 mmol) 
and AgNO3 (3.23 mg, 0.019 mmol) in THF (2.0 mL) was employed. Purification by 
FC (neutral Al2O3, EtOAc/hexane, 5:95) gave TMS germane 49 as a colourless oil 
(0.052 g, 96%). Rf 0.45 (Et2O/petrol, 5:95); 1H NMR (400 MHz; CDCl3): , 0.04 (s, 
9H, 3 ( CH3Si), 1.05–1.09 (m, 2H, CH2CH2Ge), 1.93–2.06 (m, 2H, CH2CH2Ge), 
2.57 (d, J = 12.4 Hz, 2H, GeCH2Np), 2.61 (d, J = 12.4 Hz, 2H, GeCH2Np), 7.18 (dd, 
J = 8.8, 2.0 Hz, 2H, ArH), 7.39–7.48 (m, 6H, ArH), 7.68 (d, J = 8.0 Hz, 2H, ArH), 
7.75 (d, J = 8.4 Hz, 2H, ArH), 7.81 (d, J = 8.0 Hz, 2H, ArH); 13C NMR (100 MHz; 
CDCl3) , –0.7 (s), 2.6 (t), 22.4 (2t), 27.7 (2t), 108.4 (s), 110.2 (s), 110.7 (s), 110.8 (s), 
111.1 (s), 111.2 (s), 117.1 (s), 118.0 (s), 124.7 (2d), 125.2 (2d), 126.1 (2d), 126.9 
(2d), 127.4 (2d), 127.6 (2d), 128.1 (2d), 131.1 (2s), 133.8 (2s), 138.5 (2s); 19F NMR 
(376 MHz; CDCl3) , -126.1 (s, 2F), -123.5 (s, 2F), -122.7 (s, 2F), -121.8 (m, 6F), -
116.4 (m, 2F), -80.7 (t, J = 10.1 Hz, 3F, (CF2)6CF2CF3]; IR/max (neat) 3054 (w), 2987 
(w), 1598 (C=C), 1507 (w), 1414 (m), 1238 (m), 1145 (m), 818, 744 cm-1; m/z (EI+) 
(rel. intensity) 876 [(M+H)+, 3], 735 [(M-Np)+, 65], 307 (96), 215 (63), 141 (100); 
HRMS (EI+) calcd. for C35H31F1774GeSi (M+H)+ 876.1135, found 876.1139 (? 0.4 
ppm).  
 
Using method C: germyl hydride 42 (0.050 g, 0.062 mmol), TMEDA (0.03 mL, 
0.205 mmol), tBuLi (0.13 mL, 0.186 mmol, 1.6 M), TMSCl (0.03 mL, 0.187 mmol) 
and ZnCl2!TMEDA (6 µL, 0.019 mmol) in THF (2.0 mL) was employed. 
Purification by FC (neutral Al2O3, EtOAc/hexane, 5:95) gave TMS germane 49 as a 
colourless oil (0.046 g, 83%). Analytical data as shown above. 
  
Chemical Formula: C35H31F17GeSi
Exact Mass: 876.11
Molecular Weight: 875.32
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3.2.2.3. Preparation of Authentic Germylation Products 
(3,3,4,4,5,5,6,6,7,7,8,8,9,9,10,10,10-Heptadecafluorodecyl)bis(naphthalen-2-yl-
methyl)para-tolylgermane 45170 
 
 
To a solution of bromogermane 40 (0.05 g, 0.057 mmol) in Et2O (1.0 mL) was added 
a solution of para-tolylmagnesiumbromide (0.28 mL, 0.283 mmol, 1.0 M) dropwise. 
The resulting mixture was stirred at 0 °C for 1 h and then at rt for 16 h. The reaction 
mixture was diluted with Et2O (10 mL), washed with a solution of NH4Cl (10 mL, 
1.0 M) and water (2 ( 10 mL). The combined organic extracts were dried over 
MgSO4, then concentrated in vacuo to give crude para-tolyl germane 45 as a green 
oil. Purification by FC (hexane/EtOAc, 99:1 to 97:3) gave para-tolyl germane 45 as 
a brown oil (0.04 g, 82%).170 1H NMR (400 MHz; CDCl3): , 1.12–1.16 (m, 2H, 
CH2CH2Ge), 1.76–1.90 (m, 2H, CH2CH2Ge), 2.41 (s, 3H, GeC6H4CH3), 2.73 (s, 4H, 
2 ( GeCH2Np), 7.08 (dd, J = 8.4, 1.6 Hz, 2H, ArH), 7.22 (d, J = 8.4 Hz, 2H, ArH), 
7.28 (d, J = 6.8 Hz, 2H, ArH), 7.39 (d, J = 7.6 Hz, 2H, ArH), 7.41–7.46 (m, 4H, 
ArH), 7.63 (d, J = 7.6 Hz, 2H, ArH), 7.69 (d, J = 8.4 Hz, 2H, ArH), 7.79 (d, J = 7.6 
Hz, 2H, ArH); m/z. (EI+) (rel. intensity) 894 (M+, 20), 753 [(M-Np)+, 78], 322 (57), 
282 (7), 141 (100). 
  
Chemical Formula: C39H29F17Ge
Exact Mass: 894.12
Molecular Weight: 893.26
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3,4-dimethoxyphenyl(3,3,4,4,5,5,6,6,7,7,8,8,9,9,10,10,10-
Heptadecafluorodecyl)bis(naphthalen-2-yl-methyl)- germane 50  
 
 
To a solution of 4-bromoveratrole (10 µL, 0.068 mmol) in THF (1 mL) was added 
tBuLi (71 µL, 0.114 mmol, 1.6 M) dropwise at -78 °C. The resulting mixture was 
stirred for 30 min and then added to a solution of bromogermane 40 (0.050 g, 0.057 
mmol) in THF (1 mL) at -78 °C. The resulting reaction mixture was slowly warmed 
up to rt and stirred for 3 h. A sat. solution of NH4Cl was added and the mixture was 
then extracted with Et2O (5 mL) and washed with water (2 ( 5 mL). The combined 
organic extracts were dried over MgSO4 and evaporated in vacuo. Purification by FC 
(petro/Et2O, 95:5) gave germyl veratrole 50 as a colourless oil (0.047 g, 88%). Rf 
0.08 (Et2O/petrol, 5:95); 1H NMR (400 MHz; CDCl3): , 1.16–1.21 (m, 2H, 
CH2CH2Ge), 1.84–1.97 (m, 2H, CH2CH2Ge), 2.75 (s, 4H, 2 ( GeCH2Np), 3.52 (s, 
3H, OCH3), 3.92 (s, 3H, OCH3), 6.51 (s, 1H, ArH), 6.92–6.93 (m, 2H, ArH), 7.11 
(dd, J = 6.3, 1.7 Hz, 2H, ArH), 7.40–7.43 (m, 6H, ArH), 7.64 (d, J = 7.8 Hz, 2H, 
ArH), 7.71 (d, J = 8.4 Hz, 2H, ArH), 7.79 (d, J = 7.7 Hz, 2H, ArH); 13C NMR (100 
MHz; CDCl3) , 2.1 (d), 22.9 (2d), 26.4 (d), 55.5 (q), 55.7 (q), 108.4 (s), 110.2 (s), 
110.7 (s), 111.1 (s), 111.2 (d), 112.0 (s), 115.3 (s), 116.1 (d), 116.9 (s), 118.0 (s), 
124.9 (2d), 125.7 (2d), 126.7 (2d), 127.0 (2d), 127.4 (2d), 127.6 (2d), 128.0 (2d), 
131.2 (2s), 133.7 (2s), 136.6 (2s), 148.8 (s), 150.0 (s); 19F NMR (376 MHz; CDCl3) , 
-125.1 (s, 2F), -122.5 (s, 2F), -121.8 (s, 2F), -121.0 (m, 6F), -115.3 (m, 2F), -79.8 (t, 
J = 9.9 Hz, 3F, (CF2)6CF2CF3]; IR/max (neat) 3056 (w), 2964 (w), 1600 (C=C, w), 
1508 (C-O, m), 1445 (m), 1234 (s), 1203 (s), 1148 (m), 893 (m), 856 (m), 743 (m) 
cm-1; m/z (EI+) (rel. intensity) 940 [(M+H)+, 15], 799 [(M-Np)+, 100], 371 (75), 141 
(100); HRMS (EI+) calcd. for C40H32F1774GeO2 (M+H)+ 941.1343, found 941.1339 (
? -0.4 ppm). 
  
C8F17
Ge OMe
OMe
Chemical Formula: C40H31F17GeO2
Exact Mass: 940.13
Molecular Weight: 939.29
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3.2.2.4. By-product from the Germylation of Aryl Iodides 
Bis[(3,3,4,4,5,5,6,6,7,7,8,8,9,9,10,10,10-Heptadecafluorodecyl)bis(naphthalen-2-
yl-methyl)]-digermoxane 46  
 
 
Digermoxane 46 was formed as a by-product in the germylation of aryl iodides with 
silyl germanes 44 and 49 (see section 2.2.2.2, section 2.2.2.4 and section 2.2.2.6). It 
was also the product from unsuccessful synthesis of germyl veratrole 50 via Grignard 
reaction. Purification by FC (petro/Et2O, 95:5) gave digermoxane 46 as a yellow oil 
(0.047 g, 88%). Rf 0.05 (Et2O/petrol, 5:95); 1H NMR (400 MHz; CDCl3): , 0.89–
0.93 (m, 4H, CH2CH2Ge), 1.77–1.86 (m, 4H, CH2CH2Ge), 2.28 (d, J = 12.8 Hz, 4H, 
2 ( GeCH2Np), 2.47 (d, J = 12.8 Hz, 4H, 2 ( GeCH2Np), 7.02 (dd, J = 1.6, 8.4 Hz, 
4H, ArH), 7.24 (s, 4H, ArH), 7.44–7.55 (m, 8H, ArH), 7.65 (d, J = 7.9 Hz, 4H, ArH), 
7.72 (d, J = 8.4 Hz, 4H, ArH), 7.82 (d, J = 7.8 Hz, 4H, ArH); 13C NMR (100 MHz; 
CDCl3) , 6.5 (d), 25.3 (2d), 26.5 (d), 108.4 (s), 110.2 (s), 110.7 (s), 111.1 (s), 111.2 
(d), 112.0 (s), 115.3 (s), 116.1 (d), 116.9 (s), 118.0 (s), 125.1 (2d), 125.8 (2d), 126.4 
(2d), 127.0 (2d), 127.2 (2d), 127.7 (2d), 128.3 (2d), 131.4 (2s), 133.7 (2s), 135.0 (2s); 
19F NMR (376 MHz; CDCl3) , -126.2 (s, 2F), -123.8 (s, 2F), -122.8 (s, 2F), -122.0 
(m, 6F), -116.4 (m, 2F), -80.9 (t, J = 9.6 Hz, 3F, (CF2)6CF2CF3]; IR/max (neat) 3056 
(w), 2959 (w), 1600 (C=C, w), 1510 (w), 1237 (s), 1203 (s), 1148 (s), 858 (m), 819 
(m), 745 (s) cm-1; m/z (ESI+) (rel. intensity) 1621 (M+, 50), 844 (100); HRMS (EI+) 
calcd. for C64H44F3474Ge2O (M+H)+ 1622.1343, found 1622.1339 (? -0.4 ppm). 
  
C8F17
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Chemical Formula: C64H44F34Ge2O
Exact Mass: 1622.13
Molecular Weight: 1620.26
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3.2.3. Conditions Screened for the Germylation of Aryl Iodides 
3.2.3.1. Germylation of 4-Iodotoluene with Silyl Germanes 
1) Conditions adapted from Jones, Martin and Buchwald: 
 
Method A (Jones’178): 
Pd2dba3 (2.5 mg, 5 mol%) and P(tBu)2diph (3.3 mg, 20 mol%) were dissolved in 
anhydrous 1,4-dioxane (200 %L) and stirred at rt for 15 min. The degassed catalyst 
solution was then added to a degassed solution of TBS germane 44 (50 mg, 0.055 
mmol), 4-iodotoluene (11.88 mg, 0.055 mmol), and iPr2NEt (20 %L, 0.112 mmol) in 
anhydrous 1,4-dioxane (800 %L). The resulting mixture was allowed to stir for 16 h. 
The crude mixture was diluted with EtOAc (10.0 mL) and washed with water (3 ( 
5.0 mL). The organic extracts was dried over MgSO4 and evaporated in vacuo to 
give a yellow oil. The crude reaction mixture was then subjected to 1H NMR and 
LCMS analyses. See Table 45 for condition modifications and corresponding 
outcomes. 
 
Method B (Martin’s180): 
Pd2dba3 (0.8 mg, 1.5 mol%) and P(tBu)3 (3.8 %L, 6 mol%) were dissolved in 
anhydrous 1,4-dioxane (200 %L) and stirred at rt for 15 min. The degassed catalyst 
solution was then added to a degassed solution of TBS germane 44 (50 mg, 0.055 
mmol), 4-iodotoluene (11.88 mg, 0.055 mmol), and K3PO4 (34.7 mg, 0.164 mmol) in 
anhydrous 1,4-dioxane (800 %L). The resulting mixture was allowed to stir for 16 h. 
The crude mixture was diluted with EtOAc (10.0 mL) and washed with water (3 ( 
5.0 mL). The organic extracts was dried over MgSO4 and evaporated in vacuo to 
give a yellow oil. The crude reaction mixture was then subjected to 1H NMR and 
LCMS analyses. See Table 45 for condition modifications and corresponding 
outcomes. 
 
Method C (Buchwald’s213): 
Pd2dba3 (0.8 mg, 1.5 mol%) and P(Cy)2diph (0.9 mg, 6 mol%) were dissolved in 
anhydrous 1,4-dioxane (200 %L) and stirred at rt for 15 min. The degassed catalyst 
C8F17
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solution was then added to a degassed solution of TBS germane 44 (50 mg, 0.055 
mmol) and 4-iodotoluene (11.88 mg, 0.055 mmol) in anhydrous 1,4-dioxane (800 
%L). The resulting mixture was allowed to stir for 16 h. The crude mixture was 
diluted with EtOAc (10.0 mL) and washed with water (3 ( 5.0 mL). The organic 
extracts was dried over MgSO4 and evaporated in vacuo to give a yellow oil. The 
crude reaction mixture was then subjected to 1H NMR and LCMS analyses. See 
Table 45 for condition modifications and corresponding outcomes. 
 
Modification of Jones’, Martin’s and Buchwald’s conditions: 
Modifications of reaction conditions were attempted with Jones’,178 Martin’s180 and 
Buchwald’s213 conditions (Table 45). 
Entry Method F- (5 eq.) Temp Outcome 
1 A CsF rt S.M. recovered 
2 B KF rt S.M. recovered 
3 C KF rt S.M. recovered 
4 A CsF 100 °C S.M. recovered 
5 B KF 100 °C S.M. recovered 
6 C KF 100 °C S.M. recovered 
7 A - 100 °C S.M. recovered 
8 B - 100 °C S.M. recovered 
9 C - 100 °C S.M. recovered 
 
Table 45: Attempted germylation of 4-iodotoluene with TBS germane 44 using Jones’178, 
Martin’s180 and Buchwald’s213 conditions. 
(‘-’ = no fluoride was used) 
 
2) Conditions adapted from Yamanoi and Nishihara, Murata and Oshima: 
 
Method A (Yamanoi and Nishihara’s188,189): 
[Rh(cod)2]BF4 (1.2 mg, 5 mol%) was dissolved in anhydrous NMP (200 %L). The 
degassed catalyst solution was then added to a degassed solution of TBS germane 44 
(55.0 mg, 0.060 mmol), 4-iodotoluene (6.54 mg, 0.030 mmol), and K3PO4 (19.1 mg, 
0.090 mmol) in anhydrous NMP (800 %L). The resulting mixture was allowed to stir 
at rt for 16 h. The crude mixture was diluted with EtOAc (10.0 mL) and washed with 
water (3 ( 5.0 mL). The organic extracts was dried over MgSO4 and evaporated in 
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vacuo to give a yellow oil. The crude reaction mixture was then subjected to 1H 
NMR and MS (EI) analysis, and trace amount of the desired product was identified. 
 
Method B (Murata’s187): 
[Rh(cod)(MeCN)2]BF4 (0.4 mg, 1.5 mol%) was dissolved in anhydrous DMF (200 
%L) and stirred at rt for 15 min. The degassed catalyst solution was then added to a 
degassed solution of TBS germane 44 (55.0 mg, 0.060 mmol), 4-iodotoluene (6.54 
mg, 0.030 mmol), and DABCO (16.8 mg, 0.150 mmol) in anhydrous DMF (800 %L). 
The resulting mixture was allowed to stir at 80 °C for 16 h. The crude mixture was 
diluted with EtOAc (10.0 mL) and washed with water (3 ( 5.0 mL). The organic 
extracts was dried over MgSO4 and evaporated in vacuo to give a yellow oil. The 
crude reaction mixture was then subjected to 1H NMR and MS (EI) analysis, and 
trace amount of the desired product was identified. 
 
Method C (Oshima’s163): 
Pd(OAc)2 (0.6 mg, 5 mol%) and dppf (1.5 mg, 5 mol%) were dissolved in anhydrous 
DMF (200 %L) and stirred at rt for 15 min. The degassed catalyst solution was then 
added to a degassed solution of TBS germane 44 (50.0 mg, 0.055 mmol), 4-
iodotoluene (14.3 mg, 0.065 mmol), and Cs2CO3 (19.7 mg, 0.061 mmol) in 
anhydrous DMF (800 %L). The resulting mixture was allowed to stir at rt for 16 h. 
The crude mixture was diluted with EtOAc (10.0 mL) and washed with water (3 ( 
5.0 mL). The organic extracts was dried over MgSO4 and evaporated in vacuo to 
give a yellow oil. The isolated yields of the desired product 45 were then obtained by 
subjecting the crude reaction mixture to PLC (Hexane/Et2O, 95:5) for purification. 
See Table 46 for condition modifications and corresponding outcomes from PLC 
purification.  
  
Chapter 3 
 131 
Modification of Oshima’s Conditions: 
Modifications of reaction conditions were attempted with Oshima’s conditions163 
(Table 46). 
Entry Cat. (mol%) Lig. (mol%) Add. Temp. T/d Outcome 
1 Pd(OAc)2 (5) dppf (5) - rt 2-7 9% 
2 Pd(OAc)2 (5) dppf (5) 
- 40 °C" 
100 °C 7 
3% 
3 Pd(OAc)2 (10) dppf (10) - rt"100 °C 7 2% 
4 PdCl2(dppf) (5) - - rt 3 Trace 
5 Pd(OAc)2 (5) dppp (5) 
- rt 7 S.M. recovered 
6 PdCl2(dppp) (5) - 
- rt 7 S.M. recovered 
7 Pd(OAc)2 (5) dppb (5) - rt 7 S.M. recovered 
8 Pd(OAc)2 (5) DPEphos (5) - rt 3 Trace 
9 Pd(OAc)2 (5) Xantphos (5) - rt 3 Trace 
10 Pd(OAc)2 (5) dppf (5) KF rt 3 Trace 
11 Pd(OAc)2 (5) dppf (5) CsF rt 3 Trace 
12 Pd(OAc)2 (5) dppf (5) Ag2O rt 3 Trace 
 
Table 46: Attempted optimisation of 4-iodotoluene with TBS germane 44 using Oshima’s 
conditions.163 
(‘-’ = no ligand or additive was used) 
 
Germylation of 4-iodotoluene with different silyl germanes using Oshima’s 
conditions: 
Germylation of 4-iodotoluene with three different silyl germanes 44, 48 and 49 was 
attempted using Oshima’s conditions.163 The crude reaction mixture was then 
subjected to 1H NMR analysis. See Table 47 for corresponding outcomes. 
  
Entry SiR3 Outcome  
1 TBS Trace 
2 TES Trace 
3 TMS Trace 
 
Table 47: Attempted germylation of 4-iodotoluene with three different silyl germanes 44, 48 an 
49 using Oshima's conditions.163 
  
C8F17
Ge
SiR3
2-Np 2-Np
+
I
C8F17
Ge
2-Np 2-Np
SiR3 = TBS 44
SiR3 = TES 48
SiR3 = TMS 49
45
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3.2.3.2. Germylation of 1-Iodoveratrole with TMS Germane 
 
1) Conditions adapted from Oshima and Murata: 
Method A (Oshima’s163): 
Pd(OAc)2 (0.3 mg, 5 mol%) and dppf (0.8 mg, 5 mol%) were dissolved in anhydrous 
DMF (200 %L) and stirred at rt for 15 min. The degassed catalyst solution was then 
added to a degassed solution of TMS germane 49 (24.8 mg, 0.028 mmol), 1-
iodoveratrole (9.0 mg, 0.034 mmol), and Cs2CO3 (9.7 mg, 0.031 mmol) in anhydrous 
DMF (800 %L). The resulting mixture was allowed to stir at rt for 16 h. The crude 
mixture was diluted with EtOAc (10.0 mL) and washed with water (3 ( 5.0 mL). The 
organic extracts was dried over MgSO4 and evaporated in vacuo to give a yellow oil. 
The crude reaction mixture was then subjected to 1H NMR analysis, and trace 
amount of the desired product was identified. 
 
Method B (Murata’s187): 
Rh(acac)(C2H4)2 (0.4 mg, 5 mol%) was dissolved in anhydrous DMF (200 %L) and 
stirred at rt for 15 min. The degassed catalyst solution was then added to a degassed 
solution of TMS germane 49 (24.8 mg, 0.028 mmol), 1-iodoveratrole (9.0 mg, 0.034 
mmol), and DABCO (7.6 mg, 0.070 mmol) in anhydrous DMF (800 %L). The 
resulting mixture was allowed to stir at 80 °C for 16 h. The crude mixture was 
diluted with EtOAc (10.0 mL) and washed with water (3 ( 5.0 mL). The organic 
extracts was dried over MgSO4 and evaporated in vacuo to give a yellow oil. The 
ratio of components in the crude reaction mixture was then determined by 1H NMR 
analysis. See Table 48 for condition modifications and corresponding outcomes. 
 
Method C (Murata’s187): 
[Rh(cod)(MeCN)2]BF4 (0.5 mg, 10 mol%) was dissolved in anhydrous DMF (200 
%L) and stirred at rt for 15 min. The degassed catalyst solution was then added to a 
degassed solution of TMS germane 49 (24.8 mg, 0.028 mmol), 1-iodoveratrole (9.0 
mg, 0.034 mmol), and DABCO (7.6 mg, 0.070 mmol) in anhydrous DMF (800 %L). 
The resulting mixture was allowed to stir at 80 °C for 16 h. The crude mixture was 
C8F17
Ge
Si
2-Np 2-Np
+
I
OMe
C8F17
Ge
2-Np 2-Np
OMe
Method A/B/COMe OMe
49 50
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diluted with EtOAc (10.0 mL) and washed with water (3 ( 5.0 mL). The organic 
extracts was dried over MgSO4 and evaporated in vacuo to give a yellow oil. The 
crude reaction mixture was then subjected to 1H NMR analysis, and trace amount of 
the desired product was identified. 
 
Modification of Murata’s Conditions (Method B): 
Modifications of reaction conditions were attempted with Murata’s conditions187 
(Table 48). 
Entry Slow Additions Outcome (1H NMR) 
1 No slow addition 
Ge-Ver: Ge-TMS: Ge-O-Ge 
(2.23: 1.00: 0) 
2 1-Iodoveratrole (3.17: 1.00: 0) 
3 TMS germane 49 (1.90: 1.00: 0) 
4 1-Iodoveratrole + Rh(acac)(C2H4)2 (1.08: 1.00: 0) 
5 TMS germane 49 + Rh(acac)(C2H4)2 (0.64: 1.00: 0) 
6 Rh(acac)(C2H4)2  (1.03: 1.00: 0.53) 
7 Rh(acac)(cod) (1.03: 1.00: 1.13) 
 
Table 48: Attempted optimisation of Murata's conditions187 for germylation of 1-iodoveratrole 
with TMS germane 49. 
(‘slow addition’ = reagents were added at 0.1 mL/h using a syringe pump) 
 
The ratio of components in the crude reaction mixture was calculated based on the 
chemical shifts of CH2CH2Ge protons in 1H NMR spectra (Table 49). 
Component 
1H NMR (400 MHz, CDCl3): 
CH2CH2Ge ()/ppm) 
Ge-Ver 1.16–1.21 (m, 2H) 
Ge-TMS 1.05–1.09 (m, 2H) 
Ge-O-Ge 0.89–0.93 (m, 4H) 
 
Table 49: The chemical shifts of CH2CH2Ge protons of different components in the crude 
reaction mixture. 
 
2) Conditions adapted from Marder: 
Method D (Marder’s228): 
CuI (0.6 mg, 10 mol%) and nBu3P (0.8 %L, 13 mol%) were dissolved in anhydrous 
THF (200 %L) and stirred at rt for 15 min. The degassed catalyst solution was then 
added to a degassed solution of TMS germane 49 (30.0 mg, 0.034 mmol), 1-
iodoveratrole (8.2 mg, 0.034 mmol), and KOtBu (3.9 mg, 0.051 mmol) in anhydrous 
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DMF (800 %L). The resulting mixture was allowed to stir at rt for 16 h. The crude 
mixture was diluted with EtOAc (10.0 mL) and washed with water (3 ( 5.0 mL). The 
organic extracts was dried over MgSO4 and evaporated in vacuo to give a yellow oil. 
The ratio of components in the crude reaction mixture was then determined by 1H 
NMR analysis. The isolated yields of the desired product 50 were then obtained by 
subjecting the crude reaction mixture to PLC (Hexane/Et2O, 95:5) for purification. 
See Table 50 for condition modifications and corresponding outcomes. 
 
Method E (Marder’s228): 
CuCl (0.2 mg, 7.5 mol%) and (iPr)NHC.Cl (0.9 mg, 7.5 mol%) were dissolved in 
anhydrous THF (200 %L) and stirred at rt for 15 min. The degassed catalyst solution 
was then added to a degassed solution of TMS germane 49 (25.0 mg, 0.029 mmol), 
1-iodoveratrole (7.5 mg, 0.029 mmol), and KOtBu (1.0 mg, 30 mol%) in anhydrous 
DMF (800 %L). The resulting mixture was allowed to stir at rt for 16 h. The crude 
mixture was diluted with EtOAc (10.0 mL) and washed with water (3 ( 5.0 mL). The 
organic extracts was dried over MgSO4 and evaporated in vacuo to give a yellow oil. 
The crude reaction mixture was then subjected to 1H NMR analysis, and trace 
amount of the desired product was identified. 
 
Modification of Marder’s conditions: 
Modifications of reaction conditions were attempted with Marder’s conditions228 
(Table 50). 
Entry Temperature Solvent Quench Outcome (1H NMR) 
1 rt " 60 °C THF H2O 
Ge-Ver: Ge-H (0.63: 1.00) 
Ge-Ver (14% isolated yield) 
2 rt " 80 °C THF D2O  
Ge-Ver: Ge-H (0.34: 1.00) 
Ge-Ver (not isolated) 
3 rt " 80 °C DMF H2O 
Ge-Ver: Ge-H (trace: trace) 
Ge-O-Ge dimer present 
 
Table 50: Attempted optimisation of Marder's conditions228 for germylation of 1-iodoveratrole 
with TMS germane 49. 
 
The ratio of components in the crude reaction mixture was calculated based on the 
chemical shifts of CH2CH2Ge protons and GeH proton in 1H NMR spectra (Table 
51). 
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Component 
1H NMR (400 MHz, CDCl3): 
CH2CH2Ge ()/ppm) GeH ()/ppm) 
Ge-Ver 1.16–1.21 (m, 2H) ( 
Ge-TMS 1.05–1.09 (m, 2H) ( 
Ge-H 1.03–1.08 (m, 2H) 4.30 (s, 1H) 
 
Table 51: The chemical shifts of CH2CH2Ge protons and GeH proton of different components in 
the crude reaction mixture. 
 
3.2.3.3. Germylation of aryl iodides using the combined conditions of Oshima 
and Marder 
1) Germylation of 1-iodoveratrole with TMS germane: 
 
The combined conditions of Oshima163 and Marder228: 
Pd(OAc)2 (0.4 mg, 5 mol%) and dppf (0.9 mg, 5 mol%) were pre-activated in 
anhydrous THF (200 %L) and stirred at rt for 15 min. The degassed catalyst solution 
was then added to a degassed solution of 1-iodoveratrole (8.8 mg, 0.029 mmol) and 
stirred at rt for a further 15 min. CuI (6.9 mg, 0.031 mmol) and nBu3P (11.6 %L, 
0.040 mmol) and Cs2CO3 (11.1 mg, 0.031 mmol) were pre-activated in anhydrous 
THF (200 %L) and stirred at rt for 15 min. A degassed solution of TMS germane 49 
(28.8 mg, 0.029 mmol) in anhydrous THF (800 %L) was then added to the copper 
mixture. The resulting mixture was allowed to stir at rt for a further 15 min. The Pd-
catalyst-1-iodoveratrol mixture was then added to the Cu-TMS germane mixture and 
allowed to stir at 80 °C for 16 h. The crude mixture was diluted with EtOAc (20.0 
mL) and washed with NH4Cl (10.0 mL) followed by water (2 ( 10.0 mL). The 
organic extracts was dried over MgSO4 and evaporated in vacuo to give a yellow oil. 
The ratio of components in the crude reaction mixture was then determined by 1H 
NMR analysis. The isolated yields of the desired product 50 were then obtained by 
subjecting the crude reaction mixture to PLC (Hexane/Et2O, 95:5) for purification. 
See Table 52 for condition modifications and corresponding outcomes. 
 
  
C8F17
Ge
Si
2-Np 2-Np
+
I
OMe
C8F17
Ge
2-Np 2-Np
OMe
OMe
OMe
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Modification of the combined conditions of Oshima and Marder: 
Modifications of reaction conditions were attempted with combined conditions of 
Oshima163 and Marder228 (Table 52). 
 
Entry Ligand Additive Temperature Outcome 
1 nBu3P - 60 °C 
Ge-Ver: Ge-H (0.29: 1.00) 
Ge-Ver (38% isolated) 
2 nBu3P KHMDS 80 °C 
Ge-H (no presence) 
Ge-Ver (8% isolated) 
3 nBu3P KHMDS 50 °C 
Ge-Ver: Ge-H (1.01: 1.00) 
Ge-Ver (not isolated) 
4 Lig 1 - 50 °C S.M. recovered 
6 Lig 2 - 50 °C 25% (isolated yield) 
7 Lig 3 - 50 °C S.M. recovered + Trace Ge-H 
8 Lig 4 - 50 °C 33% (isolated yield) 
9 Lig 5 - 50 °C S.M. recovered 
10 Lig 6 - 50 °C S.M. recovered 
11 Lig 7 - 50 °C 64% (isolated yield)* 
 
Table 52: Attempted optimisation of combined conditions of Oshima163 and Marder228 for 
germylation of 1-iodoveratrole with TMS germane 49. 
(‘*’ = irreproducible result; ‘-’ = no additive was used) 
 
The ratio of components in the crude reaction mixture was calculated based on the 
chemical shifts of CH2CH2Ge protons and GeH proton in 1H NMR spectra (Table 
53). 
Component 
1H NMR (400 MHz, CDCl3): 
CH2CH2Ge ()/ppm) GeH ()/ppm) 
Ge-Ver 1.16–1.21 (m, 2H) ( 
Ge-TMS 1.05–1.09 (m, 2H) ( 
Ge-H 1.03–1.08 (m, 2H) 4.30 (s, 1H) 
 
Table 53: The chemical shifts of CH2CH2Ge protons and GeH proton of different components in 
the crude reaction mixture. 
 
  
NN N N N N
tBu tBu
N
OH
Lig. 4 Lig. 5 Lig. 6 Lig. 7
N
O
Lig. 3
OH
N
O
Lig. 2
OH
N
Lig. 1
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2) Germylation of a range of aryl iodides with TMS germane: 
The combined conditions of Oshima163 and Marder228 were applied to a range of aryl 
iodide substrates. The crude reaction mixture was then subjected to 1H NMR 
analysis. The isolated yields of the desired product 51a were then obtained by 
subjecting the crude reaction mixture to PLC (Hexane/Et2O, 95:5) for purification 
(Table 54). 
 
 
Entry ArI Outcome 
1 1 33% (isolated yield) 
2 2 Trace 
3 3 S.M. recovered 
4 4 S.M. recovered 
5 5 S.M. recovered 
6 6 S.M. recovered 
 
Table 54: Combined conditions of Oshima163 and Marder228 were applied to a range of aryl 
iodides. 
 
C8F17
Ge
Si
2-Np 2-Np
+
I
C8F17
Ge
2-Np 2-Np
R
R
49 51a-f
I I I IOMe
OMe OMe
ArI 1 ArI 2 AtI 3 ArI 4
I
CO2MeFmocNH
OMe
NBoc2MeO2C
OMe
I
ArI 6ArI 5
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Chapter 4. Appendices 
4.1. HPLC-MS Profiles for the Syntheses of Peptidic Inhibitors 
Template of HPLC-MS Profile (BM3110 in section 0 used as an example): 
 
NB: (M-H) of peptidic inhibitor is extracted from negative mass trace to show the 
purity of the peptidic inhibitor according to its desired Mw. 
 
 
  
Q3100 - S/N: F09310279W20-Mar-2011
Time
0.00 1.00 2.00 3.00 4.00 5.00 6.00 7.00 8.00 9.00 10.00 11.00 12.00 13.00 14.00 15.00
%
0
0.00 1.00 2.00 3.00 4.00 5.00 6.00 7.00 8.00 9.00 10.00 11.00 12.00 13.00 14.00 15.00
%
0
0.00 1.00 2.00 3.00 4.00 5.00 6.00 7.00 8.00 9.00 10.00 11.00 12.00 13.00 14.00 15.00
A
U
0.0
5.0e+1
0.00 1.00 2.00 3.00 4.00 5.00 6.00 7.00 8.00 9.00 10.00 11.00 12.00 13.00 14.00 15.00
%
0
100
A_BM3110A_p 2: Scan ES- 
1090
1.15e8
9.23
9.29
A_BM3110A_p 3: Diode Array 
Range: 1.029e+29.22
1.23
A_BM3110A_p 2: Scan ES- 
TIC
2.85e8
9.23
0.98
9.36
10.34 10.75
A_BM3110A_p 1: Scan ES+ 
TIC
5.43e9
9.24
10.32 10.73
Q3100 - SN: F09310279W
m/z
400 500 600 700 800 900 1000 1100 1200 1300 1400 1500 1600 1700 1800 1900
%
0
100
A_BM3110A_p 359 (9.234) Cm (355:369) 2: Scan ES- 
7.62e61089.81
544.61
520.41
612.52
1090.77
1091.86
1092.82
(M-H) averaged from ES- 
peak at Rt = 9.23 min. 
UV Trace 
Negative Mass (ES-) Trace 
Positive Mass (ES+) Trace 
(M-H) Extract from Negative Mass Trace 
(M-H) of 
BM3110 
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4.1.1. Literature Reported Peptidic Inhibitors 
IGE07 1 
 
 
 
 
 
  
Glu
Thr
Cys
Arg
Pro
Leu
Asn
9Pro
Trp
Gly
Trp
Val
Cys
Met
8Gly S S15
10
!-Hairpin Peptide 1
C77H111N21O20S3
Mw = 1747.03 g/mol
NH2
OH
Q3100 - S/N: F09310279W02-Apr-2011
Time
0.00 1.00 2.00 3.00 4.00 5.00 6.00 7.00 8.00 9.00 10.00 11.00 12.00 13.00 14.00 15.00
%
0
0.00 1.00 2.00 3.00 4.00 5.00 6.00 7.00 8.00 9.00 10.00 11.00 12.00 13.00 14.00 15.00
%
1
0.00 1.00 2.00 3.00 4.00 5.00 6.00 7.00 8.00 9.00 10.00 11.00 12.00 13.00 14.00 15.00
A
U
0.0
2.0e+1
0.00 1.00 2.00 3.00 4.00 5.00 6.00 7.00 8.00 9.00 10.00 11.00 12.00 13.00 14.00 15.00
%
0
100
A_beta hairpin repeat 2: Scan ES- 
1746
7.58e6
11.29
4.99
A_beta hairpin repeat 3: Diode Array 
Range: 5.737e+111.29
0.00
1.17 1.47
A_beta hairpin repeat 2: Scan ES- 
TIC
1.11e8
11.29
11.060.05 10.57
9.90
14.5314.3013.9113.2512.7311.78
A_beta hairpin repeat 1: Scan ES+ 
TIC
7.98e8
11.30
11.25
0.01
Q3100 - SN: F09310279W
m/z
400 500 600 700 800 900 1000 1100 1200 1300 1400 1500 1600 1700 1800 1900
%
0
100
A_beta hairpin repeat 439 (11.291) Cm (435:445) 2: Scan ES- 
1.68e6872.32
872.12
871.87
835.96
873.15
873.34
1746.06
895.61
896.06 1745.67
896.64
921.98
922.50 1163.55990.09
1746.57
1747.21
1747.40
1751.62
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A-B Loop Peptide 2 
 
 
 
  
Pro
Ser
Pro
Arg
Ser
Leu
Cys
NH2PheAsp
Leu
Phe
Ile
Ser
Pro
Thr
Ile
Thr
Ser
Cys
OHLys
Arg
21
S
S
340
357
A-B Loop Peptide 2
C105H168N28O30S2
Mw = 2366.76 g/mol
Q3100 - S/N: F09310279W19-Mar-2011
Time
0.00 1.00 2.00 3.00 4.00 5.00 6.00 7.00 8.00 9.00 10.00 11.00 12.00 13.00 14.00 15.00
%
0
0.00 1.00 2.00 3.00 4.00 5.00 6.00 7.00 8.00 9.00 10.00 11.00 12.00 13.00 14.00 15.00
%
1
0.00 1.00 2.00 3.00 4.00 5.00 6.00 7.00 8.00 9.00 10.00 11.00 12.00 13.00 14.00 15.00
A
U
0.0
2.0e+1
4.0e+1
0.00 1.00 2.00 3.00 4.00 5.00 6.00 7.00 8.00 9.00 10.00 11.00 12.00 13.00 14.00 15.00
%
0
100
A_BM3075B modified 2: Scan ES- 
1183
3.59e7
12.01
12.27
14.3312.76
A_BM3075B modified 3: Diode Array 
Range: 6.017e+111.93
0.00
1.18 1.47
A_BM3075B modified 2: Scan ES- 
TIC
2.22e8
11.75
11.63
11.55
1.030.950.05 10.3910.01
12.06
12.47
12.76
13.09
14.9214.7114.25
A_BM3075B modified 1: Scan ES+ 
TIC
1.80e10
12.2812.10
11.87
12.43
12.92
13.25
13.69 14.41
Q3100 - SN: F09310279W
m/z
400 500 600 700 800 900 1000 1100 1200 1300 1400 1500 1600 1700 1800 1900
%
0
100
A_BM3075B modified 457 (11.754) Cm (457:475) 2: Scan ES- 
1.86e61182.31
1181.86
851.51
808.12
1177.89
851.64 1144.60
1182.63
1183.14
1183.33
1183.65
1183.84
1184.35
1200.55
1333.70 1773.26
1577.041341.19 1520.64 1691.32 1778.83
Chapter 4 
 141 
C-C’ Cyclo-L-262 Loop Peptide 3 
 
 
 
N.B.: The (M-H) extract from ES- trace showed possibility of two conformers 
present in the desired product. The ratios of conformers were calculated by 
measuring the areas under the peaks of UV trace. 
  
Asp
Lys
Tyr
Tyr
Ile
Cys
NH2
Glu
Ala
Leu
Lys
Tyr
Cys
OH
Gly 13
S
S
C-C' Cyclo-L-262 Loop Peptide 3
C71H103N15O21S2
Mw = 1566.80 g/mol
119
129
Q3100 - S/N: F09310279W19-Mar-2011
Time
0.00 1.00 2.00 3.00 4.00 5.00 6.00 7.00 8.00 9.00 10.00 11.00 12.00 13.00 14.00 15.00
%
0
0.00 1.00 2.00 3.00 4.00 5.00 6.00 7.00 8.00 9.00 10.00 11.00 12.00 13.00 14.00 15.00
%
1
0.00 1.00 2.00 3.00 4.00 5.00 6.00 7.00 8.00 9.00 10.00 11.00 12.00 13.00 14.00 15.00
A
U
0.0
2.5e+1
5.0e+1
7.5e+1
0.00 1.00 2.00 3.00 4.00 5.00 6.00 7.00 8.00 9.00 10.00 11.00 12.00 13.00 14.00 15.00
%
0
100
A_BM3084 CC 2: Scan ES- 
1565
4.78e7
9.39
9.59
A_BM3084 CC 3: Diode Array 
Range: 8.985e+19.599.40
0.00
1.17
A_BM3084 CC 2: Scan ES- 
TIC
3.35e8
9.39
1.060.13
1.18
9.49
9.88
13.6811.09 12.4211.70
A_BM3084 CC 1: Scan ES+ 
TIC
1.12e10
9.659.47
*Conformers of the desired peptide 
(63:37) 
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The averaged (M-H) under the peaks of ES- showed the same mass pattern, which 
confirmed the formation of conformers. 
 
 
 
 
  
Q3100 - SN: F09310279W
m/z
400 500 600 700 800 900 1000 1100 1200 1300 1400 1500 1600 1700 1800 1900
%
0
100
%
0
100
A_BM3084 CC 370 (9.517) Cm (370:378) 2: Scan ES- 
3.26e6782.13
781.94
773.05
721.65
535.46
782.39
783.03
1564.75
814.46
815.61
828.54
1444.01864.00 1071.701000.52871.61
1546.76
1565.78
1566.80
1567.82
1656.94
A_BM3084 CC 365 (9.388) Cm (362:370) 2: Scan ES- 
4.71e6782.13
781.81
700.66
782.39
1564.82
783.03
783.61
814.46
871.42
816.38 872.51 1000.52
1565.90
1566.74
1567.76
1568.78
Q3100 - SN: F09310279W
m/z
400 500 600 700 800 900 1000 1100 1200 1300 1400 1500 1600 1700 1800 1900
%
0
100
A_BM3084 CC 365 (9.388) Cm (362:378) 2: Scan ES- 
4.06e6782.13
773.05
721.52
782.39
1564.82
783.03
783.48
814.46
815.61
871.42
1444.071000.52 1546.76
1565.90
1566.86
1567.82
1568.78
(M-H) Extract from peak at Rt = 9.51 min 
(M-H) Extract from peak at Rt = 9.39 min 
Combined (M-H) Extract from ES- !! !!!!! !
!! !!!!!
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4.1.2. &Fc#RI C-Region Mimic Y116-D123 Series 
BM3110 10 
 
 
 
 
 
 
  
Val
Ile
Tyr
Tyr
Lys
AspLys
Tyr
H
OH
116
123
BM3110 10
C54H78N10O14
Mw = 1091.26 g/mol
(Fc!RI C-Region Mimic Y116-D123)
Q3100 - S/N: F09310279W20-Mar-2011
Time
0.00 1.00 2.00 3.00 4.00 5.00 6.00 7.00 8.00 9.00 10.00 11.00 12.00 13.00 14.00 15.00
%
0
0.00 1.00 2.00 3.00 4.00 5.00 6.00 7.00 8.00 9.00 10.00 11.00 12.00 13.00 14.00 15.00
%
0
0.00 1.00 2.00 3.00 4.00 5.00 6.00 7.00 8.00 9.00 10.00 11.00 12.00 13.00 14.00 15.00
A
U
0.0
5.0e+1
0.00 1.00 2.00 3.00 4.00 5.00 6.00 7.00 8.00 9.00 10.00 11.00 12.00 13.00 14.00 15.00
%
0
100
A_BM3110A_p 2: Scan ES- 
1090
1.15e8
9.23
9.29
A_BM3110A_p 3: Diode Array 
Range: 1.029e+29.22
1.23
A_BM3110A_p 2: Scan ES- 
TIC
2.85e8
9.23
0.98
9.36
10.34 10.75
A_BM3110A_p 1: Scan ES+ 
TIC
5.43e9
9.24
10.32 10.73
Q3100 - SN: F09310279W
m/z
400 500 600 700 800 900 1000 1100 1200 1300 1400 1500 1600 1700 1800 1900
%
0
100
A_BM3110A_p 359 (9.234) Cm (356:370) 2: Scan ES- 
7.77e61089.81
544.61
520.41
612.52
1090.77
1091.73
1092.69
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Ac-BM3110 11 
 
 
 
 
 
 
  
Val
Ile
Tyr
Tyr
Lys
AspLys
Tyr
Ac
OH
116
123
Ac-BM3110 11
C56H80N10O15
Mw = 1133.29 g/mol
(Fc!RI C-Region Mimic Y116-D123)
Q3100 - S/N: F09310279W20-Mar-2011
Time
0.00 1.00 2.00 3.00 4.00 5.00 6.00 7.00 8.00 9.00 10.00 11.00 12.00 13.00 14.00 15.00
%
0
0.00 1.00 2.00 3.00 4.00 5.00 6.00 7.00 8.00 9.00 10.00 11.00 12.00 13.00 14.00 15.00
%
1
0.00 1.00 2.00 3.00 4.00 5.00 6.00 7.00 8.00 9.00 10.00 11.00 12.00 13.00 14.00 15.00
A
U
0.0
2.0e+1
0.00 1.00 2.00 3.00 4.00 5.00 6.00 7.00 8.00 9.00 10.00 11.00 12.00 13.00 14.00 15.00
%
0
100
A_BM3110B_p 2: Scan ES- 
1132
9.43e7
10.37
10.31
A_BM3110B_p 3: Diode Array 
Range: 4.756e+110.33
0.00
1.17 1.46
A_BM3110B_p 2: Scan ES- 
TIC
3.60e8
10.37
10.31
0.10
10.47
14.6313.04
A_BM3110B_p 1: Scan ES+ 
TIC
5.44e9
10.32
Q3100 - SN: F09310279W
m/z
400 500 600 700 800 900 1000 1100 1200 1300 1400 1500 1600 1700 1800 1900
%
0
100
A_BM3110B_p 403 (10.365) Cm (399:407) 2: Scan ES- 
6.08e61131.74
565.35
533.86
565.73
566.25
566.37
741.62
583.72
1067.66
994.76742.52
995.65
1132.76
1133.85
1134.74
1154.84
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BM3110-Am 6 
 
 
 
 
 
 
  
Val
Ile
Tyr
Tyr
Lys
AspLys
Tyr
H
NH2
116
123
BM3110-Am 6
C54H79N11O13
Mw = 1090.27 g/mol
(Fc!RI C-Region Mimic Y116-D123)
Q3100 - S/N: F09310279W20-Mar-2011
Time
0.00 1.00 2.00 3.00 4.00 5.00 6.00 7.00 8.00 9.00 10.00 11.00 12.00 13.00 14.00 15.00
%
0
0.00 1.00 2.00 3.00 4.00 5.00 6.00 7.00 8.00 9.00 10.00 11.00 12.00 13.00 14.00 15.00
%
1
0.00 1.00 2.00 3.00 4.00 5.00 6.00 7.00 8.00 9.00 10.00 11.00 12.00 13.00 14.00 15.00
A
U
0.0
2.0e+1
4.0e+1
0.00 1.00 2.00 3.00 4.00 5.00 6.00 7.00 8.00 9.00 10.00 11.00 12.00 13.00 14.00 15.00
%
0
100
A_BM3110C_p 2: Scan ES- 
1089
8.87e7
8.93
8.98
A_BM3110C_p 3: Diode Array 
Range: 6.27e+18.93
0.00
1.18 1.50
A_BM3110C_p 2: Scan ES- 
TIC
2.01e8
8.93
0.08
1.06
9.00
14.6114.0713.8613.3710.7010.199.36 11.19
14.81
A_BM3110C_p 1: Scan ES+ 
TIC
4.67e9
8.93
Q3100 - SN: F09310279W
m/z
400 500 600 700 800 900 1000 1100 1200 1300 1400 1500 1600 1700 1800 1900
%
0
100
A_BM3110C_p 347 (8.925) Cm (344:356) 2: Scan ES- 
5.34e61088.79
611.43
544.16
1089.81
1090.71
1091.67
1125.85
Chapter 4 
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Ac-BM3110-Am 12 
 
 
 
 
 
 
  
Val
Ile
Tyr
Tyr
Lys
AspLys
Tyr
Ac
NH2
116
123
Ac-BM3110-Am 12
C56H81N11O14
Mw = 1132.31 g/mol
(Fc!RI C-Region Mimic Y116-D123)
Q3100 - S/N: F09310279W20-Mar-2011
Time
0.00 1.00 2.00 3.00 4.00 5.00 6.00 7.00 8.00 9.00 10.00 11.00 12.00 13.00 14.00 15.00
%
0
0.00 1.00 2.00 3.00 4.00 5.00 6.00 7.00 8.00 9.00 10.00 11.00 12.00 13.00 14.00 15.00
%
1
0.00 1.00 2.00 3.00 4.00 5.00 6.00 7.00 8.00 9.00 10.00 11.00 12.00 13.00 14.00 15.00
A
U
0.0
2.0e+1
4.0e+1
6.0e+1
0.00 1.00 2.00 3.00 4.00 5.00 6.00 7.00 8.00 9.00 10.00 11.00 12.00 13.00 14.00 15.00
%
0
100
A_BM3110D 2: Scan ES- 
1131
1.09e8
10.03
10.08
A_BM3110D 3: Diode Array 
Range: 7.421e+110.02
0.00
1.17
A_BM3110D 2: Scan ES- 
TIC
3.04e8
10.03
9.98
0.10
10.13
10.52
13.17
A_BM3110D 1: Scan ES+ 
TIC
6.31e9
10.07
10.30
Q3100 - SN: F09310279W
m/z
400 500 600 700 800 900 1000 1100 1200 1300 1400 1500 1600 1700 1800 1900
%
0
100
A_BM3110D 390 (10.031) Cm (386:399) 2: Scan ES- 
7.00e61130.78
565.22
993.73724.47 1066.70
1131.74
1132.76
1166.62
1167.71
Chapter 4 
 147 
BM1149 13 
 
 
 
 
 
 
  
Val
Ile
Tyr
Tyr
Lys
Asp Lys
Tyr
OH
H 123
116
BM1149 13
C54H78N10O14
Mw = 1091.26 g/mol
(Retro Fc!RI C-Region Mimic Y116-D123)
Q3100 - S/N: F09310279W19-Mar-2011
Time
0.00 1.00 2.00 3.00 4.00 5.00 6.00 7.00 8.00 9.00 10.00 11.00 12.00 13.00 14.00 15.00
%
0
0.00 1.00 2.00 3.00 4.00 5.00 6.00 7.00 8.00 9.00 10.00 11.00 12.00 13.00 14.00 15.00
%
1
0.00 1.00 2.00 3.00 4.00 5.00 6.00 7.00 8.00 9.00 10.00 11.00 12.00 13.00 14.00 15.00
A
U
0.0
2.0e+1
0.00 1.00 2.00 3.00 4.00 5.00 6.00 7.00 8.00 9.00 10.00 11.00 12.00 13.00 14.00 15.00
%
0
100
A_BM1149 2: Scan ES- 
1090
9.19e7
9.39
A_BM1149 3: Diode Array 
Range: 4.314e+19.37
0.00
1.17 1.44
A_BM1149 2: Scan ES- 
TIC
2.57e8
9.44
0.05
1.03
14.6614.04
13.0412.3511.29
A_BM1149 1: Scan ES+ 
TIC
5.04e9
9.40
Q3100 - SN: F09310279W
m/z
400 500 600 700 800 900 1000 1100 1200 1300 1400 1500 1600 1700 1800 1900
%
0
100
A_BM1149 367 (9.439) Cm (362:370) 2: Scan ES- 
7.14e61089.68
544.61
1090.71
1091.79
1111.70
1112.66
Chapter 4 
 148 
Ac-BM1149 14 
 
 
 
N.B.: Both UV and mass traces showed the presence of impurities. The percentage 
purity of the desired peptide was calculated by measuring the areas under the peaks 
of UV trace. The impurities in the final product could not be separated by preparative 
LCMS. 
  
Val
Ile
Tyr
Tyr
Lys
Asp Lys
Tyr
OH
Ac 123
116
Ac-BM1149 14
C56H80N10O15
Mw = 1133.29 g/mol
(Retro Fc!RI C-Region Mimic Y116-D123)
Q3100 - S/N: F09310279W19-Mar-2011
Time
0.00 1.00 2.00 3.00 4.00 5.00 6.00 7.00 8.00 9.00 10.00 11.00 12.00 13.00 14.00 15.00
%
0
0.00 1.00 2.00 3.00 4.00 5.00 6.00 7.00 8.00 9.00 10.00 11.00 12.00 13.00 14.00 15.00
%
0
0.00 1.00 2.00 3.00 4.00 5.00 6.00 7.00 8.00 9.00 10.00 11.00 12.00 13.00 14.00 15.00
A
U
0.0
2.0e+1
4.0e+1
6.0e+1
0.00 1.00 2.00 3.00 4.00 5.00 6.00 7.00 8.00 9.00 10.00 11.00 12.00 13.00 14.00 15.00
%
0
100
A_Ac-BM1149 2: Scan ES- 
1132
1.37e8
9.98
A_Ac-BM1149 3: Diode Array 
Range: 7.959e+19.94
0.00 10.39
A_Ac-BM1149 2: Scan ES- 
TIC
3.94e8
9.98
9.90
0.03
9.590.95
10.06
10.42 10.70
A_Ac-BM1149 1: Scan ES+ 
TIC
6.05e9
9.96
10.07
10.43
10.71
*The desired peptide has a purity of 82%. 
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(M-H) averaged from ES- for impurity peaks, which contains trace amount of the 
desired product. Average (M-H) of the desired product is also shown for comparison. 
 
  
Q3100 - SN: F09310279W
m/z
400 500 600 700 800 900 1000 1100 1200 1300 1400 1500 1600 1700 1800 1900
%
0
100
A_Ac-BM1149 388 (9.979) Cm (383:394) 2: Scan ES- 
1.08e71131.74
565.35
1132.76
1133.72
1134.81
1699.451153.76
Q3100 - SN: F09310279W
m/z
400 500 600 700 800 900 1000 1100 1200 1300 1400 1500 1600 1700 1800 1900
%
0
100
%
0
100
A_Ac-BM1149 405 (10.417) Cm (401:422) 2: Scan ES- 
5.89e5840.51
725.62
647.09
615.15
615.02
577.00
419.65 574.50
433.42
725.36
647.60
647.79
712.43
796.66
726.71
727.60
1294.78
1294.65
1230.70841.53
1173.73
1154.72
862.65
1131.67
988.16863.35
987.65 1025.67
1295.80
1296.83
1317.51
1318.72
1671.411375.76 1638.18 1822.871768.14 1943.08
A_Ac-BM1149 388 (9.979) Cm (383:394) 2: Scan ES- 
1.08e71131.74
565.35
1132.76
1133.72
1134.81
1699.45
(M-H) averaged from ES- at Rt = 9.98 min 
Averaged (M-H) of the 
impurity from ES- at Rt = 
10.42 min 
Averaged (M-H) of the 
desired product from ES- at 
Rt = 9.98 min 
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BM1149-Am 7 
 
 
 
 
N.B.: Both UV and mass traces showed the presence of impurities. The percentage 
purity of the desired peptide was calculated by measuring the areas under the peaks 
of UV trace. The impurities in the final product could not be separated by preparative 
LCMS. 
  
Val
Ile
Tyr
Tyr
Lys
Asp Lys
Tyr
NH2
H 123
116
BM1149-Am 7
C54H79N11O13
Mw = 1090.27 g/mol
(Retro Fc!RI C-Region Mimic Y116-D123)
Q3100 - S/N: F09310279W19-Mar-2011
Time
0.00 1.00 2.00 3.00 4.00 5.00 6.00 7.00 8.00 9.00 10.00 11.00 12.00 13.00 14.00 15.00
%
0
0.00 1.00 2.00 3.00 4.00 5.00 6.00 7.00 8.00 9.00 10.00 11.00 12.00 13.00 14.00 15.00
%
1
0.00 1.00 2.00 3.00 4.00 5.00 6.00 7.00 8.00 9.00 10.00 11.00 12.00 13.00 14.00 15.00
A
U
0.0
2.5e+1
5.0e+1
0.00 1.00 2.00 3.00 4.00 5.00 6.00 7.00 8.00 9.00 10.00 11.00 12.00 13.00 14.00 15.00
%
0
100
A_BM1149-Am 2: Scan ES- 
1089
1.57e8
8.93
9.00
A_BM1149-Am 3: Diode Array 
Range: 8.188e+18.87
0.00 9.60
A_BM1149-Am 2: Scan ES- 
TIC
3.42e8
8.87
0.05
0.93
9.00
9.49 9.65
14.7414.4013.129.90 10.44
A_BM1149-Am 1: Scan ES+ 
TIC
6.02e9
8.91
9.50 9.63
9.89
13.38
*The desired peptide has a purity of 87%. 
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(M-H) averaged from ES- for impurity peaks, which contains trace amount of the 
desired product. Average (M-H) of the desired product is also shown for comparison. 
 
  
Q3100 - SN: F09310279W
m/z
400 500 600 700 800 900 1000 1100 1200 1300 1400 1500 1600 1700 1800 1900
%
0
100
A_BM1149-Am 345 (8.874) Cm (342:355) 2: Scan ES- 
1.12e71088.79
1089.81
1090.77
1091.67
Q3100 - SN: F09310279W
m/z
400 500 600 700 800 900 1000 1100 1200 1300 1400 1500 1600 1700 1800 1900
%
0
100
%
0
100
A_BM1149-Am 369 (9.491) Cm (362:379) 2: Scan ES- 
6.16e51251.76
1089.75
1089.62
601.51
561.51
544.61
474.58
444.17
601.90 1088.85
625.90
626.41 1072.721005.57
632.30
1187.88
1187.75
1252.85
1253.62
1254.26
1309.82
1380.76 1760.781622.821576.21
A_BM1149-Am 345 (8.874) Cm (342:355) 2: Scan ES- 
1.12e71088.79
1089.81
1090.77
1091.67
(M-H) averaged from ES- at Rt = 8.87 min 
Averaged (M-H) of the 
impurity from ES- at Rt = 
9.49 min 
Averaged (M-H) of the 
desired product from ES- at 
Rt = 8.87 min 
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 Ac-BM1149-Am 15 
 
 
 
 
N.B.: Both UV and mass traces showed the presence of impurities. The percentage 
purity of the desired peptide was calculated by measuring the areas under the peaks 
of UV trace. The impurities in the final product could not be separated by preparative 
LCMS. 
  
Val
Ile
Tyr
Tyr
Lys
Asp Lys
Tyr
NH2
Ac 123
116
Ac-BM1149-Am 15
C56H81N11O14
Mw = 1132.31 g/mol
(Retro Fc!RI C-Region Mimic Y116-D123)
Q3100 - S/N: F09310279W19-Mar-2011
Time
0.00 1.00 2.00 3.00 4.00 5.00 6.00 7.00 8.00 9.00 10.00 11.00 12.00 13.00 14.00 15.00
%
0
0.00 1.00 2.00 3.00 4.00 5.00 6.00 7.00 8.00 9.00 10.00 11.00 12.00 13.00 14.00 15.00
%
0
0.00 1.00 2.00 3.00 4.00 5.00 6.00 7.00 8.00 9.00 10.00 11.00 12.00 13.00 14.00 15.00
A
U
0.0
2.0e+1
4.0e+1
0.00 1.00 2.00 3.00 4.00 5.00 6.00 7.00 8.00 9.00 10.00 11.00 12.00 13.00 14.00 15.00
%
0
100
A_Ac-BM1149-Am 2: Scan ES- 
1131
1.93e8
9.75
9.70 9.83
A_Ac-BM1149-Am 3: Diode Array 
Range: 7.319e+19.70
0.00
A_Ac-BM1149-Am 2: Scan ES- 
TIC
4.20e8
9.75
9.70
0.05
9.210.95
9.83
10.16
10.34
A_Ac-BM1149-Am 1: Scan ES+ 
TIC
5.78e9
9.73
9.22
10.09
*The desired peptide has a purity of 91%. 
Chapter 4 
 153 
 
 
 
 
(M-H) averaged from ES- for impurity peaks, which contains trace amount of the 
desired product. Average (M-H) of the desired product is also shown for comparison. 
 
  
Q3100 - SN: F09310279W
m/z
400 500 600 700 800 900 1000 1100 1200 1300 1400 1500 1600 1700 1800 1900
%
0
100
A_Ac-BM1149-Am 379 (9.748) Cm (374:387) 2: Scan ES- 
1.15e71130.71
565.22
1131.74
1132.76
1133.72
Q3100 - SN: F09310279W
m/z
400 500 600 700 800 900 1000 1100 1200 1300 1400 1500 1600 1700 1800 1900
%
0
100
%
0
100
A_Ac-BM1149-Am 395 (10.159) Cm (387:403) 2: Scan ES- 
3.38e51293.761229.74
1130.71
622.70
622.44
622.19
565.29
401.34
402.37 517.53
565.48
622.89
724.47
647.60
647.85
724.72
725.68
1003.33
760.37 1002.95
839.67
939.46
1003.59
1004.81
1294.84
1296.00
1296.83
1296.96
1575.571360.14 1463.79 1953.061776.401664.37 1855.71
A_Ac-BM1149-Am 379 (9.748) Cm (374:387) 2: Scan ES- 
1.15e71130.71
565.22
1131.74
1132.76
1133.72
(M-H) averaged from ES- at Rt = 9.75 min 
Averaged (M-H) of the 
impurity from ES- at Rt = 
10.16 min 
Averaged (M-H) of the 
desired product from ES- at 
Rt = 9.75 min 
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Ro25-9612 4 
 
 
 
N.B.: The (M-H) extract from ES- trace showed possibility of two conformers 
present in the desired product. The ratios of conformers were calculated by 
measuring the areas under the peaks of UV trace. 
  
Val
Cys
Tyr
Tyr
Lys
AspLys
Tyr
Val
NH2H
Val
Cys
Tyr
Tyr
Lys
AspLys
Tyr
Val
H
S
S
 Ro25-9612 4
 C112H162N24O28S2
Mw = 2356.76 g/mol
(Fc!RI C-Region Mimic Y115-D123 Dimer)
9
115 123
NH2
Q3100 - S/N: F09310279W25-Nov-2010
Time
0.00 1.00 2.00 3.00 4.00 5.00 6.00 7.00 8.00 9.00 10.00 11.00 12.00 13.00 14.00 15.00
%
0
0.00 1.00 2.00 3.00 4.00 5.00 6.00 7.00 8.00 9.00 10.00 11.00 12.00 13.00 14.00 15.00
%
1
0.00 1.00 2.00 3.00 4.00 5.00 6.00 7.00 8.00 9.00 10.00 11.00 12.00 13.00 14.00 15.00
A
U
0.0
2.0e+1
4.0e+1
6.0e+1
0.00 1.00 2.00 3.00 4.00 5.00 6.00 7.00 8.00 9.00 10.00 11.00 12.00 13.00 14.00 15.00
%
0
100
A_BM3107A_02p 2: Scan ES- 
1177
2.85e7
8.67
8.15
9.16
A_BM3107A_02p 3: Diode Array 
Range: 7.819e+18.628.23
1.20 7.35
A_BM3107A_02p 2: Scan ES- 
TIC
5.67e8
8.67
8.31
7.43
1.83
A_BM3107A_02p 1: Scan ES+ 
TIC
6.74e9
8.68
8.32
*Conformers of the desired peptide 
(34:66) 
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The averaged (M-H) under the peaks of ES- showed the same mass pattern, which 
confirmed the formation of conformers. 
 
 
 
 
  
Q3100 - SN: F09310279W
m/z
400 500 600 700 800 900 1000 1100 1200 1300 1400 1500 1600 1700 1800 1900
%
0
100
%
0
100
A_BM3107A_02p 337 (8.668) Cm (328:347) 2: Scan ES- 
1.01e61177.41
611.14
588.34
588.09
1176.77
1134.71
1134.26
929.33612.29
868.25
655.38
863.52
928.63
873.69
929.65
930.03 1128.24
1001.55
1178.63
1258.72
1259.23
1685.08
1290.28
1321.91
1403.66 1923.691687.51 1861.42 1958.38
A_BM3107A_02p 323 (8.308) Cm (312:326) 2: Scan ES- 
8.41e51177.80
1177.48
1176.71
879.65
611.20
588.34
879.33
611.39
655.25
657.23
868.64
726.25
1176.32880.16
1127.41
1127.09880.61
1090.73880.93
1078.50928.43
1209.23
1646.421209.49
1209.74
1241.18
1242.14
1361.73
1258.78 1362.37
1560.511367.11
1760.74
1667.92 1869.68 1924.59
Q3100 - SN: F09310279W
m/z
400 500 600 700 800 900 1000 1100 1200 1300 1400 1500 1600 1700 1800 1900
%
0
100
A_BM3107A_02p 337 (8.668) Cm (313:347) 2: Scan ES- 
9.04e51177.54
1176.77
611.07
588.34
611.33
879.65
655.38
868.25
656.27
656.53
863.52657.23
863.32
726.25
1134.71
1127.54
929.33
1127.28
929.52
1090.73946.42
1178.63
1209.36
1209.49
1241.18
1646.42
1259.23
1290.28 1361.79
1362.62
1372.68
1685.08
1759.59 1791.91 1923.69
(M-H) Extract from peak at Rt = 8.67 min 
(M-H) Extract from peak at Rt = 8.31 min 
Combined (M-H) Extract from ES- 
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Ro25-9960 5 
 
 
 
N.B.: Both UV and mass traces showed the presence of impurities. The percentage 
purity of the desired peptide was calculated by measuring the areas under the peaks 
of UV trace. The impurities in the final product could not be separated by preparative 
LCMS. 
  
Val
Cys
Tyr
Tyr
Lys
AspLys
Tyr
H
NH2
Val
Cys
Tyr
Tyr
Lys
AspLys
Tyr
H
NH2
S
S
Ro25-9960 5
 C102H144N22O26S2
Mw = 2158.50 g/mol
(Fc!RI C-Region Mimic Y116-D123 Dimer)
8
123
116
Q3100 - S/N: F09310279W26-Nov-2010
Time
0.00 1.00 2.00 3.00 4.00 5.00 6.00 7.00 8.00 9.00 10.00 11.00 12.00 13.00 14.00 15.00
%
0
0.00 1.00 2.00 3.00 4.00 5.00 6.00 7.00 8.00 9.00 10.00 11.00 12.00 13.00 14.00 15.00
%
1
0.00 1.00 2.00 3.00 4.00 5.00 6.00 7.00 8.00 9.00 10.00 11.00 12.00 13.00 14.00 15.00
A
U
0.0
2.0e+1
4.0e+1
0.00 1.00 2.00 3.00 4.00 5.00 6.00 7.00 8.00 9.00 10.00 11.00 12.00 13.00 14.00 15.00
%
0
100
A_BM3108A_02p~ 2: Scan ES- 
1079
8.61e7
8.13
8.57
A_BM3108A_02p~ 3: Diode Array 
Range: 7.251e+17.98
7.55
1.190.990.00
7.14
A_BM3108A_02p~ 2: Scan ES- 
TIC
6.61e8
8.02
7.61
1.03
0.05
1.18
7.20
2.50
8.13
A_BM3108A_02p~ 1: Scan ES+ 
TIC
6.78e9
8.09
0.91 1.24
*The desired peptide has a 
purity of 81%. 
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(M-H) averaged from ES- for impurity peaks. Average (M-H) of the desired product 
is also shown for comparison. 
 
  
Q3100 - SN: F09310279W
m/z
400 500 600 700 800 900 1000 1100 1200 1300 1400 1500 1600 1700 1800 1900
%
0
100
A_BM3108A_02p~ 316 (8.128) Cm (313:323) 2: Scan ES- 
4.31e61078.44
1035.41
911.60
911.15
880.03
598.33
538.79 824.21
655.25
957.18
1079.46
1079.65
1080.36
1081.51
1197.51
1824.751759.521241.63
Q3100 - SN: F09310279W
m/z
400 500 600 700 800 900 1000 1100 1200 1300 1400 1500 1600 1700 1800 1900
%
0
100
%
0
100
A_BM3108A_02p~ 296 (7.613) Cm (276:303) 2: Scan ES- 
2.97e6611.26
612.29
655.19
1223.38714.28
656.34 730.35
882.53
731.12
1224.60
1267.30
A_BM3108A_02p~ 316 (8.128) Cm (313:323) 2: Scan ES- 
4.31e61078.44
1035.41
911.60
880.03
598.33
538.79 824.21655.25 957.18
1079.46
1080.36
1081.51
1197.51
1824.751759.521241.63
(M-H) averaged from ES- at Rt = 8.13 min 
Averaged (M-H) of the 
impurity from ES- at Rt = 
7.61 min 
Averaged (M-H) of the 
desired product from ES- at 
Rt = 8.13 min 
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BM3108B 16 
 
 
 
N.B.: Both UV and mass traces showed the presence of impurities. The percentage 
purity of the desired peptide was calculated by measuring the areas under the peaks 
of UV trace. The impurities in the final product could not be separated by preparative 
LCMS. 
  
Val
Cys
Tyr
Tyr
Lys
AspLys
Tyr
H
OH
Val
Cys
Tyr
Tyr
Lys
AspLys
Tyr
H
OH
S
S
BM3108B 16
C102H142N20O28S2
Mw = 2160.47 g/mol
(Fc!RI C-Region Mimic Y116-D123 Dimer)
8
123
116
Q3100 - S/N: F09310279W26-Nov-2010
Time
0.00 1.00 2.00 3.00 4.00 5.00 6.00 7.00 8.00 9.00 10.00 11.00 12.00 13.00 14.00 15.00
%
0
0.00 1.00 2.00 3.00 4.00 5.00 6.00 7.00 8.00 9.00 10.00 11.00 12.00 13.00 14.00 15.00
%
1
0.00 1.00 2.00 3.00 4.00 5.00 6.00 7.00 8.00 9.00 10.00 11.00 12.00 13.00 14.00 15.00
A
U
0.0
2.5e+1
5.0e+1
0.00 1.00 2.00 3.00 4.00 5.00 6.00 7.00 8.00 9.00 10.00 11.00 12.00 13.00 14.00 15.00
%
0
100
A_BM3108B_02p 2: Scan ES- 
1080
7.30e7
7.927.82
A_BM3108B_02p 3: Diode Array 
Range: 9.218e+17.74
7.41
0.00
1.19
A_BM3108B_02p 2: Scan ES- 
TIC
6.83e8
7.977.82
7.48
0.05
1.03 9.00
A_BM3108B_02p 1: Scan ES+ 
TIC
8.48e9
7.78
7.49
*The desired peptide has a 
purity of 86%. 
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(M-H) averaged from ES- for impurity peaks. Average (M-H) of the desired product 
is also shown for comparison. 
 
  
Q3100 - SN: F09310279W
m/z
400 500 600 700 800 900 1000 1100 1200 1300 1400 1500 1600 1700 1800 1900
%
0
100
A_BM3108B_02p 310 (7.974) Cm (300:316) 2: Scan ES- 
5.31e61079.20
1078.88
1075.43
839.44
569.46
539.17
537.44
628.23
907.50
840.21
976.64
944.57
1021.78
1080.10
1139.51
1140.41
1142.97
1160.13 1439.26
1224.79
Q3100 - SN: F09310279W
m/z
400 500 600 700 800 900 1000 1100 1200 1300 1400 1500 1600 1700 1800 1900
%
0
100
%
0
100
A_BM3108B_02p 291 (7.485) Cm (284:298) 2: Scan ES- 
8.36e6628.17
570.22
629.32
848.41630.15 1257.44855.38
A_BM3108B_02p 310 (7.974) Cm (300:316) 2: Scan ES- 
5.31e61079.20
1078.88
1075.43
839.44569.46539.17
537.44
628.23
907.50
840.21 976.64
1080.10
1139.51
1140.41
1142.97
1439.261224.79
(M-H) averaged from ES- at Rt = 7.97 min 
Averaged (M-H) of the 
impurity from ES- at Rt = 
7.49 min 
Averaged (M-H) of the 
desired product from ES- at 
Rt = 7.97 min 
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BM3085A 8 
 
 
 
 
N.B.: The (M-H) extract from ES- trace showed possibility of two conformers 
present in the desired product. The ratios of conformers were calculated by 
measuring the areas under the peaks of UV trace. 
  
Val
Cys
Tyr
Tyr
Lys
Asp Lys
Tyr
Val
H 123 115
Val
Cys
Tyr
Tyr
Lys
Asp Lys
Tyr
Val
H
S
S
9
NH2
NH2
BM3085A 8 
 C112H162N24O28S2
Mw = 2356.76 g/mol
Retro Fc!RI C-Region Mimic Y115-D123 Dimer
Q3100 - S/N: F09310279W25-Nov-2010
Time
0.00 1.00 2.00 3.00 4.00 5.00 6.00 7.00 8.00 9.00 10.00 11.00 12.00 13.00 14.00 15.00
%
0
0.00 1.00 2.00 3.00 4.00 5.00 6.00 7.00 8.00 9.00 10.00 11.00 12.00 13.00 14.00 15.00
%
0
0.00 1.00 2.00 3.00 4.00 5.00 6.00 7.00 8.00 9.00 10.00 11.00 12.00 13.00 14.00 15.00
A
U
0.0
2.5e+1
5.0e+1
7.5e+1
0.00 1.00 2.00 3.00 4.00 5.00 6.00 7.00 8.00 9.00 10.00 11.00 12.00 13.00 14.00 15.00
%
0
100
A_BM3109A_02p 2: Scan ES- 
1178
1.67e8
9.29
10.39
9.49
A_BM3109A_02p 3: Diode Array 
Range: 9.705e+19.21
9.12
8.94
0.00
8.571.18 1.35
10.289.69
A_BM3109A_02p 2: Scan ES- 
TIC
1.05e9
10.319.29
9.18
9.00
0.05
9.36
9.77
A_BM3109A_02p 1: Scan ES+ 
TIC
1.19e10
9.29 9.42
10.359.81
*Conformers of the desired peptide 
(70:13:17) 
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The averaged (M-H) under the peaks of ES- showed the same mass pattern, which 
confirmed the formation of conformers. 
 
 
 
  
Q3100 - SN: F09310279W
m/z
400 500 600 700 800 900 1000 1100 1200 1300 1400 1500 1600 1700 1800 1900
%
0
100
%
0
100
%
0
100
A_BM3109A_02p 401 (10.314) Cm (397:412) 2: Scan ES- 
7.24e61177.28
1169.35
813.45
1569.85
1187.78
1276.52
1766.121577.47
1790.57
A_BM3109A_02p 366 (9.414) Cm (365:374) 2: Scan ES- 
3.70e61161.60
771.39
650.58577.27531.23
483.40
770.75
651.22
1037.59
934.39772.54
870.49
773.44 872.61
935.16
970.56
1160.83
1038.68
1097.45
1177.60
1178.50
1179.59
1260.58
1263.58 1763.811372.55 1933.04
A_BM3109A_02p 361 (9.285) Cm (358:366) 2: Scan ES- 
7.92e61177.60
1161.60
531.23
771.45
588.47
620.29
1160.64
772.48
1097.581063.58870.69807.11
1178.50
1179.59
1180.29
1276.32
Q3100 - SN: F09310279W
m/z
400 500 600 700 800 900 1000 1100 1200 1300 1400 1500 1600 1700 1800 1900
%
0
100
A_BM3109A_02p 401 (10.314) Cm (358:412) 2: Scan ES- 
3.63e61177.28
1161.60
531.23
771.45
588.47 650.32
973.70934.52870.62
813.45
1037.59
1157.63
1178.50
1179.59
1569.85
1569.531209.74
1210.38
1276.64 1559.48 1766.241577.47
(M-H) Extract from peak 
at Rt = 10.31 min 
(M-H) Extract from peak 
at Rt = 9.41 min 
(M-H) Extract from peak 
at Rt = 9.29 min 
Combined (M-H) Extract from ES- 
Chapter 4 
 162 
BM3109A 17 
 
 
 
 
N.B.: The (M-H) extract from ES- trace showed possibility of two conformers 
present in the desired product. The ratios of conformers were calculated by 
measuring the areas under the peaks of UV trace. 
  
Val
Cys
Tyr
Tyr
Lys
Asp Lys
Tyr
Val
H 123 115
Val
Cys
Tyr
Tyr
Lys
Asp Lys
Tyr
Val
H
S
S
9
OH
OH
BM3109A 17 
C112H162N24O28S2
Mw = 2358.73 g/mol
Retro Fc!RI C-Region Mimic Y115-D123 Dimer
Q3100 - S/N: F09310279W02-Apr-2011
Time
0.00 1.00 2.00 3.00 4.00 5.00 6.00 7.00 8.00 9.00 10.00 11.00 12.00 13.00 14.00 15.00
%
0
0.00 1.00 2.00 3.00 4.00 5.00 6.00 7.00 8.00 9.00 10.00 11.00 12.00 13.00 14.00 15.00
%
2
0.00 1.00 2.00 3.00 4.00 5.00 6.00 7.00 8.00 9.00 10.00 11.00 12.00 13.00 14.00 15.00
A
U
-1.0e+1
0.0
1.0e+1
0.00 1.00 2.00 3.00 4.00 5.00 6.00 7.00 8.00 9.00 10.00 11.00 12.00 13.00 14.00 15.00
%
0
100
A_BM3085A 2: Scan ES- 
1179
1.06e7
10.70
9.85
10.26 10.96
A_BM3085A 3: Diode Array 
Range: 3.492e+110.65
0.00
9.85
1.18
1.49
A_BM3085A 2: Scan ES- 
TIC
6.70e7
10.70
10.199.85
0.10
0.52 0.95 9.269.038.49
14.7114.2211.01 13.7313.5013.0712.35
A_BM3085A 1: Scan ES+ 
TIC
1.35e9
10.71
9.89
10.89
*Conformers of the desired peptide 
(9:91) 
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The averaged (M-H) under the peaks of ES- showed the same mass pattern, which 
confirmed the formation of conformers. 
 
 
 
  
Q3100 - SN: F09310279W
m/z
400 500 600 700 800 900 1000 1100 1200 1300 1400 1500 1600 1700 1800 1900
%
0
100
%
0
100
%
0
100
A_BM3085A 416 (10.699) Cm (410:425) 2: Scan ES- 
4.47e51178.15
1177.89
785.08
617.20
596.33441.16 473.49
784.76
618.09 704.11
785.33
793.14 1177.44
1120.66850.87 909.12
1179.04
1179.23
1179.36
1179.62
1189.22 1571.671189.80 1259.89 1570.96 1572.37 1885.991793.431768.46 1939.94
A_BM3085A 396 (10.185) Cm (391:402) 2: Scan ES- 
1.70e5613.16
604.91
604.78
548.45
548.32415.69
613.42
1177.95
613.93 1177.83
647.34 1021.58886.01828.86662.45 946.18 1121.75
1178.79
1291.90
1525.761494.391421.47 1634.66 1864.421765.52 1949.03
A_BM3085A 383 (9.851) Cm (379:388) 2: Scan ES- 
3.54e5589.03
588.90
566.05492.12
589.42
1178.85589.74
599.85 1178.53
638.51
1100.76855.16776.18 879.80 1073.04
1178.98
1179.81
1772.751583.771350.031284.54 1375.76 1549.32 1651.95 1868.70 1914.21
Q3100 - SN: F09310279W
m/z
400 500 600 700 800 900 1000 1100 1200 1300 1400 1500 1600 1700 1800 1900
%
0
100
A_BM3085A 416 (10.699) Cm (380:423) 2: Scan ES- 
1.83e51178.79
1178.15
1177.89
589.03
588.90
588.26
417.99
785.08589.22
589.42
613.16
617.20
617.71
638.19
750.20
785.40
785.65
1177.44793.14
1120.66
846.84 1107.92909.12 989.38
1179.23
1179.36
1179.62
1189.22
1571.671189.80
1234.80 1571.22
1259.89
1273.78 1570.96
1572.37
1885.991793.431589.40 1768.46 1889.31 1957.93
(M-H) Extract from peak 
at Rt = 10.70 min 
(M-H) Extract from peak 
at Rt = 10.19 min 
(M-H) Extract from peak 
at Rt = 9.85 min 
Combined (M-H) Extract from ES- 
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BM3085B 9 
 
 
 
 
 
 
  
Val
Cys
Tyr
Tyr
Lys
Asp Lys
Tyr
NH2
H 123
116
Val
Cys
Tyr
Tyr
Lys
Asp Lys
Tyr
NH2
H
S
S
8
BM3085B 9
 C102H144N22O26S2
Mw = 2158.50 g/mol
Retro Fc!RI C-Region Mimic Y116-D123 Dimer
Q3100 - S/N: F09310279W26-Nov-2010
Time
0.00 1.00 2.00 3.00 4.00 5.00 6.00 7.00 8.00 9.00 10.00 11.00 12.00 13.00 14.00 15.00
%
0
0.00 1.00 2.00 3.00 4.00 5.00 6.00 7.00 8.00 9.00 10.00 11.00 12.00 13.00 14.00 15.00
%
1
0.00 1.00 2.00 3.00 4.00 5.00 6.00 7.00 8.00 9.00 10.00 11.00 12.00 13.00 14.00 15.00
A
U
0.0
2.5e+1
5.0e+1
0.00 1.00 2.00 3.00 4.00 5.00 6.00 7.00 8.00 9.00 10.00 11.00 12.00 13.00 14.00 15.00
%
0
100
A_BM3109B_02p~ 2: Scan ES- 
1079
2.70e7
9.39
9.70
A_BM3109B_02p~ 3: Diode Array 
Range: 8.275e+19.35
0.00
8.94
1.37
A_BM3109B_02p~ 2: Scan ES- 
TIC
8.88e8
9.44
9.000.05
A_BM3109B_02p~ 1: Scan ES+ 
TIC
1.34e10
9.40
9.53
Q3100 - SN: F09310279W
m/z
400 500 600 700 800 900 1000 1100 1200 1300 1400 1500 1600 1700 1800 1900
%
0
100
A_BM3109B_02p~ 367 (9.439) Cm (362:376) 2: Scan ES- 
1.97e61077.73
1077.54
1041.37
895.59
646.48
645.77
895.08
646.67
887.65
714.34
969.21
895.97
968.77
1040.60
969.73
1078.18
1127.48
1127.67
1159.74
1208.78
1209.81
1210.06
1791.461232.98 1437.91
1282.34 1437.46 1438.10
1524.91
1712.541630.60 1891.82 1939.82
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BM3109B 18 
 
 
 
 
 
 
  
Val
Cys
Tyr
Tyr
Lys
Asp Lys
Tyr
OH
H 123
116
Val
Cys
Tyr
Tyr
Lys
Asp Lys
Tyr
OH
H
S
S
8
BM3109B 18
C102H142N20O28S2
Mw = 2160.47 g/mol
Retro Fc!RI C-Region Mimic Y116-D123 Dimer
Q3100 - S/N: F09310279W02-Apr-2011
Time
0.00 1.00 2.00 3.00 4.00 5.00 6.00 7.00 8.00 9.00 10.00 11.00 12.00 13.00 14.00 15.00
%
0
0.00 1.00 2.00 3.00 4.00 5.00 6.00 7.00 8.00 9.00 10.00 11.00 12.00 13.00 14.00 15.00
%
2
0.00 1.00 2.00 3.00 4.00 5.00 6.00 7.00 8.00 9.00 10.00 11.00 12.00 13.00 14.00 15.00
A
U
0.0
2.0e+1
0.00 1.00 2.00 3.00 4.00 5.00 6.00 7.00 8.00 9.00 10.00 11.00 12.00 13.00 14.00 15.00
%
0
100
A_BM3085B_p 2: Scan ES- 
1080
1.26e7
10.47
10.37
10.57
10.80 11.32
A_BM3085B_p 3: Diode Array 
Range: 4.443e+110.40
0.00
1.17 1.46
A_BM3085B_p 2: Scan ES- 
TIC
7.31e7
10.42
0.03
0.34 9.650.90 8.828.417.667.25
10.57
14.5614.4313.66
13.3212.4211.6510.88
14.92
A_BM3085B_p 1: Scan ES+ 
TIC
2.10e9
10.40
10.48
Q3100 - SN: F09310279W
m/z
400 500 600 700 800 900 1000 1100 1200 1300 1400 1500 1600 1700 1800 1900
%
0
100
A_BM3085B_p 405 (10.417) Cm (399:418) 2: Scan ES- 
7.57e51079.18
1078.74
719.16
718.96 1057.36
880.38
1079.31
1079.76
1080.21
1080.40
1439.59
1080.59 1439.33
1080.91
1438.89
1438.691090.00
1129.24
1129.94
1439.85
1440.17
1440.29 1619.68
1440.49 1619.36
1472.24
1518.98
1625.25
1732.29
1824.86 1856.99
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4.1.3. Alanine-Scan Analogues of BM1149-Am 
[D1A] BM1149-Am 19 
 
 
 
 
 
 
  
Val
Ile
Tyr
Tyr
Lys
1Ala Lys
Tyr
NH2
H
[D1A] BM1149-Am 19
C53H79N11O11
Mw = 1046.26 g/mol
Q3100 - S/N: F09310279W14-Sep-2011
Time
0.00 1.00 2.00 3.00 4.00 5.00 6.00 7.00 8.00 9.00 10.00 11.00 12.00 13.00 14.00 15.00
%
0
0.00 1.00 2.00 3.00 4.00 5.00 6.00 7.00 8.00 9.00 10.00 11.00 12.00 13.00 14.00 15.00
%
2
0.00 1.00 2.00 3.00 4.00 5.00 6.00 7.00 8.00 9.00 10.00 11.00 12.00 13.00 14.00 15.00
A
U
0.0
2.0e+1
0.00 1.00 2.00 3.00 4.00 5.00 6.00 7.00 8.00 9.00 10.00 11.00 12.00 13.00 14.00 15.00
%
0
100
A_AT011A_p2 f10f11 2: Scan ES- 
1045
2.30e6
9.34
9.26
9.39
9.44
13.359.62
11.2710.08 14.9414.81
A_AT011A_p2 f10f11 3: Diode Array 
Range: 5.413e+19.23
1.23
0.00
1.73
A_AT011A_p2 f10f11 2: Scan ES- 
TIC
4.36e7
9.26
8.207.647.055.710.10 0.85 4.30
14.5113.5513.4312.7112.29
11.7311.2410.19
A_AT011A_p2 f10f11 1: Scan ES+ 
TIC
1.39e9
9.27
Q3100 - SN: F09310279W
m/z
400 500 600 700 800 900 1000 1100 1200 1300 1400 1500 1600 1700 1800 1900
%
0
100
A_AT011A_p2 f10f11 360 (9.259) Cm (356:371) 2: Scan ES- 
1.07e61091.16
1045.08
1092.19
1093.08
1159.07 1743.48
1569.131160.22 1592.18 1743.80
(M-H) of the 
desired product 
(M-H) of the desired product + 
formic acid (Mw = 46 g/mol) 
Chapter 4 
 167 
[K2A] BM1149-Am 20 
 
 
 
 
 
 
  
Val
Ile
Tyr
Tyr
2Ala
Asp Lys
Tyr
NH2
H
[K2A] BM1149-Am 20
C51H71N9O14
Mw = 1034.16 g/mol
Q3100 - S/N: F09310279W26-Nov-2010
Time
0.00 1.00 2.00 3.00 4.00 5.00 6.00 7.00 8.00 9.00 10.00 11.00 12.00 13.00 14.00 15.00
%
0
0.00 1.00 2.00 3.00 4.00 5.00 6.00 7.00 8.00 9.00 10.00 11.00 12.00 13.00 14.00 15.00
%
1
0.00 1.00 2.00 3.00 4.00 5.00 6.00 7.00 8.00 9.00 10.00 11.00 12.00 13.00 14.00 15.00
A
U
0.0
2.0e+1
4.0e+1
0.00 1.00 2.00 3.00 4.00 5.00 6.00 7.00 8.00 9.00 10.00 11.00 12.00 13.00 14.00 15.00
%
0
100
A_AT011B_pII f14 2: Scan ES- 
1032
2.86e8
9.59
A_AT011B_pII f14 3: Diode Array 
Range: 5.965e+19.51
0.00
1.37
A_AT011B_pII f14 2: Scan ES- 
TIC
7.82e8
9.59
0.03
0.93
A_AT011B_pII f14 1: Scan ES+ 
TIC
6.24e9
9.60
Q3100 - SN: F09310279W
m/z
400 500 600 700 800 900 1000 1100 1200 1300 1400 1500 1600 1700 1800 1900
%
0
100
A_AT011B_pII f14 373 (9.594) Cm (369:380) 2: Scan ES- 
1.24e71031.51
1015.63
515.48
1032.40
1033.30
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[Y3A] BM1149-Am 21 
 
 
 
N.B.: Both UV and mass traces showed the presence of impurities. The percentage 
purity of the desired peptide was calculated by measuring the areas under the peaks 
of UV trace. The impurities in the final product could not be separated by preparative 
LCMS. 
  
Val
Ile
Tyr
3Ala
Lys
Asp Lys
Tyr
NH2
H
[Y3A] BM1149-Am 21
C48H74N10O13
Mw = 999.16 g/mol
Q3100 - S/N: F09310279W26-Nov-2010
Time
0.00 1.00 2.00 3.00 4.00 5.00 6.00 7.00 8.00 9.00 10.00 11.00 12.00 13.00 14.00 15.00
%
0
0.00 1.00 2.00 3.00 4.00 5.00 6.00 7.00 8.00 9.00 10.00 11.00 12.00 13.00 14.00 15.00
%
1
0.00 1.00 2.00 3.00 4.00 5.00 6.00 7.00 8.00 9.00 10.00 11.00 12.00 13.00 14.00 15.00
A
U
0.0
5.0e+1
0.00 1.00 2.00 3.00 4.00 5.00 6.00 7.00 8.00 9.00 10.00 11.00 12.00 13.00 14.00 15.00
%
0
100
A_AT011C_p f9andf10 2: Scan ES- 
997
2.89e8
7.777.66 7.97
8.46
A_AT011C_p f9andf10 3: Diode Array 
Range: 1.026e+27.60
0.00
1.36
8.41 10.028.89
A_AT011C_p f9andf10 2: Scan ES- 
TIC
8.96e8
7.977.77
0.05
8.05
8.46
8.95
10.08
A_AT011C_p f9andf10 1: Scan ES+ 
TIC
7.15e9
7.62 7.75
8.47
8.93
10.07
*The desired peptide has a 
purity of 91%. 
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(M-H) averaged from ES- for impurity peaks, which contains trace amount of the 
desired product. Average (M-H) of the desired product is also shown for comparison. 
 
  
Q3100 - SN: F09310279W
m/z
400 500 600 700 800 900 1000 1100 1200 1300 1400 1500 1600 1700 1800 1900
%
0
100
A_AT011C_p f9andf10 310 (7.974) Cm (294:328) 2: Scan ES- 
2.05e7996.55
997.51
998.60
1994.79
Q3100 - SN: F09310279W
m/z
400 500 600 700 800 900 1000 1100 1200 1300 1400 1500 1600 1700 1800 1900
%
0
100
%
0
100
A_AT011C_p f9andf10 348 (8.951) Cm (336:361) 2: Scan ES- 
1.23e61002.63
996.55
994.63
993.93
1003.21
1024.53
1054.68
1055.52
1056.41
1143.67 1287.59
A_AT011C_p f9andf10 310 (7.974) Cm (294:328) 2: Scan ES- 
2.05e7996.55
997.51
998.60
1994.79
(M-H) averaged from ES- at Rt = 7.97 min 
Averaged (M-H) of the 
impurity from ES- at Rt = 
8.95 min 
Averaged (M-H) of the 
desired product from ES- at 
Rt = 7.97 min 
Chapter 4 
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[Y4A] BM1149-Am 22 
 
 
 
 
 
 
  
Val
Ile
4Ala
Tyr
Lys
Asp Lys
Tyr
NH2
H
[Y4A] BM1149-Am 22
C48H74N10O13
Mw = 999.16 g/mol
Q3100 - S/N: F09310279W26-Nov-2010
Time
0.00 1.00 2.00 3.00 4.00 5.00 6.00 7.00 8.00 9.00 10.00 11.00 12.00 13.00 14.00 15.00
%
0
0.00 1.00 2.00 3.00 4.00 5.00 6.00 7.00 8.00 9.00 10.00 11.00 12.00 13.00 14.00 15.00
%
0
0.00 1.00 2.00 3.00 4.00 5.00 6.00 7.00 8.00 9.00 10.00 11.00 12.00 13.00 14.00 15.00
A
U
0.0
2.5e+1
5.0e+1
7.5e+1
0.00 1.00 2.00 3.00 4.00 5.00 6.00 7.00 8.00 9.00 10.00 11.00 12.00 13.00 14.00 15.00
%
0
100
A_AT011D_p f15andf16 2: Scan ES- 
997
3.11e8
8.15 8.33
A_AT011D_p f15andf16 3: Diode Array 
Range: 9.968e+18.08
0.00
1.36
A_AT011D_p f15andf16 2: Scan ES- 
TIC
9.80e8
8.338.20
0.05
0.95 9.26
A_AT011D_p f15andf16 1: Scan ES+ 
TIC
7.66e9
8.148.21
9.27
Q3100 - SN: F09310279W
m/z
400 500 600 700 800 900 1000 1100 1200 1300 1400 1500 1600 1700 1800 1900
%
0
100
A_AT011D_p f15andf16 324 (8.334) Cm (313:338) 2: Scan ES- 
2.18e7996.55
997.51
998.47
1994.73
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[I5A] BM1149-Am 23 
 
 
 
 
 
 
  
Val
5Ala
Tyr
Tyr
Lys
Asp Lys
Tyr
NH2
H
[I5A] BM1149-Am 23
C51H72N10O14
Mw = 1049.18 g/mol
Q3100 - S/N: F09310279W26-Nov-2010
Time
0.00 1.00 2.00 3.00 4.00 5.00 6.00 7.00 8.00 9.00 10.00 11.00 12.00 13.00 14.00 15.00
%
0
0.00 1.00 2.00 3.00 4.00 5.00 6.00 7.00 8.00 9.00 10.00 11.00 12.00 13.00 14.00 15.00
%
1
0.00 1.00 2.00 3.00 4.00 5.00 6.00 7.00 8.00 9.00 10.00 11.00 12.00 13.00 14.00 15.00
A
U
0.0
5.0e+1
1.0e+2
0.00 1.00 2.00 3.00 4.00 5.00 6.00 7.00 8.00 9.00 10.00 11.00 12.00 13.00 14.00 15.00
%
0
100
A_AT011E_p f40andf41 2: Scan ES- 
1047
2.35e8
7.84
7.74 7.97
8.05
A_AT011E_p f40andf41 3: Diode Array 
Range: 1.264e+27.69
1.21
A_AT011E_p f40andf41 2: Scan ES- 
TIC
6.31e8
7.847.74 7.97
A_AT011E_p f40andf41 1: Scan ES+ 
TIC
6.14e9
7.83
Q3100 - SN: F09310279W
m/z
400 500 600 700 800 900 1000 1100 1200 1300 1400 1500 1600 1700 1800 1900
%
0
100
A_AT011E_p f40andf41 305 (7.845) Cm (299:321) 2: Scan ES- 
1.59e71046.62
1047.58
1048.47
1570.81
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[V6A] BM1149-Am 24 
 
 
 
 
 
 
  
6Ala
Ile
Tyr
Tyr
Lys
Asp Lys
Tyr
NH2
H
[V6A] BM1149-Am 24
C52H74N10O14
Mw = 1063.20 g/mol
Q3100 - S/N: F09310279W26-Nov-2010
Time
0.00 1.00 2.00 3.00 4.00 5.00 6.00 7.00 8.00 9.00 10.00 11.00 12.00 13.00 14.00 15.00
%
0
0.00 1.00 2.00 3.00 4.00 5.00 6.00 7.00 8.00 9.00 10.00 11.00 12.00 13.00 14.00 15.00
%
1
0.00 1.00 2.00 3.00 4.00 5.00 6.00 7.00 8.00 9.00 10.00 11.00 12.00 13.00 14.00 15.00
A
U
0.0
5.0e+1
0.00 1.00 2.00 3.00 4.00 5.00 6.00 7.00 8.00 9.00 10.00 11.00 12.00 13.00 14.00 15.00
%
0
100
A_AT011F_p f43andf44 2: Scan ES- 
1061
3.11e8
8.208.08
8.31
A_AT011F_p f43andf44 3: Diode Array 
Range: 1.129e+27.97
0.00
A_AT011F_p f43andf44 2: Scan ES- 
TIC
7.86e8
8.20
8.08
0.05
8.28
A_AT011F_p f43andf44 1: Scan ES+ 
TIC
6.67e9
7.98 8.19
Q3100 - SN: F09310279W
m/z
400 500 600 700 800 900 1000 1100 1200 1300 1400 1500 1600 1700 1800 1900
%
0
100
A_AT011F_p f43andf44 319 (8.205) Cm (308:333) 2: Scan ES- 
1.79e71060.51
1061.53
1062.43
1591.94
Chapter 4 
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[K7A] BM1149-Am 25 
 
 
 
 
 
 
  
Val
Ile
Tyr
Tyr
Lys
Asp 7Ala
Tyr
NH2
H
[K7A] BM1149-Am 25
C51H71N9O14
Mw = 1034.16 g/mol
Q3100 - S/N: F09310279W26-Nov-2010
Time
0.00 1.00 2.00 3.00 4.00 5.00 6.00 7.00 8.00 9.00 10.00 11.00 12.00 13.00 14.00 15.00
%
0
0.00 1.00 2.00 3.00 4.00 5.00 6.00 7.00 8.00 9.00 10.00 11.00 12.00 13.00 14.00 15.00
%
1
0.00 1.00 2.00 3.00 4.00 5.00 6.00 7.00 8.00 9.00 10.00 11.00 12.00 13.00 14.00 15.00
A
U
0.0
2.5e+1
5.0e+1
0.00 1.00 2.00 3.00 4.00 5.00 6.00 7.00 8.00 9.00 10.00 11.00 12.00 13.00 14.00 15.00
%
0
100
A_AT011G_p f52 2: Scan ES- 
1032
3.08e8
9.57
9.47
A_AT011G_p f52 3: Diode Array 
Range: 8.76e+19.44
0.00
1.37
A_AT011G_p f52 2: Scan ES- 
TIC
7.88e8
9.57
9.47
0.05 9.90
A_AT011G_p f52 1: Scan ES+ 
TIC
5.98e9
9.50
Q3100 - SN: F09310279W
m/z
400 500 600 700 800 900 1000 1100 1200 1300 1400 1500 1600 1700 1800 1900
%
0
100
A_AT011G_p f52 372 (9.568) Cm (364:381) 2: Scan ES- 
1.51e71031.51
1032.40
1033.49
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[Y8A] BM1149-Am 26 
 
 
 
N.B.: Both UV and mass traces showed the presence of impurities. The percentage 
purity of the desired peptide was calculated by measuring the areas under the peaks 
of UV trace. The impurities in the final product could not be separated by preparative 
LCMS. 
  
Val
Ile
Tyr
Tyr
Lys
Asp Lys
8Ala
NH2
H
[Y8A] BM1149-Am 26
C48H74N10O13
Mw = 999.16 g/mol
Q3100 - S/N: F09310279W26-Nov-2010
Time
0.00 1.00 2.00 3.00 4.00 5.00 6.00 7.00 8.00 9.00 10.00 11.00 12.00 13.00 14.00 15.00
%
0
0.00 1.00 2.00 3.00 4.00 5.00 6.00 7.00 8.00 9.00 10.00 11.00 12.00 13.00 14.00 15.00
%
1
0.00 1.00 2.00 3.00 4.00 5.00 6.00 7.00 8.00 9.00 10.00 11.00 12.00 13.00 14.00 15.00
A
U
0.0
2.5e+1
5.0e+1
0.00 1.00 2.00 3.00 4.00 5.00 6.00 7.00 8.00 9.00 10.00 11.00 12.00 13.00 14.00 15.00
%
0
100
A_AT011H_p f49 2: Scan ES- 
997
2.64e8
7.97 8.13
A_AT011H_p f49 3: Diode Array 
Range: 8.096e+17.89
0.00
1.38
9.37
A_AT011H_p f49 2: Scan ES- 
TIC
8.74e8
8.00
0.05
8.13
9.44
A_AT011H_p f49 1: Scan ES+ 
TIC
6.24e9
7.98
9.45
*The desired peptide has a 
purity of 98%. 
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(M-H) averaged from ES- for impurity peaks. Average (M-H) of the desired product 
is also shown for comparison. 
 
  
Q3100 - SN: F09310279W
m/z
400 500 600 700 800 900 1000 1100 1200 1300 1400 1500 1600 1700 1800 1900
%
0
100
A_AT011H_p f49 311 (7.999) Cm (304:326) 2: Scan ES- 
1.52e7996.62
997.58
998.60
1994.79
Q3100 - SN: F09310279W
m/z
400 500 600 700 800 900 1000 1100 1200 1300 1400 1500 1600 1700 1800 1900
%
0
100
%
0
100
A_AT011H_p f49 367 (9.439) Cm (363:372) 2: Scan ES- 
1.82e6565.36
564.72
565.68
1131.44
566.00
1130.61
1031.32
566.89 1016.53 1032.40
1033.49
1131.76
1132.34
1133.43
1133.81
1154.30
1506.031313.52 1698.331573.44
A_AT011H_p f49 311 (7.999) Cm (304:326) 2: Scan ES- 
1.52e7996.62
997.58
998.60
1994.79
(M-H) averaged from ES- at Rt = 8.00 min 
Averaged (M-H) of the 
impurity from ES- at Rt = 
9.44 min 
Averaged (M-H) of the 
desired product from ES- at 
Rt = 8.00 min 
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4.1.4. Truncated Analogues of BM1149-Am 
["1] BM1149-Am 27 
 
 
 
 
N.B.: Both UV and mass traces showed the presence of impurities. The percentage 
purity of the desired peptide was calculated by measuring the areas under the peaks 
of UV trace. The impurities in the final product could not be separated by preparative 
LCMS. 
  
Val
Ile
Tyr
Tyr
Lys
H Lys
Tyr
NH2
[!1] BM1149-Am 27
C50H74N10O10
Mw = 975.18 g/mol
Q3100 - S/N: F09310279W19-Mar-2011
Time
0.00 1.00 2.00 3.00 4.00 5.00 6.00 7.00 8.00 9.00 10.00 11.00 12.00 13.00 14.00 15.00
%
0
0.00 1.00 2.00 3.00 4.00 5.00 6.00 7.00 8.00 9.00 10.00 11.00 12.00 13.00 14.00 15.00
%
1
0.00 1.00 2.00 3.00 4.00 5.00 6.00 7.00 8.00 9.00 10.00 11.00 12.00 13.00 14.00 15.00
A
U
0.0
2.0e+1
4.0e+1
0.00 1.00 2.00 3.00 4.00 5.00 6.00 7.00 8.00 9.00 10.00 11.00 12.00 13.00 14.00 15.00
%
0
100
A_BM3131A 2: Scan ES- 
974
1.11e8
8.598.51
8.72
9.16
A_BM3131A 3: Diode Array 
Range: 7.442e+18.50
0.00
1.17 1.52
9.28
A_BM3131A 2: Scan ES- 
TIC
3.73e8
8.51
0.03
8.59
8.69
9.29
14.6313.7312.7810.19
A_BM3131A 1: Scan ES+ 
TIC
5.80e9
8.52 8.63
9.27
*The desired peptide has a 
purity of 86%. 
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(M-H) averaged from ES- for impurity peaks, which contains trace amount of the 
desired product. Average (M-H) of the desired product is also shown for comparison. 
 
 
  
Q3100 - SN: F09310279W
m/z
400 500 600 700 800 900 1000 1100 1200 1300 1400 1500 1600 1700 1800 1900
%
0
100
A_BM3131A 331 (8.514) Cm (328:347) 2: Scan ES- 
6.82e6973.70
974.60
1009.74
1010.63
1949.411019.72
1020.621087.70
1461.74
Q3100 - SN: F09310279W
m/z
400 500 600 700 800 900 1000 1100 1200 1300 1400 1500 1600 1700 1800 1900
%
0
100
%
0
100
A_BM3131A 361 (9.285) Cm (350:372) 2: Scan ES- 
6.91e51136.86
909.63
567.85
547.43 682.54 846.52
973.70
910.53
945.54
987.59
1072.66
1137.69
1172.64
1174.82
1175.90
1205.99 1305.15
1707.39
A_BM3131A 331 (8.514) Cm (328:347) 2: Scan ES- 
6.82e6973.70
974.60
1009.74
1010.63
1949.411019.72
1087.70 1461.74
(M-H) averaged from ES- at Rt = 8.51 min 
Averaged (M-H) of the 
impurity from ES- at Rt = 
9.29 min 
Averaged (M-H) of the 
desired product from ES- at 
Rt = 8.51 min 
(M-H) of the 
desired product 
(M-H) of the desired product + 
formic acid (Mw = 46 g/mol) 
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["1,2] BM1149-Am 28 
 
 
 
 
N.B.: Both UV and mass traces showed the presence of impurities. The percentage 
purity of the desired peptide was calculated by measuring the areas under the peaks 
of UV trace. The impurities in the final product could not be separated by preparative 
LCMS. 
  
Val
Ile
Tyr
Tyr
H
Lys
Tyr
NH2
[!1,2] BM1149-Am 28
C44H62N8O9
Mw = 847.01 g/mol
Q3100 - S/N: F09310279W19-Mar-2011
Time
0.00 1.00 2.00 3.00 4.00 5.00 6.00 7.00 8.00 9.00 10.00 11.00 12.00 13.00 14.00 15.00
%
0
0.00 1.00 2.00 3.00 4.00 5.00 6.00 7.00 8.00 9.00 10.00 11.00 12.00 13.00 14.00 15.00
%
0
0.00 1.00 2.00 3.00 4.00 5.00 6.00 7.00 8.00 9.00 10.00 11.00 12.00 13.00 14.00 15.00
A
U
0.0
2.0e+1
4.0e+1
0.00 1.00 2.00 3.00 4.00 5.00 6.00 7.00 8.00 9.00 10.00 11.00 12.00 13.00 14.00 15.00
%
0
100
A_BM3131B 2: Scan ES- 
846
1.38e8
9.31
9.23
A_BM3131B 3: Diode Array 
Range: 7.467e+19.25
0.00
1.17
9.78
A_BM3131B 2: Scan ES- 
TIC
4.51e8
9.31
9.23
0.05
9.39
9.80
10.03
A_BM3131B 1: Scan ES+ 
TIC
6.81e9
9.27
9.32
9.81
10.04
*The desired peptide has a 
purity of 91%. 
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(M-H) averaged from ES- for impurity peaks. Average (M-H) of the desired product 
is also shown for comparison. 
 
  
Q3100 - SN: F09310279W
m/z
400 500 600 700 800 900 1000 1100 1200 1300 1400 1500 1600 1700 1800 1900
%
0
100
A_BM3131B 362 (9.311) Cm (356:370) 2: Scan ES- 
1.04e7845.56
846.59
881.53
882.56
1693.18
1692.15
884.67
Q3100 - SN: F09310279W
m/z
400 500 600 700 800 900 1000 1100 1200 1300 1400 1500 1600 1700 1800 1900
%
0
100
%
0
100
A_BM3131B 381 (9.799) Cm (375:392) 2: Scan ES- 
6.28e51008.71
859.71
781.49
561.38
561.25
515.49400.00
597.48
597.67 670.38725.24
782.71
817.72
860.73
895.68 1005.32
1031.75
1032.65
1032.84
1044.62
1045.58
1047.63
1300.731133.34 1192.61 1561.361380.56 1437.73 1870.371584.28 1656.24 1930.41
A_BM3131B 362 (9.311) Cm (356:370) 2: Scan ES- 
1.04e7845.56
846.59
881.53
882.56
1693.18
884.67
(M-H) averaged from ES- at Rt = 9.31 min 
Averaged (M-H) of the 
impurity from ES- at Rt = 
9.80 min 
Averaged (M-H) of the 
desired product from ES- at 
Rt = 9.31 min 
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["1,2,3] BM1149-Am 29 
 
 
 
 
N.B.: Both UV and mass traces showed the presence of impurities. The percentage 
purity of the desired peptide was calculated by measuring the areas under the peaks 
of UV trace. The impurities in the final product could not be separated by preparative 
LCMS. 
  
Val
Ile
Tyr
H Lys
Tyr
NH2
[!1,2,3] BM1149-Am 29
C35H53N7O7
Mw = 683.84 g/mol
Q3100 - S/N: F09310279W19-Mar-2011
Time
0.00 1.00 2.00 3.00 4.00 5.00 6.00 7.00 8.00 9.00 10.00 11.00 12.00 13.00 14.00 15.00
%
0
0.00 1.00 2.00 3.00 4.00 5.00 6.00 7.00 8.00 9.00 10.00 11.00 12.00 13.00 14.00 15.00
%
0
0.00 1.00 2.00 3.00 4.00 5.00 6.00 7.00 8.00 9.00 10.00 11.00 12.00 13.00 14.00 15.00
A
U
0.0
2.0e+1
4.0e+1
6.0e+1
0.00 1.00 2.00 3.00 4.00 5.00 6.00 7.00 8.00 9.00 10.00 11.00 12.00 13.00 14.00 15.00
%
0
100
A_BM3131C 2: Scan ES- 
683
1.25e8
8.41
8.31 8.49
8.54
A_BM3131C 3: Diode Array 
Range: 7.95e+18.29
0.00
1.171.53
9.16
A_BM3131C 2: Scan ES- 
TIC
3.75e8
8.398.31
0.05
8.49
9.009.18
14.56
10.16
A_BM3131C 1: Scan ES+ 
TIC
4.49e9
8.34
9.17
*The desired peptide has a 
purity of 95%. 
Chapter 4 
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(M-H) averaged from ES- for impurity peaks. Average (M-H) of the desired product 
is also shown for comparison. 
 
  
Q3100 - SN: F09310279W
m/z
400 500 600 700 800 900 1000 1100 1200 1300 1400 1500 1600 1700 1800 1900
%
0
100
A_BM3131C 326 (8.385) Cm (320:339) 2: Scan ES- 
1.18e7682.54
683.57
718.52
1365.97
720.44
728.56796.66
Q3100 - SN: F09310279W
m/z
400 500 600 700 800 900 1000 1100 1200 1300 1400 1500 1600 1700 1800 1900
%
0
100
%
0
100
A_BM3131C 350 (9.002) Cm (344:362) 2: Scan ES- 
8.83e5618.48
618.67
696.43
619.50
654.51
696.63
697.59
732.53
738.68
845.50
764.47 846.52
883.71 1393.75
A_BM3131C 326 (8.385) Cm (320:339) 2: Scan ES- 
1.18e7682.54
683.57
718.52
1365.97720.44 796.66
(M-H) averaged from ES- at Rt = 8.39 min 
Averaged (M-H) of the 
impurity from ES- at Rt = 
9.00 min 
Averaged (M-H) of the 
desired product from ES- at 
Rt = 8.39 min 
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["8] BM1149-Am 30 
 
 
 
 
N.B.: Both UV and mass traces showed the presence of impurities. The percentage 
purity of the desired peptide was calculated by measuring the areas under the peaks 
of UV trace. The impurities in the final product could not be separated by preparative 
LCMS. 
  
Val
Ile
Tyr
Tyr
Lys
Asp Lys
HH
[!8] BM1149-Am 30
C45H70N10O11
Mw = 927.10 g/mol
Q3100 - S/N: F09310279W19-Mar-2011
Time
0.00 1.00 2.00 3.00 4.00 5.00 6.00 7.00 8.00 9.00 10.00 11.00 12.00 13.00 14.00 15.00
%
0
0.00 1.00 2.00 3.00 4.00 5.00 6.00 7.00 8.00 9.00 10.00 11.00 12.00 13.00 14.00 15.00
%
0
0.00 1.00 2.00 3.00 4.00 5.00 6.00 7.00 8.00 9.00 10.00 11.00 12.00 13.00 14.00 15.00
A
U
0.0
2.0e+1
4.0e+1
0.00 1.00 2.00 3.00 4.00 5.00 6.00 7.00 8.00 9.00 10.00 11.00 12.00 13.00 14.00 15.00
%
0
100
A_BM3131D 2: Scan ES- 
926
1.99e8
8.39
8.31 8.46
A_BM3131D 3: Diode Array 
Range: 5.65e+18.33
0.00
1.18 1.51
A_BM3131D 2: Scan ES- 
TIC
4.20e8
8.39
0.05
8.46
8.69
13.229.08 10.03
A_BM3131D 1: Scan ES+ 
TIC
5.31e9
8.37
8.68
8.86
10.04
*The desired peptide has a 
purity of 90%. 
Chapter 4 
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(M-H) averaged from ES- for impurity peaks, which contains trace amount of the 
desired product. Average (M-H) of the desired product is also shown for comparison. 
 
 
  
Q3100 - SN: F09310279W
m/z
400 500 600 700 800 900 1000 1100 1200 1300 1400 1500 1600 1700 1800 1900
%
0
100
A_BM3131D 326 (8.385) Cm (320:333) 2: Scan ES- 
1.17e7925.63
926.66
927.62
1853.34928.64
Q3100 - SN: F09310279W
m/z
400 500 600 700 800 900 1000 1100 1200 1300 1400 1500 1600 1700 1800 1900
%
0
100
%
0
100
A_BM3131D 338 (8.694) Cm (334:357) 2: Scan ES- 
1.18e6875.64
520.16
531.55
876.67
925.76
939.71
1040.71940.61
943.87 1041.48
A_BM3131D 326 (8.385) Cm (320:333) 2: Scan ES- 
1.17e7925.63
926.66
927.62
1853.34928.64
(M-H) averaged from ES- at Rt = 8.39 min 
Averaged (M-H) of the 
impurity from ES- at Rt = 
8.69 min 
Averaged (M-H) of the 
desired product from ES- at 
Rt = 8.39 min 
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["7,8] BM1149-Am 31 
 
 
 
 
 
 
  
Val
Ile
Tyr
Tyr
Lys
Asp H
H
[!7,8] BM1149-Am 31
C39H58N8O10
Mw = 798.93 g/mol
Q3100 - S/N: F09310279W14-Dec-2010
Time
0.00 1.00 2.00 3.00 4.00 5.00 6.00 7.00 8.00 9.00 10.00 11.00 12.00 13.00 14.00 15.00
%
0
0.00 1.00 2.00 3.00 4.00 5.00 6.00 7.00 8.00 9.00 10.00 11.00 12.00 13.00 14.00 15.00
%
1
0.00 1.00 2.00 3.00 4.00 5.00 6.00 7.00 8.00 9.00 10.00 11.00 12.00 13.00 14.00 15.00
A
U
0.0
5.0e+1
1.0e+2
0.00 1.00 2.00 3.00 4.00 5.00 6.00 7.00 8.00 9.00 10.00 11.00 12.00 13.00 14.00 15.00
%
0
100
A_BM3131E_p 2: Scan ES- 
798
8.60e7
8.858.77
8.69
8.44
8.93
9.16
A_BM3131E_p 3: Diode Array 
Range: 1.306e+28.54
0.00
A_BM3131E_p 2: Scan ES- 
TIC
3.41e8
9.03
8.878.49
0.900.08 7.971.18 13.43
A_BM3131E_p 1: Scan ES+ 
TIC
2.93e9
8.50
7.98
8.88
Q3100 - SN: F09310279W
m/z
400 500 600 700 800 900 1000 1100 1200 1300 1400 1500 1600 1700 1800 1900
%
0
100
A_BM3131E_p 351 (9.028) Cm (329:353) 2: Scan ES- 
7.51e6797.56
733.62
683.70 734.64
798.58
845.56
846.65
847.67
1596.06
1693.11
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["6,7,8] BM1149-Am 32 
 
 
 
 
N.B.: Both UV and mass traces showed the presence of impurities. The percentage 
purity of the desired peptide was calculated by measuring the areas under the peaks 
of UV trace. The impurities in the final product could not be separated by preparative 
LCMS. 
  
H
Ile
Tyr
Tyr
Lys
Asp
H
[!6,7,8] BM1149-Am 32
C34H49N7O9
Mw = 699.79 g/mol
Q3100 - S/N: F09310279W14-Dec-2010
Time
0.00 1.00 2.00 3.00 4.00 5.00 6.00 7.00 8.00 9.00 10.00 11.00 12.00 13.00 14.00 15.00
%
0
0.00 1.00 2.00 3.00 4.00 5.00 6.00 7.00 8.00 9.00 10.00 11.00 12.00 13.00 14.00 15.00
%
1
0.00 1.00 2.00 3.00 4.00 5.00 6.00 7.00 8.00 9.00 10.00 11.00 12.00 13.00 14.00 15.00
A
U
0.0
5.0e+1
0.00 1.00 2.00 3.00 4.00 5.00 6.00 7.00 8.00 9.00 10.00 11.00 12.00 13.00 14.00 15.00
%
0
100
A_BM3131F_p 2: Scan ES- 
699
8.76e7
8.108.00
7.747.38
7.33
8.23
A_BM3131F_p 3: Diode Array 
Range: 1.076e+27.31
0.00 6.87
1.33
8.49
9.47
A_BM3131F_p 2: Scan ES- 
TIC
2.89e8
7.23
6.89
0.08
0.88
8.108.00 8.23
8.56
9.49
9.29 13.7910.93 13.5012.19
A_BM3131F_p 1: Scan ES+ 
TIC
2.67e9
7.24
6.90
0.01
7.557.91
8.11
8.50 9.50
10.91
*The desired peptide has a 
purity of 97%. 
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(M-H) averaged from ES- for impurity peaks, which contains trace amount of the 
desired product. Average (M-H) of the desired product is also shown for comparison. 
 
  
Q3100 - SN: F09310279W
m/z
400 500 600 700 800 900 1000 1100 1200 1300 1400 1500 1600 1700 1800 1900
%
0
100
A_BM3131F_p 281 (7.228) Cm (281:326) 2: Scan ES- 
1.08e7698.55
634.54
699.51
1397.79
700.47
1399.83
Q3100 - SN: F09310279W
m/z
400 500 600 700 800 900 1000 1100 1200 1300 1400 1500 1600 1700 1800 1900
%
0
100
%
0
100
%
0
100
%
0
100
A_BM3131F_p 369 (9.491) Cm (364:374) 2: Scan ES- 
3.59e61031.56
1032.59
1033.80
1034.63
A_BM3131F_p 331 (8.514) Cm (327:340) 2: Scan ES- 
4.89e6746.55
698.61
648.62
747.57
748.66
1494.90814.46
A_BM3131F_p 280 (7.202) Cm (263:280) 2: Scan ES- 
7.52e6634.54
616.36
635.50
1269.88636.59
A_BM3131F_p 315 (8.102) Cm (282:328) 2: Scan ES- 
1.07e7698.55
634.48
699.51
1397.79700.53
(M-H) averaged from ES- at Rt = 7.23 min 
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4.1.5. Arg-Addition Analogues of [Y8A] BM1149-Am 
BM3135A 33 
 
 
 
 
 
 
  
Val
Ile
Tyr
Tyr
Lys
Asp Lys
Tyr
NH2
Arg
BM3135A 33
C54H87N15O13
Mw = 1154.36 g/mol
H
Q3100 - S/N: F09310279W02-Apr-2011
Time
0.00 1.00 2.00 3.00 4.00 5.00 6.00 7.00 8.00 9.00 10.00 11.00 12.00 13.00 14.00 15.00
%
0
0.00 1.00 2.00 3.00 4.00 5.00 6.00 7.00 8.00 9.00 10.00 11.00 12.00 13.00 14.00 15.00
%
2
0.00 1.00 2.00 3.00 4.00 5.00 6.00 7.00 8.00 9.00 10.00 11.00 12.00 13.00 14.00 15.00
A
U
-1.0e+1
0.0
1.0e+1
2.0e+1
0.00 1.00 2.00 3.00 4.00 5.00 6.00 7.00 8.00 9.00 10.00 11.00 12.00 13.00 14.00 15.00
%
0
100
A_BM3135A repeat 2: Scan ES- 
1153
4.78e6
7.69
7.64 7.77
7.92
7.97
8.08 14.9714.5810.858.56 12.96
A_BM3135A repeat 3: Diode Array 
Range: 3.579e+17.62
1.22
0.00
1.59
A_BM3135A repeat 2: Scan ES- 
TIC
5.02e7
7.69
5.250.44 1.260.85 2.441.34 1.80
4.99
3.55 7.056.33
14.5814.3813.91
13.3712.4012.2411.70
10.91
14.76
A_BM3135A repeat 1: Scan ES+ 
TIC
5.21e8
7.67
7.75
14.4614.00
Q3100 - SN: F09310279W
m/z
400 500 600 700 800 900 1000 1100 1200 1300 1400 1500 1600 1700 1800 1900
%
0
100
A_BM3135A repeat 299 (7.691) Cm (295:316) 2: Scan ES- 
2.05e51153.95
576.29
575.91
572.58
404.23
533.41
1153.05
576.68
624.94
625.84
626.16
626.35 815.48
741.43
1083.791048.65
872.12 984.64
1198.89
1199.91
1200.04
1200.17
1200.36
1201.13
1569.231203.05
1549.901255.99
1317.31 1603.101625.32 1773.45
1677.68 1953.96
(M-H) of the 
desired product 
(M-H) of the desired product + 
formic acid (Mw = 46 g/mol) 
Chapter 4 
 188 
BM3135B 34 
 
 
 
 
 
 
  
Val
Ile
Tyr
Tyr
Lys
Asp Lys
Tyr
Arg
H
BM3135B 34
C54H87N15O13
Mw = 1154.36 g/mol
NH2
Q3100 - S/N: F09310279W02-Apr-2011
Time
0.00 1.00 2.00 3.00 4.00 5.00 6.00 7.00 8.00 9.00 10.00 11.00 12.00 13.00 14.00 15.00
%
0
0.00 1.00 2.00 3.00 4.00 5.00 6.00 7.00 8.00 9.00 10.00 11.00 12.00 13.00 14.00 15.00
%
4
0.00 1.00 2.00 3.00 4.00 5.00 6.00 7.00 8.00 9.00 10.00 11.00 12.00 13.00 14.00 15.00
A
U
-1.0e+1
0.0
0.00 1.00 2.00 3.00 4.00 5.00 6.00 7.00 8.00 9.00 10.00 11.00 12.00 13.00 14.00 15.00
%
0
100
A_BM3135B_repeat 2: Scan ES- 
1153
6.93e6
7.23
1.18
7.10
6.89
1.36 6.76
6.486.401.832.19 5.863.912.52 5.02
7.30
7.48
7.59
7.77
13.3010.52 12.73 14.81
A_BM3135B_repeat 3: Diode Array 
Range: 2.339e+17.211.18
0.00
1.37
A_BM3135B_repeat 2: Scan ES- 
TIC
3.66e7
7.307.23
1.21
0.05
0.31
0.52
7.02
1.36
6.611.67 2.11
2.39
5.863.60
7.41 14.17
7.46 13.91
13.40
12.9612.35
11.93
14.97
A_BM3135B_repeat 1: Scan ES+ 
TIC
4.67e8
1.19
0.01
7.26
7.13
6.98
6.88
1.37
7.36
14.9814.8013.90
Q3100 - SN: F09310279W
m/z
400 500 600 700 800 900 1000 1100 1200 1300 1400 1500 1600 1700 1800 1900
%
0
100
A_BM3135B_repeat 284 (7.305) Cm (256:300) 2: Scan ES- 
3.00e51152.86
625.39
625.00
576.10
625.64
674.22
939.01 1001.67
1153.88
1198.89
1199.01
1199.91
1201.00
1202.41
1203.05
1250.87
1252.98
1753.291267.51 1554.83 1603.42 1953.19
(M-H) of the 
desired product 
(M-H) of the desired product + 
formic acid (Mw = 46 g/mol) 
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4.2. IC50 Profiles for the Peptidic Inhibitors 
4.2.1. Literature Reported Peptidic Inhibitors 
IGE07 1 
 
 
  
Glu
Thr
Cys
Arg
Pro
Leu
Asn
9Pro
Trp
Gly
Trp
Val
Cys
Met
8Gly S S15
10
!-Hairpin Peptide 1
C77H111N21O20S3
Mw = 1747.03 g/mol
NH2
OH
[Inhibitor] microM
10-3 10-2 10-1 1 101 102
%
 A
ct
iv
ity
0
20
40
60
80
100
120
IGE07
IC50 = 4893 +/- 2361
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A-B Loop Peptide 2 
 
 
 
C-C’ Cyclo-L-262 Loop Peptide 3 
 
  
Pro
Ser
Pro
Arg
Ser
Leu
Cys
NH2PheAsp
Leu
Phe
Ile
Ser
Pro
Thr
Ile
Thr
Ser
Cys
OHLys
Arg
21
S
S
340
357
A-B Loop Peptide 2
C105H168N28O30S2
Mw = 2366.76 g/mol
[Inhibitor] microM
10-3 10-2 10-1 1 101 102
%
 A
ct
iv
ity
0
20
40
60
80
100
A-B Loop
Asp
Lys
Tyr
Tyr
Ile
Cys
NH2
Glu
Ala
Leu
Lys
Tyr
Cys
OH
Gly 13
S
S
C-C' Cyclo-L-262 Loop Peptide 3
C71H103N15O21S2
Mw = 1566.80 g/mol
119
129
[Inhibitor] microM
10-3 10-2 10-1 1 101 102
%
 A
ct
iv
ity
0
20
40
60
80
100
120
C-C' Cyclo-L-262
Chapter 4 
 191 
4.2.2. &Fc#RI C-Region Mimic Y116-D123 Series 
BM3110 10 
 
  
 
Ac-BM3110 11 
 
  
Val
Ile
Tyr
Tyr
Lys
AspLys
Tyr
H
OH
116
123
BM3110 10
C54H78N10O14
Mw = 1091.26 g/mol
(Fc!RI C-Region Mimic Y116-D123)
[Inhibitor] microM
10-2 10-1 1 101 102 103
%
 A
ct
iv
ity
0
20
40
60
80
100
120
BM3110
IC50 = 1626 +/- 33
Reduced Chi? 3.2478
Parameter Value Std. Error
Y Range 97.1466 1.9585
IC 50 1479.2256 30.4562
Slope factor 4.0164 0.2648
Background 11.6256 1.9023
Reduced Chi? 6.0511
Parameter Value Std. Error
Y Range 108.9781 0.4800
IC 50 1626.0113 33.4563
Slope factor 3.0679 0.1725
Val
Ile
Tyr
Tyr
Lys
AspLys
Tyr
Ac
OH
116
123
Ac-BM3110 11
C56H80N10O15
Mw = 1133.29 g/mol
(Fc!RI C-Region Mimic Y116-D123)
[Inhibitor] microM
10-2 10-1 1 101 102 103
%
 A
ct
iv
ity
0
20
40
60
80
100
120
Ac-BM3110
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BM3110-Am 6 
 
 
 
Ac-BM3110-Am 12 
 
 
  
Val
Ile
Tyr
Tyr
Lys
AspLys
Tyr
H
NH2
116
123
BM3110-Am 6
C54H79N11O13
Mw = 1090.27 g/mol
(Fc!RI C-Region Mimic Y116-D123)
[Inhibitor] microM
10-2 10-1 1 101 102 103
%
 A
ct
iv
ity
0
20
40
60
80
100
120
BM3110-Am
Val
Ile
Tyr
Tyr
Lys
AspLys
Tyr
Ac
NH2
116
123
Ac-BM3110-Am 12
C56H81N11O14
Mw = 1132.31 g/mol
(Fc!RI C-Region Mimic Y116-D123)
[Inhibitor] microM
10-2 10-1 1 101 102 103
%
 A
ct
iv
ity
0
20
40
60
80
100
120
Ac-BM3110-Am
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BM1149 13 
 
 
 
  
 
 
  
  
Val
Ile
Tyr
Tyr
Lys
Asp Lys
Tyr
OH
H 123
116
BM1149 13
C54H78N10O14
Mw = 1091.26 g/mol
(Retro Fc!RI C-Region Mimic Y116-D123)
[Inhibitor] microM
10-3 10-2 10-1 1 101 102 103
%
 A
ct
iv
ity
0
20
40
60
80
100
120
BM1149
IC50 = 69 +/-8
Reduced Chi? 18.9034
Parameter Value Std. Error
Y Range 106.6694 7.2704
IC 50 58.7100 13.2958
Slope factor 0.8320 0.1176
Background 5.6769 6.6008
Reduced Chi? 18.4346
Parameter Value Std. Error
Y Range 112.8207 1.6639
IC 50 69.0065 8.1677
Slope factor 0.7559 0.0600
[Inhibitor] microM
10-3 10-2 10-1 1 101 102 103
%
 A
ct
iv
ity
0
20
40
60
80
100
BM1149 repeat
IC50 = 85 +/- 6
Reduced Chi? 6.1646
Parameter Value Std. Error
Y Range 99.1295 2.5441
IC 50 78.2576 6.8633
Slope factor 1.0124 0.0779
Background 3.2026 2.2686
Reduced Chi? 6.6362
Parameter Value Std. Error
Y Range 102.5390 0.9153
IC 50 85.0877 5.6717
Slope factor 0.9415 0.0516
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Ac-BM1149 14 
 
 
 
  
 
 
  
  
Val
Ile
Tyr
Tyr
Lys
Asp Lys
Tyr
OH
Ac 123
116
Ac-BM1149 14
C56H80N10O15
Mw = 1133.29 g/mol
(Retro Fc!RI C-Region Mimic Y116-D123)
[Inhibitor] microM
10-3 10-2 10-1 1 101 102
%
 A
ct
iv
ity
0
20
40
60
80
100
Ac-BM1149
IC50 = 142 +/- 9
Reduced Chi? 5.1445
Parameter Value Std. Error
Y Range 66.2221 2.1061
IC 50 127.3169 5.2590
Slope factor 3.8076 0.9410
Background 6.8780 1.9360
Reduced Chi? 8.4055
Parameter Value Std. Error
Y Range 73.3341 0.8397
IC 50 141.7821 8.6796
Slope factor 2.4636 0.3242
[Inhibitor] microM
10-2 10-1 1 101 102 103
%
 A
ct
iv
ity
0
20
40
60
80
100
120
Ac-BM1149 repeat
IC50 = 131 +/- 11
Reduced Chi? 8.4216
Parameter Value Std. Error
Y Range 91.3965 1.6046
IC 50 89.9914 3.8611
Slope factor 1.9809 0.1476
Background 17.0745 1.3843
Reduced Chi? 37.6431
Parameter Value Std. Error
Y Range 109.3798 1.5629
IC 50 131.1019 11.4760
Slope factor 1.2234 0.1090
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BM1149-Am 7 
 
 
 
  
 
 
  
  
Val
Ile
Tyr
Tyr
Lys
Asp Lys
Tyr
NH2
H 123
116
BM1149-Am 7
C54H79N11O13
Mw = 1090.27 g/mol
(Retro Fc!RI C-Region Mimic Y116-D123)
[Inhibitor] microM
10-3 10-2 10-1 1 101 102
%
 A
ct
iv
ity
0
20
40
60
80
100
120
BM1149-Am
IC50 = 102 +/- 13
Reduced Chi? 21.5805
Parameter Value Std. Error
Y Range 93.5309 13.3144
IC 50 61.7045 29.8931
Slope factor 0.6944 0.1490
Background 14.1707 12.5051
Reduced Chi? 21.4184
Parameter Value Std. Error
Y Range 108.2934 1.9194
IC 50 101.7518 13.1000
Slope factor 0.5904 0.0567
[Inhibitor] microM
10-2 10-1 1 101 102 103
%
 A
ct
iv
ity
0
20
40
60
80
100
120
BM1149-Am repeat
IC50 = 51 +/- 8
Reduced Chi? 18.0018
Parameter Value Std. Error
Y Range 88.8596 2.5579
IC 50 33.0568 3.1435
Slope factor 1.1402 0.1069
Background 16.8922 2.0015
Reduced Chi? 44.0692
Parameter Value Std. Error
Y Range 109.7704 2.4157
IC 50 51.0093 7.8247
Slope factor 0.6679 0.0580
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Ac-BM1149-Am 15 
 
 
 
  
 
 
  
  
Val
Ile
Tyr
Tyr
Lys
Asp Lys
Tyr
NH2
Ac 123
116
Ac-BM1149-Am 15
C56H81N11O14
Mw = 1132.31 g/mol
(Retro Fc!RI C-Region Mimic Y116-D123)
[Inhibitor] microM
10-2 10-1 1 101 102 103
%
 A
ct
iv
ity
0
20
40
60
80
100
120
Ac-BM1149-Am
IC50 = 335 +/- 46
Reduced Chi? 24.4690
Parameter Value Std. Error
Y Range 77.1585 3.5889
IC 50 136.6783 17.4690
Slope factor 1.3475 0.1851
Background 27.9274 3.1630
Reduced Chi? 41.2716
Parameter Value Std. Error
Y Range 107.6162 1.9172
IC 50 334.7896 45.5405
Slope factor 0.6766 0.0616
[Inhibitor] microM
10-1 1 101 102 103
%
 A
ct
iv
ity
0
20
40
60
80
100
120
Ac-BM1149-Am repeat
IC50 = 967 +/- 64
Reduced Chi? 9.8696
Parameter Value Std. Error
Y Range 374.9893 996.0735
IC 50 4540.8832 14145.1442
Slope factor 1.1449 0.4799
Background -266.4736 995.6019
Reduced Chi? 9.3672
Parameter Value Std. Error
Y Range 108.1192 0.9955
IC 50 967.3507 63.5636
Slope factor 1.5614 0.1793
Chapter 4 
 197 
Ro25-9612 4 
 
 
 
  
  
Val
Cys
Tyr
Tyr
Lys
AspLys
Tyr
Val
NH2H
Val
Cys
Tyr
Tyr
Lys
AspLys
Tyr
Val
H
S
S
 Ro25-9612 4
 C112H162N24O28S2
Mw = 2356.76 g/mol
(Fc!RI C-Region Mimic Y115-D123 Dimer)
9
115 123
NH2
[Inhibitor] microM
10-2 10-1 1 101 102 103
%
 A
ct
iv
ity
0
20
40
60
80
100
120
Ro25-9612
IC50 = 4316 +/- 611
Reduced Chi? 85.9073
Parameter Value Std. Error
Y Range 60.7311 38.2016
IC 50 2882.6856 13644.0959
Slope factor 1.0688 0.2469
Background 39.6988 37.1791
Reduced Chi? 22.4771
Parameter Value Std. Error
Y Range 108.7116 1.0267
IC 50 4315.6234 610.5074
Slope factor 1.0210 0.1588
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Ro25-9960 5 
 
 
 
 
  
Val
Cys
Tyr
Tyr
Lys
AspLys
Tyr
H
NH2
Val
Cys
Tyr
Tyr
Lys
AspLys
Tyr
H
NH2
S
S
Ro25-9960 5
 C102H144N22O26S2
Mw = 2158.50 g/mol
(Fc!RI C-Region Mimic Y116-D123 Dimer)
8
123
116
[Inhibitor] microM
10-2 10-1 1 101 102 103
%
 A
ct
iv
ity
0
20
40
60
80
100
120
Ro25-9960
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BM3108B 16 
 
 
 
  
  
Val
Cys
Tyr
Tyr
Lys
AspLys
Tyr
H
OH
Val
Cys
Tyr
Tyr
Lys
AspLys
Tyr
H
OH
S
S
BM3108B 16
C102H142N20O28S2
Mw = 2160.47 g/mol
(Fc!RI C-Region Mimic Y116-D123 Dimer)
8
123
116
[Inhibitor] microM
10-2 10-1 1 101 102 103
%
 A
ct
iv
ity
0
20
40
60
80
100
120
140
BM3108B
IC50 = 433 +/- 22
Reduced Chi? 17.4548
Parameter Value Std. Error
Y Range 105.8360 3.5250
IC 50 369.1422 21.9013
Slope factor 2.1972 0.2375
Background 11.3098 3.3075
Reduced Chi? 22.0922
Parameter Value Std. Error
Y Range 117.4739 1.0362
IC 50 432.6564 21.7223
Slope factor 1.7511 0.1284
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BM3085A 8 
 
 
 
 
  
Val
Cys
Tyr
Tyr
Lys
Asp Lys
Tyr
Val
H 123 115
Val
Cys
Tyr
Tyr
Lys
Asp Lys
Tyr
Val
H
S
S
9
NH2
NH2
BM3085A 8 
 C112H162N24O28S2
Mw = 2356.76 g/mol
Retro Fc!RI C-Region Mimic Y115-D123 Dimer
[Inhibitor] microM
10-3 10-2 10-1 1 101 102
%
 A
ct
iv
ity
0
20
40
60
80
100
120
140
BM3085A
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BM3109A 17 
 
 
 
  
  
Val
Cys
Tyr
Tyr
Lys
Asp Lys
Tyr
Val
H 123 115
Val
Cys
Tyr
Tyr
Lys
Asp Lys
Tyr
Val
H
S
S
9
OH
OH
BM3109A 17 
C112H162N24O28S2
Mw = 2358.73 g/mol
Retro Fc!RI C-Region Mimic Y115-D123 Dimer
[Inhibitor] microM
10-2 10-1 1 101 102 103
%
 A
ct
iv
ity
0
20
40
60
80
100
120
BM3109A
IC50 = 544 +/- 53
Reduced Chi? 22.3212
Parameter Value Std. Error
Y Range 98.8606 10.3434
IC 50 353.9199 114.8112
Slope factor 0.7685 0.1105
Background 13.8497 9.7280
Reduced Chi? 22.7164
Parameter Value Std. Error
Y Range 113.4131 1.3785
IC 50 543.7277 52.9259
Slope factor 0.6585 0.0458
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BM3085B 9 
 
 
 
 
  
Val
Cys
Tyr
Tyr
Lys
Asp Lys
Tyr
NH2
H 123
116
Val
Cys
Tyr
Tyr
Lys
Asp Lys
Tyr
NH2
H
S
S
8
BM3085B 9
 C102H144N22O26S2
Mw = 2158.50 g/mol
Retro Fc!RI C-Region Mimic Y116-D123 Dimer
[Inhibitor] microM
10-3 10-2 10-1 1 101 102
%
 A
ct
iv
ity
0
20
40
60
80
100
BM3085B
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BM3109B 18 
 
 
 
  
  
Val
Cys
Tyr
Tyr
Lys
Asp Lys
Tyr
OH
H 123
116
Val
Cys
Tyr
Tyr
Lys
Asp Lys
Tyr
OH
H
S
S
8
BM3109B 18
C102H142N20O28S2
Mw = 2160.47 g/mol
Retro Fc!RI C-Region Mimic Y116-D123 Dimer
[Inhibitor] microM
10-2 10-1 1 101 102 103
%
 A
ct
iv
ity
0
20
40
60
80
100
120
140
BM3109B
IC50 = 605 +/- 67
Reduced Chi? 16.9566
Parameter Value Std. Error
Y Range 74.5348 2.5465
IC 50 292.4499 14.5327
Slope factor 4.1087 0.6820
Background 41.3967 2.3662
Reduced Chi? 59.9907
Parameter Value Std. Error
Y Range 117.9567 1.7511
IC 50 605.2265 67.0458
Slope factor 1.0547 0.1343
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4.2.3. Alanine-Scan Analogues of BM1149-Am 
[D1A] BM1149-Am 19 
 
 
 
  
  
Val
Ile
Tyr
Tyr
Lys
1Ala Lys
Tyr
NH2
H
[D1A] BM1149-Am 19
C53H79N11O11
Mw = 1046.26 g/mol
[Inhibitor] microM
10-1 1 101 102 103
%
 A
ct
iv
ity
0
20
40
60
80
100
120
[D1A] BM1149-Am
IC50 = 654 +/- 62
Reduced Chi? 4.8454
Parameter Value Std. Error
Y Range 94.9019 7.9334
IC 50 294.0214 80.6143
Slope factor 0.6120 0.0696
Background 21.6455 7.0132
Reduced Chi? 6.0479
Parameter Value Std. Error
Y Range 118.6348 1.6183
IC 50 654.4654 61.9514
Slope factor 0.4839 0.0269
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[K2A] BM1149-Am 20 
 
 
 
  
 
 
  
  
Val
Ile
Tyr
Tyr
2Ala
Asp Lys
Tyr
NH2
H
[K2A] BM1149-Am 20
C51H71N9O14
Mw = 1034.16 g/mol
[Inhibitor] microM
10-2 10-1 1 101 102 103
%
 A
ct
iv
ity
0
20
40
60
80
100
120
[K2A] BM1149-Am
IC50 = 43 +/- 4
Reduced Chi? 11.5188
Parameter Value Std. Error
Y Range 101.6558 3.5398
IC 50 31.7256 3.7628
Slope factor 0.7365 0.0569
Background 9.1285 2.9012
Reduced Chi? 14.0707
Parameter Value Std. Error
Y Range 112.2122 1.3773
IC 50 42.7053 3.7688
Slope factor 0.6206 0.0300
[Inhibitor] microM
10-1 1 101 102 103
%
 A
ct
iv
ity
0
20
40
60
80
100
120
[K2A] BM1149-Am repeat
IC50 = 182 +/- 24
Reduced Chi? 6.1214
Parameter Value Std. Error
Y Range 79.6441 3.1409
IC 50 83.8251 7.4008
Slope factor 1.4227 0.1473
Background 29.7831 2.7453
Reduced Chi? 25.2242
Parameter Value Std. Error
Y Range 112.3161 2.4957
IC 50 182.2358 23.9955
Slope factor 0.7804 0.0839
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[Y3A] BM1149-Am 21 
 
 
 
  
 
 
  
  
Val
Ile
Tyr
3Ala
Lys
Asp Lys
Tyr
NH2
H
[Y3A] BM1149-Am 21
C48H74N10O13
Mw = 999.16 g/mol
[Inhibitor] microM
10-2 10-1 1 101 102 103
%
 A
ct
iv
ity
0
20
40
60
80
100
120
[Y3A] BM1149-Am
IC50 = 413 +/- 55
Reduced Chi? 111.1645
Parameter Value Std. Error
Y Range 209.1259 103.8349
IC 50 2018.5067 2260.3306
Slope factor 0.6954 0.2148
Background -104.1164 102.8694
Reduced Chi? 101.7914
Parameter Value Std. Error
Y Range 101.6352 2.2756
IC 50 413.1791 55.2861
Slope factor 1.6148 0.2784
[Inhibitor] microM
10-1 1 101 102 103
%
 A
ct
iv
ity
0
20
40
60
80
100
120
[Y3A] BM1149-Am repeat
IC50 = 309 +/- 79
Reduced Chi? 154.5050
Parameter Value Std. Error
Y Range 156.5614 68.1524
IC 50 892.3925 2093.2890
Slope factor 0.4880 0.1673
Background -48.2575 64.0622
Reduced Chi? 128.0697
Parameter Value Std. Error
Y Range 99.4160 4.3880
IC 50 309.1865 78.7717
Slope factor 1.1086 0.2500
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[Y4A] BM1149-Am 22 
 
 
 
  
 
 
  
  
Val
Ile
4Ala
Tyr
Lys
Asp Lys
Tyr
NH2
H
[Y4A] BM1149-Am 22
C48H74N10O13
Mw = 999.16 g/mol
[Inhibitor] microM
10-2 10-1 1 101 102 103
%
 A
ct
iv
ity
0
20
40
60
80
100
120
140
[Y4A] BM1149-Am
IC50 = 308 +/- 21
Reduced Chi? 17.1242
Parameter Value Std. Error
Y Range 120.8032 8.0392
IC 50 326.9086 66.0381
Slope factor 0.7886 0.0805
Background -2.2915 7.5344
Reduced Chi? 16.5925
Parameter Value Std. Error
Y Range 118.3932 1.1039
IC 50 308.2219 21.1781
Slope factor 0.8091 0.0424
[Inhibitor] microM
10-1 1 101 102 103
%
 A
ct
iv
ity
0
20
40
60
80
100
120
[Y4A] BM1149-Am repeat
IC50 = 259 +/- 27
Reduced Chi? 19.0800
Parameter Value Std. Error
Y Range 100.0761 5.5728
IC 50 204.4868 30.1139
Slope factor 1.1150 0.1549
Background 9.5741 4.8389
Reduced Chi? 21.7574
Parameter Value Std. Error
Y Range 110.5380 1.9353
IC 50 258.9894 27.3516
Slope factor 0.9291 0.0812
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[I5A] BM1149-Am 23 
 
 
 
  
 
 
  
  
Val
5Ala
Tyr
Tyr
Lys
Asp Lys
Tyr
NH2
H
[I5A] BM1149-Am 23
C51H72N10O14
Mw = 1049.18 g/mol
[Inhibitor] microM
10-2 10-1 1 101 102 103
%
 A
ct
iv
ity
0
20
40
60
80
100
120
140
[I5A] BM1149-Am
IC50 = 311 +/- 42
Reduced Chi? 69.6945
Parameter Value Std. Error
Y Range 124.5232 19.6123
IC 50 366.6483 185.8407
Slope factor 0.7954 0.1541
Background -7.2510 18.5231
Reduced Chi? 68.2794
Parameter Value Std. Error
Y Range 116.8530 2.1854
IC 50 311.2566 41.9807
Slope factor 0.8654 0.0925
[Inhibitor] microM
10-1 1 101 102 103
%
 A
ct
iv
ity
0
20
40
60
80
100
120
[I5A] BM1149-Am repeat
IC50 = 1367 +/-188
Reduced Chi? 41.2269
Parameter Value Std. Error
Y Range 133.8698 71.7638
IC 50 2078.0259 2354.2849
Slope factor 1.1660 0.4727
Background -25.9583 70.8489
Reduced Chi? 40.2470
Parameter Value Std. Error
Y Range 107.6090 2.0102
IC 50 1366.5748 188.1938
Slope factor 1.4195 0.2314
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[V6A] BM1149-Am 24 
 
 
 
  
 
 
  
  
6Ala
Ile
Tyr
Tyr
Lys
Asp Lys
Tyr
NH2
H
[V6A] BM1149-Am 24
C52H74N10O14
Mw = 1063.20 g/mol
[Inhibitor] microM
10-2 10-1 1 101 102 103
%
 A
ct
iv
ity
0
20
40
60
80
100
120
[V6A] BM1149-Am
IC50 = 1400 +/- 79
Reduced Chi? 35.7500
Parameter Value Std. Error
Y Range 113.3645 14.8859
IC 50 1452.6956 265.0495
Slope factor 2.1318 0.3942
Background -4.9104 14.6293
Reduced Chi? 34.3252
Parameter Value Std. Error
Y Range 108.1955 1.1728
IC 50 1399.6776 79.1414
Slope factor 2.4330 0.2838
[Inhibitor] microM
10-1 1 101 102 103
%
 A
ct
iv
ity
0
20
40
60
80
100
120
[V6A] BM1149-Am repeat
IC50 = 570 +/- 80
Reduced Chi? 61.7069
Parameter Value Std. Error
Y Range 103.4989 12.3262
IC 50 531.1489 131.8865
Slope factor 1.3635 0.3787
Background 4.2212 11.4254
Reduced Chi? 57.9081
Parameter Value Std. Error
Y Range 108.0098 2.6330
IC 50 569.8328 80.2643
Slope factor 1.2698 0.1973
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[K7A] BM1149-Am 25 
 
 
 
  
 
 
  
  
Val
Ile
Tyr
Tyr
Lys
Asp 7Ala
Tyr
NH2
H
[K7A] BM1149-Am 25
C51H71N9O14
Mw = 1034.16 g/mol
[Inhibitor] microM
10-2 10-1 1 101 102
%
 A
ct
iv
ity
0
20
40
60
80
100
120
[K7A] BM1149-Am
IC50 = 99 +/- 9
Reduced Chi? 23.0598
Parameter Value Std. Error
Y Range 92.4461 5.5518
IC 50 67.8289 9.6255
Slope factor 1.2981 0.1703
Background 16.9434 5.1019
Reduced Chi? 28.0355
Parameter Value Std. Error
Y Range 110.8226 1.5309
IC 50 98.9647 8.7755
Slope factor 0.9266 0.0713
[Inhibitor] microM
10-1 1 101 102 103
%
 A
ct
iv
ity
0
20
40
60
80
100
120
[K7A] BM1149-Am repeat
IC50 = 90 +/- 15
Reduced Chi? 12.5178
Parameter Value Std. Error
Y Range 82.5183 4.1562
IC 50 51.6298 6.3214
Slope factor 1.3220 0.1741
Background 23.2045 3.4446
Reduced Chi? 30.8968
Parameter Value Std. Error
Y Range 110.3733 3.2692
IC 50 90.4500 15.1788
Slope factor 0.7227 0.0835
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[Y8A] BM1149-Am 26 
 
 
 
  
 
 
  
  
Val
Ile
Tyr
Tyr
Lys
Asp Lys
8Ala
NH2
H
[Y8A] BM1149-Am 26
C48H74N10O13
Mw = 999.16 g/mol
[Inhibitor] microM
10-2 10-1 1 101 102 103
%
 A
ct
iv
ity
0
20
40
60
80
100
120
[Y8A] BM1149-Am
IC50 = 6.3 +/- 0.6
Reduced Chi? 11.5934
Parameter Value Std. Error
Y Range 103.6506 2.1867
IC 50 5.5790 0.4185
Slope factor 0.9235 0.0594
Background 6.3309 1.3078
Reduced Chi? 19.6951
Parameter Value Std. Error
Y Range 112.3737 2.1098
IC 50 6.3253 0.6471
Slope factor 0.7644 0.0464
[Inhibitor] microM
10-4 10-3 10-2 10-1 1 101 102 103
%
 A
ct
iv
ity
0
20
40
60
80
100
120
140
[Y8A] BM1149-Am repeat
IC50 = 11.8 +/-1.1
Reduced Chi? 8.8641
Parameter Value Std. Error
Y Range 107.8024 1.8698
IC 50 9.7046 0.6675
Slope factor 1.0908 0.0703
Background 7.8955 1.4975
Reduced Chi? 19.2298
Parameter Value Std. Error
Y Range 116.4663 1.4167
IC 50 11.7819 1.0670
Slope factor 0.9081 0.0632
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4.2.4. Truncated Analogues of BM1149-Am 
["1] BM1149-Am 27 
 
 
 
 
 
 
  
  
Val
Ile
Tyr
Tyr
Lys
H Lys
Tyr
NH2
[!1] BM1149-Am 27
C50H74N10O10
Mw = 975.18 g/mol
[Inhibitor] microM
10-1 1 101 102 103
%
 A
ct
iv
ity
0
20
40
60
80
100
120
[delta1] BM1149-Am
[Inhibitor] microM
10-1 1 101 102 103
%
 A
ct
iv
ity
0
20
40
60
80
100
120
[delta1] BM1149-Am repeat
IC50 = 13036 +/- 7465
Reduced Chi? 10.9588
Parameter Value Std. Error
Y Range 33.8363 2.5683
IC 50 190.3948 33.4532
Slope factor 1.9183 0.6105
Background 75.0118 2.1809
Reduced Chi? 33.2296
Parameter Value Std. Error
Y Range 113.0131 4.2015
IC 50 13036.3672 7465.1882
Slope factor 0.3768 0.1056
Chapter 4 
 213 
["1,2] BM1149-Am 28 
 
 
 
 
 
 
  
  
Val
Ile
Tyr
Tyr
H
Lys
Tyr
NH2
[!1,2] BM1149-Am 28
C44H62N8O9
Mw = 847.01 g/mol
[Inhibitor] microM
10-1 1 101 102 103
%
 A
ct
iv
ity
0
20
40
60
80
100
[delta1,2] BM1149-Am
[Inhibitor] microM
10-1 1 101 102 103
%
 A
ct
iv
ity
0
20
40
60
80
100
120
[delta1,2] BM1149-Am repeat
IC50 = 9493 +/- 4100
Reduced Chi? 16.8197
Parameter Value Std. Error
Y Range 32.7600 3.4887
IC 50 896.0958 123.0435
Slope factor 4.7754 2.7964
Background 82.7486 3.2120
Reduced Chi? 35.4141
Parameter Value Std. Error
Y Range 116.3577 2.0713
IC 50 9492.9699 4099.8422
Slope factor 0.8295 0.2433
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["1,2,3] BM1149-Am 29 
 
 
 
 
 
 
  
  
Val
Ile
Tyr
H Lys
Tyr
NH2
[!1,2,3] BM1149-Am 29
C35H53N7O7
Mw = 683.84 g/mol
[Inhibitor] microM
10-1 1 101 102 103
%
 A
ct
iv
ity
0
20
40
60
80
100
[delta1,2,3] BM1149-Am
[Inhibitor] microM
10-1 1 101 102 103
%
 A
ct
iv
ity
0
20
40
60
80
100
120
[delta1,2,3] BM1149-Am repeat
IC50 = 8819 +/- 3499
Reduced Chi? 90.3184
Parameter Value Std. Error
Y Range 45.5753 10.0876
IC 50 3348.1432 6633.7711
Slope factor 0.1403 0.0798
Background 79.8383 6.2070
Reduced Chi? 32.2586
Parameter Value Std. Error
Y Range 113.8045 1.6925
IC 50 8819.0144 3499.4700
Slope factor 1.3374 0.5527
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["8] BM1149-Am 30 
 
 
 
  
 
 
  
  
Val
Ile
Tyr
Tyr
Lys
Asp Lys
HH
[!8] BM1149-Am 30
C45H70N10O11
Mw = 927.10 g/mol
[Inhibitor] microM
10-1 1 101 102 103
%
 A
ct
iv
ity
0
20
40
60
80
100
120
[delta8] BM1149-Am
IC50 = 802 +/- 77
Reduced Chi? 16.6983
Parameter Value Std. Error
Y Range 111.0911 19.7697
IC 50 927.2390 448.8898
Slope factor 0.8237 0.1595
Background -5.6273 18.9657
Reduced Chi? 15.5386
Parameter Value Std. Error
Y Range 105.2837 1.5162
IC 50 802.4866 76.8755
Slope factor 0.8674 0.0741
[Inhibitor] microM
10-1 1 101 102 103
%
 A
ct
iv
ity
0
20
40
60
80
100
120
[delta8] BM1149-Am repeat
IC50 = 211 +/- 34
Reduced Chi? 24.1754
Parameter Value Std. Error
Y Range 91.1263 4.1986
IC 50 126.4299 15.5970
Slope factor 1.4982 0.2346
Background 20.1434 3.4640
Reduced Chi? 47.1163
Parameter Value Std. Error
Y Range 113.9202 3.0707
IC 50 211.3146 34.4296
Slope factor 0.8517 0.1043
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["7,8] BM1149-Am 31 
 
 
 
  
 
 
  
  
Val
Ile
Tyr
Tyr
Lys
Asp H
H
[!7,8] BM1149-Am 31
C39H58N8O10
Mw = 798.93 g/mol
[Inhibitor] microM
10-1 1 101 102 103
%
 A
ct
iv
ity
0
20
40
60
80
100
120
[delta7,8] BM1149-Am
IC50 = 2420 +/- 248
Reduced Chi? 13.0257
Parameter Value Std. Error
Y Range 100.3368 38.4446
IC 50 2230.9890 2072.5890
Slope factor 0.8434 0.2279
Background 3.3575 37.8109
Reduced Chi? 12.0310
Parameter Value Std. Error
Y Range 103.7396 1.2691
IC 50 2420.1033 248.1695
Slope factor 0.8267 0.0836
[Inhibitor] microM
10-1 1 101 102 103
%
 A
ct
iv
ity
0
20
40
60
80
100
120
[delta7,8] BM1149-Am repeat
IC50 = 2376 +/- 196
Reduced Chi? 3.5768
Parameter Value Std. Error
Y Range 65.8286 4.3746
IC 50 730.9021 103.7304
Slope factor 1.2744 0.1471
Background 40.6363 4.1550
Reduced Chi? 7.9202
Parameter Value Std. Error
Y Range 107.5876 1.0695
IC 50 2376.0399 196.1635
Slope factor 0.7684 0.0608
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["6,7,8] BM1149-Am 32 
 
 
 
  
 
 
  
  
H
Ile
Tyr
Tyr
Lys
Asp
H
[!6,7,8] BM1149-Am 32
C34H49N7O9
Mw = 699.79 g/mol
[Inhibitor] microM
10-1 1 101 102 103
%
 A
ct
iv
ity
0
20
40
60
80
100
[delta6,7,8] BM1149-Am
IC50 = 928 +/- 106
Reduced Chi? 9.1220
Parameter Value Std. Error
Y Range 74.7451 3.1203
IC 50 468.6856 37.8746
Slope factor 2.0900 0.2753
Background 28.2238 2.8415
Reduced Chi? 28.7499
Parameter Value Std. Error
Y Range 103.9841 1.8563
IC 50 927.5725 105.7824
Slope factor 1.0846 0.1314
[Inhibitor] microM
10-1 1 101 102 103
%
 A
ct
iv
ity
0
20
40
60
80
100
120
[delta6,7,8] BM1149-Am repeat
IC50 = 341 +/- 32
Reduced Chi? 4.7210
Parameter Value Std. Error
Y Range 97.9221 1.7944
IC 50 256.2555 10.2933
Slope factor 2.0548 0.1455
Background 16.1758 1.5610
Reduced Chi? 28.5633
Parameter Value Std. Error
Y Range 115.3174 1.9041
IC 50 341.2731 31.5073
Slope factor 1.3151 0.1361
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4.2.5. Investigation to Improve Solubility of Peptidic Inhibitors 
BM1149 13 
 
 
 
  
 
 
  
  
Val
Ile
Tyr
Tyr
Lys
Asp Lys
Tyr
OH
H 123
116
BM1149 13
C54H78N10O14
Mw = 1091.26 g/mol
(Retro Fc!RI C-Region Mimic Y116-D123)
[Inhibitor] microM
1 101 102
%
 A
ct
iv
ity
0
20
40
60
80
100
120
BM1149 5% MeOH
IC50 = 64 +/- 7
Reduced Chi? 6.6353
Parameter Value Std. Error
Y Range 139.6059 17.7350
IC 50 106.6721 37.3378
Slope factor 0.5949 0.0908
Background -22.5725 14.8646
Reduced Chi? 10.0074
Parameter Value Std. Error
Y Range 112.6461 2.4540
IC 50 63.9066 6.5783
Slope factor 0.7763 0.0542
[Inhibitor] microM
1 101 102
%
 A
ct
iv
ity
0
20
40
60
80
100
BM1149 5% EtOH
IC50 = 43 +/- 16
Reduced Chi? 31.4477
Parameter Value Std. Error
Y Range 137.7789 16.3364
IC 50 80.4898 41.3918
Slope factor 0.4211 0.0771
Background -22.3485 11.7096
Reduced Chi? 32.8461
Parameter Value Std. Error
Y Range 109.3049 8.1133
IC 50 42.9920 16.3007
Slope factor 0.5456 0.0890
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[Inhibitor] microM
1 101 102
%
 A
ct
iv
ity
0
20
40
60
80
100
BM1149 5% MeCN
IC50 = 129 +/- 23
Reduced Chi? 6.4826
Parameter Value Std. Error
Y Range 185.1944 18.2570
IC 50 1442.6421 629.1130
Slope factor 0.3595 0.0390
Background -79.3052 17.1457
Reduced Chi? 11.1835
Parameter Value Std. Error
Y Range 99.2409 3.5026
IC 50 129.3963 23.4425
Slope factor 0.5610 0.0602
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BM1149-Am 7 
 
 
 
  
 
 
  
  
Val
Ile
Tyr
Tyr
Lys
Asp Lys
Tyr
NH2
H 123
116
BM1149-Am 7
C54H79N11O13
Mw = 1090.27 g/mol
(Retro Fc!RI C-Region Mimic Y116-D123)
[Inhibitor] microM
1 101 102
%
 A
ct
iv
ity
0
20
40
60
80
100
120
BM1149-Am 5% MeOH
IC50 = 224 +/- 60
Reduced Chi? 54.9681
Parameter Value Std. Error
Y Range 140.7723 16.7275
IC 50 544.2955 226.0549
Slope factor 0.5826 0.1245
Background -34.6994 15.8026
Reduced Chi? 57.8331
Parameter Value Std. Error
Y Range 105.1002 5.4523
IC 50 224.1041 59.8000
Slope factor 0.6864 0.1469
[Inhibitor] microM
1 101 102
%
 A
ct
iv
ity
0
20
40
60
80
100
120
BM1149-Am 5% EtOH
IC50 = 203 +/- 24
Reduced Chi? 6.6845
Parameter Value Std. Error
Y Range 175.7109 17.9820
IC 50 958.9199 361.1789
Slope factor 0.4528 0.0438
Background -60.5575 17.1193
Reduced Chi? 9.4970
Parameter Value Std. Error
Y Range 111.3609 2.5339
IC 50 202.8120 23.8799
Slope factor 0.6178 0.0537
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[Inhibitor] microM
1 101 102
%
 A
ct
iv
ity
0
20
40
60
80
100
120
BM1149-Am 5% MeCN
IC50 = 580 +/- 66
Reduced Chi? 10.4171
Parameter Value Std. Error
Y Range 85.2771 35.1805
IC 50 310.2577 372.0052
Slope factor 0.8044 0.2357
Background 21.4794 33.7033
Reduced Chi? 9.5207
Parameter Value Std. Error
Y Range 107.7110 1.9361
IC 50 579.6224 66.4776
Slope factor 0.6800 0.0740
Chapter 4 
 222 
[Y8A] BM1149-Am 26 
 
 
 
  
 
 
  
  
Val
Ile
Tyr
Tyr
Lys
Asp Lys
8Ala
NH2
H
[Y8A] BM1149-Am 26
C48H74N10O13
Mw = 999.16 g/mol
[Inhibitor] microM
10-1 1 101 102
%
 A
ct
iv
ity
0
20
40
60
80
100
120
[Y8A] BM1149-Am 5% MeOH
IC50 = 13.2 +/- 3.7
Reduced Chi? 13.8977
Parameter Value Std. Error
Y Range 158.5480 32.3297
IC 50 20.4207 8.5341
Slope factor 0.4335 0.1505
Background -25.4966 21.4413
Reduced Chi? 14.8844
Parameter Value Std. Error
Y Range 121.8595 7.6685
IC 50 13.1577 3.7157
Slope factor 0.6137 0.0750
[Inhibitor] microM
10-1 1 101 102
%
 A
ct
iv
ity
0
20
40
60
80
100
120
[Y8A] BM1149-Am 5% EtOH
IC50 = 5.2 +/- 1.4
Reduced Chi? 7.6236
Parameter Value Std. Error
Y Range 153.4134 39.5797
IC 50 4.9916 2.1282
Slope factor 0.4747 0.1554
Background -15.0731 16.5114
Reduced Chi? 9.1857
Parameter Value Std. Error
Y Range 121.4266 8.2823
IC 50 5.2325 1.4424
Slope factor 0.6508 0.0649
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[Inhibitor] microM
10-1 1 101 102
%
 A
ct
iv
ity
0
20
40
60
80
100
120
[Y8A] BM1149-Am 5% MeCN
IC50 = 11.2 +/- 2.2
Reduced Chi? 20.4538
Parameter Value Std. Error
Y Range 121.9539 23.0341
IC 50 12.6007 4.1255
Slope factor 0.7241 0.2155
Background -7.5434 14.7431
Reduced Chi? 18.2166
Parameter Value Std. Error
Y Range 111.0247 5.6957
IC 50 11.2017 2.2102
Slope factor 0.8357 0.1030
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4.2.6. Arg-Addition Analogues of [Y8A] BM1149-Am 
BM3135A 33 
 
 
 
BM3135B 34 
 
 
  
 
Val
Ile
Tyr
Tyr
Lys
Asp Lys
Tyr
NH2
Arg
BM3135A 33
C54H87N15O13
Mw = 1154.36 g/mol
H
[Inhibitor] microM
10-2 10-1 1 101 102 103
%
 A
ct
iv
ity
0
20
40
60
80
100
BM3135A
Val
Ile
Tyr
Tyr
Lys
Asp Lys
Tyr
Arg
H
BM3135B 34
C54H87N15O13
Mw = 1154.36 g/mol
NH2
[Inhibitor] microM
10-2 10-1 1 101 102
%
 A
ct
iv
ity
0
20
40
60
80
100
120
BM3135B
IC50 = 164 +/- 21
Reduced Chi? 29.6260
Parameter Value Std. Error
Y Range 75.0368 4.9541
IC 50 69.0867 9.9133
Slope factor 1.5640 0.2894
Background 32.0341 4.5204
Reduced Chi? 46.1515
Parameter Value Std. Error
Y Range 108.5188 1.9602
IC 50 164.4102 20.5150
Slope factor 0.8539 0.0932
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